mdBook Quickstart

Welcome to the demo site for mkBook Quickstart.

View source:

OB

8.1 - GI Disorders

Summary

GASTROINTESTINAL, HEPATIC, AND BILIARY DISORDERS IN PREGNANCY

GENERAL PRINCIPLES & PHYSIOLOGY

• Progesterone in pregnancy causes decreased GI motility and decreased LES tone, which can lead to constipation and GERD.
• Estrogen in pregnancy increases nausea and alters bile composition, predisposing the mother to gallstones.
• hCG peaks in the 1st trimester and is the primary hormone linked to pregnancy-related vomiting.
• Epigastric pain in the 3rd trimester is a "red flag" that requires checking blood pressure and liver enzymes to rule out preeclampsia/HELLP.
• Alkaline phosphatase levels naturally rise 3-4 fold during normal pregnancy due to placental production, not liver damage.
• AST, ALT, and Bilirubin levels do NOT change in a normal pregnancy; any elevation is considered pathologic.
• Serum Albumin and total protein concentrations decrease during normal pregnancy due to hemodilution.
• Gastrointestinal disorders in the Philippines are often complicated by high rates of anemia, malnutrition, and parasitic infections.

DIAGNOSTIC TECHNIQUES & NUTRITION

• Upper GI endoscopy is considered safe for diagnosis and management during pregnancy when indicated.
• Flexible sigmoidoscopy is the preferred method for visualizing the large bowel in pregnant women.
• Polyethylene glycol is used for bowel prep; maternal dehydration must be avoided to maintain uteroplacental perfusion.
• ERCP is useful for diagnosing and treating choledocholithiasis and pancreatic issues in pregnancy.
• Abdominal sonography is the ideal first-line technique for GI imaging due to its lack of radiation.
• Magnetic Resonance Imaging (MRI) is the preferred modality for viewing the retroperitoneal space and diagnosing appendicitis without radiation.
• Laparoscopy is the preferred surgical approach in the 1st and 2nd trimesters; it carries a risk of preterm labor in the 3rd trimester.
• Enteral nutrition (nasogastric tube) is always preferred over parenteral nutrition because it has fewer complications.
• Central Parenteral Nutrition (CPN) is reserved for conditions like short bowel syndrome and requires central venous access for hyperosmolar solutions.

UPPER GI DISORDERS: KEY FACTS

• Hyperemesis Gravidarum can cause Wernicke Encephalopathy due to thiamine deficiency, characterized by the triad of ocular signs, confusion, and ataxia.
• Vitamin K deficiency in hyperemesis can lead to maternal coagulopathy and fetal intracranial hemorrhage.
• Ondansetron (Zofran) should be reserved for cases after 8 weeks' gestation due to risks of prolonged QT interval and serotonin syndrome.
• Boerhaave Syndrome is a serious esophageal rupture caused by sustained, forceful retching in hyperemesis.
• Mallory-Weiss tears are small mucosal tears at the GE junction causing upper GI bleeding after persistent vomiting.
• Diaphragmatic hernia repair is recommended during pregnancy, even if asymptomatic, because the maternal mortality rate of rupture is approximately 45%.
• Vaginal delivery is generally contraindicated in unrepaired diaphragmatic hernias due to the risk of rupture from increased intraabdominal pressure.
• Hiatal hernias are found in 20% of multiparas in late pregnancy and may cause vomiting or epigastric pain.

INTESTINAL & COLONIC DISORDERS: KEY FACTS

• Acute diarrhea evaluation is required if it lasts >48 hours, involves fever >38°C, or grossly bloody stools.
• Loperamide (Imodium) should be avoided in acute diarrhea if the etiology is unknown, as it may prolong the presence of toxins.
• Clostridioides difficile is the most common nosocomial infection and is typically triggered by aminopenicillins or cephalosporins.
• Fecal calprotectin is a valid inflammatory biomarker used to identify IBD flares in pregnant patients.
• Toxic megacolon is a catastrophic complication of Ulcerative Colitis that may necessitate an emergency colectomy.
• Bowel obstruction in pregnancy is most commonly caused by the growing uterus exerting pressure on pre-existing adhesions.
• Tocolytics are not recommended for contractions following appendectomy due to the high risk of pulmonary edema in the setting of sepsis.

HEPATIC, BILIARY, & VIRAL DISORDERS: KEY FACTS

• Acute Liver Failure in the non-pregnant population is most commonly caused by Acetaminophen toxicity.
• Spider angiomata and palmar erythema occur in 2/3 of normal pregnancies due to high estrogen levels and are not necessarily signs of liver disease.
• Intrahepatic Cholestasis of Pregnancy (ICP) increases the risk of fetal death if bile acid levels exceed 100 µmol/L due to cardiotoxicity.
• Vaginal delivery is the preferred mode for liver failure patients to minimize incision-related bleeding, as the liver produces necessary coagulation factors.
• Hepatitis B screening should be done for ALL pregnant women at the first visit; it is a DNA virus.
• HBsAg is the first serologic marker to appear in an acute Hepatitis B infection.
• Vertical transmission of Hep B is highest (90%) if the mother is HBeAg positive at delivery.
• Neonatal intervention for Hep B involves giving the infant both HBIG and the Hep B vaccine series within 12 hours of birth.
• Hepatitis C vertical transmission is low (<5%) but higher if the mother is coinfected with HIV.
• Hepatitis A does NOT cause birth defects and maternal-fetal transmission has not been observed.
• Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease and is linked to obesity and metabolic syndrome.
• Cholelithiasis (gallstones) is more common in pregnancy because gallbladder fasting and residual volumes double after the 1st trimester.
• Bile sludge often regresses spontaneously after delivery.
• Cholecystectomy is safe in all trimesters, but prophylactic removal of asymptomatic stones is NOT warranted.

DIFFERENTIAL COMPARISONS FOR EXAMS

• Hyperemesis Gravidarum vs. Normal Morning Sickness: HG involves weight loss >5% and ketonuria; morning sickness typically resolves by 16 weeks and doesn't cause dehydration.
• Acute Fatty Liver (AFLP) vs. HELLP Syndrome: AFLP is characterized by severe hypoglycemia and prolonged clotting times/hypofibrinogenemia; HELLP focus is on hemolysis and low platelets.
• ICP vs. Viral Hepatitis: ICP presents with pruritus and high bile acids with minimal transaminase elevation; Hepatitis presents with malaise and very high transaminases (>1000 U/L).
• Ulcerative Colitis vs. Crohn Disease: UC is continuous and involves only the mucosa/submucosa of the colon; Crohn's is patchy, transmural, and can affect the small bowel (distal ileum).
• pANCA vs. ASCA: pANCA is associated with Ulcerative Colitis (70%); ASCA (Anti-S. cerevisiae) is associated with Crohn Disease (50%).
• Boerhaave Syndrome vs. Mallory-Weiss Tear: Boerhaave is a full-thickness esophageal rupture (emergency); Mallory-Weiss reflects linear mucosal tears (usually self-limiting bleeding).
• Epigastric Pain in 3rd Trimester: If BP is high, think Preeclampsia/HELLP; if BP is normal and patient has fatty food intolerance, think Cholecystitis.
• Progesterone Effects vs. Mechanical Effects: Progesterone causes decreased LES tone (GERD) and slow GI transit; the enlarging uterus increases pressure on the stomach and displaces the appendix.
• HBsAg vs. Anti-HBs: HBsAg indicates infection (active/carrier); Anti-HBs indicates immunity (previous infection or vaccination).
• HBeAg vs. Anti-HBe: HBeAg indicates high viral replication and high infectivity; Anti-HBe suggests lower viral titers.
• Enteral vs. Parenteral Nutrition: Enteral is via the GI tract (preferred); Parenteral is via the veins (used only if the GI tract must remain "quiescent").
• PPN vs. CPN: PPN is short-term and peripheral; CPN is long-term, uses 24-40 kcal/kg/day, and requires high-flow central veins for hypertonic solutions.
• Appendicitis Diagnosis: Ultrasound is first-line to rule out OB causes; MRI is the gold standard for definitive diagnosis in pregnancy.
• Treatment of C. diff: Oral Vancomycin is 1st line; avoid Loperamide which can worsen the infection.
• Hepatitis Transmission: Hep A is fecal-oral; Hep B and C are parenteral (blood/body fluids).
• Management of Bile Stones: Symptomatic gallstones = Laparoscopic Cholecystectomy; Asymptomatic gallstones = Observation until postpartum.
• Achalasia Appearance: Barium swallow shows a "bird beak" narrowing; GERD does not show this specific narrowing unless a stricture has formed.
• Methotrexate: Excellent for ectopic pregnancy but strictly contraindicated for IBD management in a viable pregnancy due to teratogenicity.
• Delivery in IBD: Vaginal delivery is the goal; Cesarean is only preferred if active perianal disease (fistulas/abscesses) is present in Crohn's.
• Delivery in ICP: Routine induction at 38 weeks; if jaundice or bile acids are >100, deliver at 36 weeks.
• Management of HG: Diclegis is the 1st step; if intractable, use IV fluids with Thiamine before any glucose-containing fluids to avoid Wernicke's.

QA

text

1. What hormones contribute to the pathogenesis of Hyperemesis Gravidarum? | hCG, estrogen, progesterone
2. Which bacterium is possibly linked to Hyperemesis Gravidarum? | Helicobacter pylori
3. What is the weight loss criteria for Hyperemesis Gravidarum? | >5% weight loss
4. Enumerate the metabolic/electrolyte imbalances in Hyperemesis Gravidarum (3). | Ketonuria, hypokalemia, alkalosis
5. What is the first-line pharmacologic treatment for Hyperemesis Gravidarum? | Diclegis
   (Doxylamine + Pyridoxine)
6. Which nutrient is given to prevent Wernicke Encephalopathy in Hyperemesis Gravidarum? | Thiamine (100mg)
7. What is the primary pathogenesis of GERD in pregnancy? | Progesterone-induced LES relaxation
8. What is the clinical term for heartburn often seen in GERD? | Pyrosis
9. When does the prevalence of GERD symptoms typically increase? | 3rd trimester
10. Which class of drugs is safe for GERD but must avoid Misoprostol? | PPIs and H2 blockers
11. Why is pregnancy considered gastroprotective against Peptic Ulcer Disease? | Low gastric acid/High mucus
12. List the components of Triple Therapy for H. pylori PUD (3). | Amoxicillin/Metronidazole,
    Clarithromycin,
    PPI
13. Which plexus is destroyed in the pathogenesis of Achalasia? | Myenteric (Auerbach) plexus
14. What classic finding is seen on a barium swallow for Achalasia? | "Bird beak" narrowing
15. What is the confirmatory diagnostic test for Achalasia? | Manometry
16. How does the position of the appendix change in Appendicitis during pregnancy? | Upward and outward
17. What is the most common site of pain in Appendicitis, even in pregnancy? | Right Lower Quadrant (RLQ)
18. What is the diagnostic modality of choice for Appendicitis in pregnancy? | MRI
19. What is the preferred surgical approach for Appendicitis in the 1st/2nd trimester? | Laparoscopy
20. Describe the extent of inflammation in Ulcerative Colitis. | Continuous, superficial mucosal inflammation
21. Where does Ulcerative Colitis inflammation always begin? | Rectum
22. Which serologic marker is found in 70% of Ulcerative Colitis cases? | pANCA
23. What medication is strictly contraindicated in Ulcerative Colitis due to teratogenicity? | Methotrexate
24. Describe the inflammatory pattern of Crohn Disease. | Transmural and patchy/segmental
25. Which specific GI complications are characteristic of Crohn Disease? | Perianal fistulas/abscesses
26. Which antibody is associated with 50% of Crohn Disease cases? | ASCA
27. What is the folic acid recommendation for patients with Crohn Disease? | 4mg
28. What causes Intrahepatic Cholestasis of Pregnancy (ICP)? | Impaired bile salt transport
29. What is the hallmark clinical manifestation of ICP? | Pruritus (palms/soles)
30. What lab result is diagnostic for ICP? | Elevated total serum bile acids
31. What is the first-line medication for ICP? | Ursodeoxycholic acid
32. When is delivery recommended for severe ICP or jaundice? | 36 weeks
33. What mitochondrial abnormality is linked to Acute Fatty Liver of Pregnancy (AFLP)? | LCHAD mutation
34. What metabolic emergency is a hallmark of AFLP? | Hypoglycemia
35. Which criteria are used to diagnose AFLP? | Swansea Criteria
36. What is the definitive management for AFLP? | Immediate delivery
37. How does Progesterone affect GI motility in pregnancy? | Decreases motility
38. How does Estrogen affect the gallbladder in pregnancy? | Predisposes to gallstones
39. When does hCG peak in pregnancy? | 1st trimester
40. Epigastric pain in the 3rd trimester is a "red flag" for which condition? | Preeclampsia/HELLP
41. Which liver enzyme rises naturally in pregnancy due to placental production? | Alkaline phosphatase
42. Which liver labs do NOT change in a normal pregnancy (3)? | AST, ALT, Bilirubin
43. Why do serum albumin levels decrease during normal pregnancy? | Hemodilution
44. Name three factors complicating Gastrointestinal disorders in the Philippines. | Anemia, malnutrition, parasitic infections
45. Which diagnostic procedure is the preferred method for viewing the large bowel in pregnancy? | Flexible sigmoidoscopy
46. Why must maternal dehydration be avoided during bowel prep with Polyethylene glycol? | Maintain uteroplacental perfusion
47. What is ERCP used for in pregnancy? | Choledocholithiasis/Pancreatic issues
48. What is the first-line imaging technique for GI issues in pregnancy? | Abdominal sonography
49. Why is MRI preferred for diagnosing appendicitis in pregnancy? | No radiation/Good retroperitoneal view
50. What is a risk of Laparoscopy performed in the 3rd trimester? | Preterm labor
51. Why is Enteral nutrition preferred over parenteral nutrition? | Fewer complications
52. Which condition specifically warrants Central Parenteral Nutrition (CPN)? | Short bowel syndrome
53. What is the classic triad of Wernicke Encephalopathy? | Ocular signs, confusion, ataxia
54. What are the neonatal risks of maternal Vitamin K deficiency? | Fetal intracranial hemorrhage
55. Why is Ondansetron reserved until after 8 weeks' gestation? | QT interval/Serotonin syndrome risk
56. Define Boerhaave Syndrome. | Full-thickness esophageal rupture
57. Define Mallory-Weiss tears. | Mucosal GE junction tears
58. What is the maternal mortality rate of a ruptured Diaphragmatic hernia? | Approximately 45%
59. Why is vaginal delivery contraindicated in unrepaired Diaphragmatic hernias? | Risk of rupture
60. What percentage of multiparas have Hiatal hernias in late pregnancy? | 20%
61. When is evaluation for Acute diarrhea required? | Duration >48 hours/Fever/Bloody stools
62. Why should Loperamide be avoided if the diarrhea etiology is unknown? | Prolongs toxin presence
63. Which antibiotics typically trigger Clostridioides difficile? | Aminopenicillins or Cephalosporins
64. What biomarker is used to identify IBD flares in pregnancy? | Fecal calprotectin
65. What is Toxic megacolon? | Catastrophic UC complication
66. What is the most common cause of Bowel obstruction in pregnancy? | Pressure on pre-existing adhesions
67. Why are tocolytics avoided after an appendectomy in septic patients? | Risk of pulmonary edema
68. What is the most common cause of Acute Liver Failure in the general population? | Acetaminophen toxicity
69. What skin signs occur in 2/3 of pregnancies due to high estrogen? | Spider angiomata/Palmar erythema
70. At what bile acid level does the risk of fetal death increase in ICP? | >100 µmol/L
71. What is the preferred mode of delivery for Liver failure patients? | Vaginal delivery
72. When should Hepatitis B screening be performed? | First prenatal visit
73. Which serologic marker appears first in acute Hepatitis B? | HBsAg
74. What HBeAg status in the mother correlates with 90% vertical transmission of Hep B? | HBeAg positive
75. What two interventions are given to Hep B exposed neonates within 12 hours? | HBIG and Hep B vaccine
76. What increases the risk of vertical transmission for Hepatitis C? | HIV coinfection
77. Is Hepatitis A associated with birth defects? | No
78. What is the most common chronic liver disease? | NAFLD
79. How do gallbladder volumes change after the 1st trimester? | They double
80. What is the management for Asymptomatic gallstones in pregnancy? | Observation/Expectant management
81. Compare Hyperemesis Gravidarum vs. Morning Sickness regarding weight loss. | HG has >5% loss; Morning sickness does not.
82. Compare AFLP vs. HELLP regarding glucose and coagulation. | AFLP: Hypoglycemia/Prolonged clotting
    HELLP: Hemolysis/Low platelets
83. Compare ICP vs. Viral Hepatitis regarding transaminases. | ICP: Minimal elevation
    Hepatitis: Very high (>1000 U/L)
84. Compare Ulcerative Colitis vs. Crohn Disease regarding thickness of inflammation. | UC: Mucosal/superficial
    Crohn's: Transmural
85. Which antibody is for UC and which is for Crohn's? | pANCA (UC); ASCA (Crohn's)
86. Compare Boerhaave vs. Mallory-Weiss severity. | Boerhaave: Rupture (Emergency)
    Mallory-Weiss: Tear (Self-limiting)
87. Epigastric pain in 3rd trimester + High BP Suggests? | Preeclampsia/HELLP
88. Epigastric pain in 3rd trimester + Normal BP + Fatty food intolerance suggests? | Cholecystitis
89. Contrast HBsAg vs. Anti-HBs. | HBsAg: Infection
    Anti-HBs: Immunity
90. Contrast HBeAg vs. Anti-HBe. | HBeAg: High infectivity
    Anti-HBe: Lower viral titers
91. Contrast Enteral vs. Parenteral Nutrition route. | Enteral: GI tract
    Parenteral: Veins
92. Contrast PPN vs. CPN duration and flow. | PPN: Short-term/Peripheral
    CPN: Long-term/Central/Hypertonic
93. What is the first-line drug for C. diff? | Oral Vancomycin
94. Contrast the transmission of Hep A vs. Hep B/C. | Hep A: Fecal-oral
    Hep B/C: Parenteral
95. Contrast Achalasia vs. GERD on barium swallow. | Achalasia: Bird beak
    GERD: No narrowing
96. When is Cesarean delivery preferred in Crohn Disease? | Active perianal disease
97. What is the routine induction timing for ICP? | 38 weeks
98. What must be given BEFORE glucose in intractable Hyperemesis Gravidarum? | Thiamine
99. What are the clinical signs of Achalasia (3)? | Dysphagia, chest pain, regurgitation
100. What is the pathogenesis of AFLP? | Microvesicular fat accumulation
101. What is the "Gold Standard" for diagnosing Appendicitis in pregnancy? | MRI
102. Which IBD type has a 1%/year risk for colon cancer? | Ulcerative Colitis
103. What are the characteristics of NAFLD? | Obesity and metabolic syndrome

8.2 - Hematologic Disorders

Summary

text

PHYSIOLOGIC ADAPTATION IN PREGNANCY

• (Maternal Physiology) Plasma volume expansion by 40-50% disproportionately exceeds the 15-25% increase in red cell mass, resulting in hemodilution and physiologic anemia.
• (Maternal Physiology) Hematocrit levels typically decrease during pregnancy to an average of 34% in singleton pregnancies and 30% in multifetal gestations.
• (Maternal Physiology) Oxygen-carrying capacity remains normal during pregnancy despite hemodilution and physiologic anemia.
• (Maternal Physiology) Whole blood viscosity decreases during pregnancy due to the decline in hemoglobin and hematocrit concentrations.
• (Maternal Physiology) Hemoglobin concentration at term is normally 12.5 g/dL; values below 11.0 g/dL are considered abnormal and usually signify iron deficiency.
• (Maternal Physiology) Maternal blood volume expansion reaches a plateau during the last weeks of pregnancy after rising most rapidly during the midtrimester.
• (Maternal Physiology) Iron requirements increase from 1 mg/day in non-pregnant women to approximately 7 mg/day in the third trimester to support the fetus, placenta, and expanded maternal red cell mass.
• (Maternal Physiology) Total iron requirement for a healthy normal pregnancy is approximately 1000 mg, with 300 mg transferred to the fetus/placenta and 200 mg lost through normal excretion.
• (Maternal Physiology) Maternal hepcidin levels are suppressed 10-fold in the second trimester compared to the first to facilitate greater iron absorption via ferroportin in enterocytes.
• (Maternal Physiology) Coagulation factors VII, VIII, IX, and X increase during pregnancy, creating a physiologic hypercoagulable state to prevent hemorrhage.
• (Maternal Physiology) Fibrinogen levels double by term (reaching up to 600+ mg/dL), while fibrinolysis is simultaneously inhibited.
• (Maternal Physiology) Protein S functional activity significantly decreases during pregnancy (dropping from ~65-140% to ~16-42% by the 3rd trimester), contributing to the prothrombotic state.
• (Maternal Physiology) Platelet counts decrease from the mid-second to third trimester due to dilution, increased spleen size (50% increase), and pooling in the intervillous space.
• (Maternal Physiology) Left ventricular mass increases throughout pregnancy, beginning at 26 to 30 weeks' gestation.
• (Maternal Physiology) Arterial blood pressure usually declines to a nadir at 24 to 26 weeks, with diastolic pressure decreasing more than systolic pressure.

ANEMIA: DIAGNOSIS AND GENERAL CAUSES

• (Anemia Diagnosis) Anemia is defined as a decreased blood concentration of hemoglobin, regardless of cause, morphology, or RBC function.
• (Anemia Diagnosis) Anemia thresholds for pregnant women differ by trimester: <11 g/dL in the first/third and <10.5 g/dL in the second trimester according to the CDC.
• (Anemia Diagnosis) Microcytic anemia evaluation requires measuring serum ferritin and performing hemoglobin electrophoresis to differentiate iron deficiency from hemoglobinopathies.
• (Anemia Diagnosis) Macrocytic anemia evaluation primarily involves checking serum folate and vitamin B12 levels.
• (Acute Blood Loss) Oral iron therapy can be provided for three months to a moderately anemic woman (Hgb ~7 g/dL) who is hemodynamically stable, able to ambulate, and not septic.
• (Chronic Anemia) Anemia of chronic disease is characterized by slightly hypochromic/microcytic cells, low transferrin saturation, high serum ferritin, and elevated hepcidin which restricts iron export.
• (Chronic Anemia) Recombinant erythropoietin is considered in pregnancies with chronic renal insufficiency when the hematocrit approximates 20 percent.

IRON DEFICIENCY ANEMIA (IDA)

• (Iron Deficiency Anemia) Iron deficiency anemia is the most common cause of anemia in pregnancy, resulting from an inability to meet the 1000 mg requirement.
• (Iron Deficiency Anemia) Serum ferritin levels below 10–15 μg/L specifically confirm iron-deficiency anemia in gravidas.
• (Iron Deficiency Anemia) Ferritin acts as an acute phase reactant, so levels up to 100 ng/mL may still be compatible with IDA in the presence of inflammation or infection.
• (Iron Deficiency Anemia) Erythropoietin (EPO) synthesis increases in pregnancy due to hypoxia sensed by the kidneys, supporting RBC mass expansion.
• (Iron Deficiency Anemia) Erythroferrone (ERFE) is upregulated by EPO to sequester hepcidin-inducer BMP6, thereby lowering hepcidin and increasing iron flow.
• (Iron Deficiency Anemia) Red cell distribution width (RDW) is high in IDA, reflecting significant anisopoikilocytosis on a peripheral smear.
• (Iron Deficiency Anemia) Bone marrow iron stores (absent) is the most sensitive and specific criterion for iron deficiency erythropoiesis, though bone marrow exam is rarely needed.
• (Iron Deficiency Anemia) Maternal complications of IDA include increased risk of infections, preterm labor, PPROM, postpartum hemorrhage, and increased mortality.
• (Iron Deficiency Anemia) Fetal complications of maternal IDA include low birth weight (LBW), IUGR, and impaired long-term neurodevelopment.
• (Iron Deficiency Anemia) Hydrops fetalis or intrauterine death can result from severe fetal anemia leading to high-output heart failure.

MEGALOBLASTIC AND APLASTIC ANEMIA

• (Megaloblastic Anemia) Folate deficiency is essential for DNA synthesis; deficiency is common in poor nutritional states or users of anticonvulsants.
• (Megaloblastic Anemia) Vitamin B12 deficiency is typically seen in vegetarians, vegans, or patients with malabsorption/GI surgery.
• (Megaloblastic Anemia) Megaloblasts are large RBC precursors caused by impaired nuclear division with relatively normal cytoplasmic maturation (asynchronous maturation).
• (Aplastic Anemia) Aplastic anemia is a grave complication characterized by pancytopenia and a markedly hypocellular bone marrow.
• (Aplastic Anemia) Diamond-Blackfan anemia is a pure red cell hypoplasia that responds well to glucocorticoid therapy but increases risk of preeclampsia and FGR.
• (Aplastic Anemia) Gaucher disease is an autosomal recessive lysosomal deficiency of acid β-glucosidase that causes anemia and thrombocytopenia worsening in pregnancy.
• (Aplastic Anemia) Red cell transfusions in aplastic anemia are indicated to maintain a hematocrit above 20 percent.

HEMOLYTIC ANEMIA AND HEMOGLOBINOPATHIES

• (Hemolytic Anemia) Evans syndrome refers to autoimmune hemolysis comorbid with thrombocytopenia.
• (Hemolytic Anemia) Paroxysmal Nocturnal Hemoglobinuria (PNH) carries a high risk of venous thromboembolism (40% of cases) and is treated with eculizumab.
• (Hemolytic Anemia) G6PD deficiency leads to episodic anemia triggered by drugs (e.g., Macrodantin) or infections; it is an X-linked recessive disorder.
• (Hemoglobinopathies) Sickle-cell crisis is a diagnosis of exclusion in pregnancy and is managed with IV fluids, prompt opioid analgesia, and oxygen.
• (Hemoglobinopathies) Acute chest syndrome in sickle cell patients presents with pleuritic chest pain, fever, and new lung infiltrates; it occurs in ~6% of pregnant women.
• (Hemoglobinopathies) Sickle-cell trait (Hb AS) occurs in ~8% of African Americans and is NOT a deterrent to pregnancy but increases risk for asymptomatic bacteriuria.
• (Hemoglobinopathies) Hemoglobin E is common in Southeast Asia; homozygous state (Hb EE) shows marked microcytosis but little anemia.
• (Thalassemia) Alpha-thalassemia major (Hb Bart disease) involves deletion of all 4 alpha genes and is incompatible with survival, often resulting in hydrops fetalis.
• (Thalassemia) Beta-thalassemia minor is characterized by elevated Hemoglobin A2 (>3.5%) and mild hypochromic microcytic anemia.
• (Polycythemia) Polycythemia vera is a myeloproliferative neoplasm associated with the JAK2 mutation and requires aggressive management with aspirin and LMWH.

PLATELET AND MICROANGIOPATHIC DISORDERS

• (Platelet Disorders) Gestational thrombocytopenia accounts for 75% of thrombocytopenia cases in pregnancy and usually requires no treatment.
• (Thrombotic Microangiopathy) Thrombotic microangiopathy (TMA) is characterized by microangiopathic hemolytic anemia (MAHA), schizocytes on smear, and end-organ damage.
• (TTP) Thrombotic thrombocytopenic purpura (TTP) is confirmed by an ADAMTS13 activity level <10% and is treated primarily with plasmapheresis.
• (TTP) TTP clinical pentad includes thrombocytopenia, hemolytic anemia, fever, neurologic manifestations, and renal injury.
• (HELLP vs TTP) HELLP syndrome is reversed by delivery, whereas delivery does NOT improve thrombotic microangiopathies like TTP.
• (TMA treatment) Eculizumab is the preferred treatment for complement-mediated TMA (aHUS) and PNH.

INHERITED COAGULATION DEFECTS

• (Hemophilia) Hemophilia A and B are X-linked recessive conditions; female carriers usually have ~50% factor activity due to lyonization but can experience bleeding if levels are <20%.
• (Hemophilia) Desmopressin can be used to stimulate factor VIII release in patients with Hemophilia A.
• (von Willebrand Disease) von Willebrand disease (VWD) is the most common inherited bleeding disorder; Type 1 is a partial quantitative deficiency, while Type 3 is a complete deficiency.
• (von Willebrand Disease) VWF levels rise appreciably during normal pregnancy for Type 1, but women with Type 2 or 3 remain at high risk for postpartum hemorrhage (PPH).
• (Thrombophilia) Inherited thrombophilias (e.g., Factor V Leiden, Prothrombin G20210A) increase the risk of venous thromboembolism (VTE) in pregnancy.
• (Thrombophilia) Antithrombin deficiency is considered a high-risk inherited thrombophilia requiring management during pregnancy.

PHILIPPINE CONTEXT AND PUBLIC HEALTH

• (Philippine Health Sector) 8-Point Action Agenda (2023-2028) aims to ensure every Filipino experiences health and well-being through humanistic leadership and good governance.
• (Philippine Diet) Rice dependence and lack of dietary diversity contribute significantly to widespread iron and zinc deficiencies among Filipinos.
• (Public Health Strategy) Biofortification is an effective approach to enrich rice with micronutrients to target vulnerable populations in the Philippines.
• (Hemophilia in PH) Hemophilia prevalence in the Philippines may be 10 times higher than the 1604 cases currently diagnosed based on worldwide estimates.

HIGH-YIELD DIFFERENTIATION AND COMPARISON

• (Comparison: Physiologic vs. Pathologic) Physiologic anemia results from expanded plasma volume (40-50%) exceeding RBC mass increase (20%), whereas iron deficiency anemia is confirmed when Hgb falls below 11 g/dL.
• (Comparison: Sickle Cell SS vs. SC) Hb SS disease has significantly higher maternal mortality (OR 11-23) compared to Hb SC disease, though both increase stillbirth risk.
• (Comparison: TTP vs. HELLP) Transaminitis (High AST/ALT) is characteristic of HELLP syndrome, whereas it is usually absent or mild in TTP.
• (Comparison: TTP vs. HELLP) ADAMTS13 deficiency (&lt10%) is the hallmark of TTP, while it is only mild-to-moderately reduced in HELLP.
• (Comparison: Delivery effect) Delivery reverses the pathology of HELLP and Preeclampsia, but has no effect on the progression of TMA/TTP.
• (Comparison: Thalassemia Types) Alpha-thalassemia is more common in Asian Americans, while Beta-thalassemia is diagnosed by elevated HbA2 levels.
• (Comparison: Hemophilia vs. vWD) Hemophilia is X-linked (mostly males affected), whereas von Willebrand disease is autosomal (affects males and females equally).
• (Comparison: Thalassemia major vs. trait) Alpha-thalassemia major (Hb Bart) leads to hydrops fetalis and stillbirth, while Alpha-thalassemia trait (2 gene deletion) presents as mild microcytic anemia with no major maternal issues.
• (Comparison: Ferritin) Low ferritin (&lt15) is specific for IDA, but Ferritin can be falsely elevated up to 100 in patients with IDA who also have liver disease or infection.
• (Comparison: Thrombophilia risk) Heterozygous Factor V Leiden is a low-risk thrombophilia, while Homozygous Factor V Leiden is a high-risk condition.
• (Comparison: Relative vs. Absolute Polycythemia) Relative polycythemia is caused by volume loss (dehydration/diuretics), while Absolute polycythemia (Polycythemia Vera) involves a JAK2 mutation and increased RBC mass.
• (Comparison: B12 vs. Folate) B12 deficiency is common in vegans/gastric surgery; Folate deficiency is common in malnutrition or anticonvulsant use.
• (Comparison: Spherocytosis vs. G6PD) Hereditary spherocytosis shows increased osmotic fragility; G6PD deficiency shows episodic hemolysis after oxidant triggers (drugs/infection).
• (Comparison: Hemophilia A vs. B) Hemophilia A is a deficiency of Factor VIII; Hemophilia B (Christmas Disease) is a deficiency of Factor IX.
• (Comparison: Schizocytes) Schizocytes are present in all TMAs (TTP, HUS, HELLP), but the severity of fragmentation is most marked in TTP.

QA

text

PHYSIOLOGIC ADAPTATION IN PREGNANCY

1. Under Physiologic Adaptation, what is the pathogenesis of hemodilution? | Plasma volume expansion (40-50%) exceeds red blood cell mass increase (15-25%).
2. What are the clinical manifestations (3) of Physiologic Adaptation? | 1) Physiologic anemia
   2) Decreased blood viscosity
   3) Increased heart rate/stroke volume
3. What are the laboratory findings (2) for Physiologic Adaptation hematocrit? | 1) ~34% (singleton)
   2) ~30% (multifetal)
4. What happens to Maternal hepcidin to augment iron absorption? | Profoundly decreased.
5. Why does Plasma volume expansion result in physiologic anemia? | It disproportionately exceeds red cell mass increase.
6. What is the typical Hematocrit level in a singleton pregnancy? | 34 percent.
7. What is the typical Hematocrit level in a multifetal gestation? | 30 percent.
8. How is Oxygen-carrying capacity affected by physiologic anemia? | Remains normal.
9. Why does Whole blood viscosity decrease during pregnancy? | Decline in hemoglobin and hematocrit.
10. What Hemoglobin concentration at term is considered abnormal/iron deficient? | Values below 11.0 g/dL.
11. When does Maternal blood volume expansion reach a plateau? | Last weeks of pregnancy.
12. What are the Iron requirements in the third trimester? | 7 mg/day. (Compared to 1 mg/day in non-pregnant).
13. What is the Total iron requirement for a healthy normal pregnancy? | Approximately 1000 mg.
14. How much total iron is transferred to the Fetus/Placenta? | 300 mg.
15. By how much is Maternal hepcidin suppressed to facilitate iron absorption? | 10-fold (in second trimester).
16. Which Coagulation factors (4) increase creating a hypercoagulable state? | Factors VII, VIII, IX, and X.
17. What happens to Fibrinogen levels by term? | They double (up to 600+ mg/dL).
18. What happens to Protein S functional activity in the 3rd trimester? | Significantly decreases (to ~16-42%).
19. What are the causes (3) of decreased Platelet counts in pregnancy? | 1) Dilution
    2) Splenic pooling
    3) Pooling in intervillous space.
20. When does Left ventricular mass begin to increase? | 26 to 30 weeks' gestation.
21. When does Arterial blood pressure reach its nadir? | 24 to 26 weeks.

ANEMIA: DIAGNOSIS AND GENERAL CAUSES

22. What is the Hemoglobin threshold for anemia in the 1st trimester? | < 11.0 g/dL.
23. What is the Hemoglobin threshold for anemia in the 2nd trimester? | < 10.5 g/dL.
24. What is the Hemoglobin threshold for anemia in the 3rd trimester? | < 11.0 g/dL.
25. How is Anemia broadly defined? | Decreased blood hemoglobin concentration.
26. What tests (2) are required for Microcytic anemia evaluation? | 1) Serum ferritin
    2) Hemoglobin electrophoresis.
27. What levels (2) are checked for Macrocytic anemia evaluation? | 1) Serum folate
    2) Vitamin B12.
28. When is Oral iron therapy indicated for moderate anemia (Hgb ~7 g/dL)? | Hemodynamically stable, ambulating, and non-septic.
29. What are the laboratory characteristics (4) of Anemia of chronic disease? | 1) High ferritin
    2) Elevated hepcidin
    3) Hypochromic/microcytic
    4) Low transferrin saturation.
30. When is Recombinant erythropoietin considered in renal insufficiency? | Hematocrit approximates 20 percent.

IRON DEFICIENCY ANEMIA (IDA)

31. What is the pathogenesis of Iron Deficiency Anemia (IDA)? | Insufficient iron to meet 1000 mg demand.
32. What are the diagnostic findings (4) for Iron Deficiency Anemia (IDA)? | 1) MCV < 80 fL
    2) Ferritin ≤ 10–15 μg/L
    3) Increased TIBC
    4) Decreased Transferrin Sat.
33. What is the oral treatment dose for Iron Deficiency Anemia (IDA)? | 200 mg elemental iron/day.
34. What is the Most common cause of anemia in pregnancy? | Iron deficiency anemia.
35. What Serum ferritin level specifically confirms iron-deficiency? | Below 10–15 μg/L.
36. Why might Ferritin be as high as 100 ng/mL in IDA? | It acts as an acute phase reactant.
37. Why does Erythropoietin (EPO) synthesis increase in pregnancy? | Renal hypoxia.
38. What is the role of Erythroferrone (ERFE) in iron metabolism? | Lowers hepcidin (via BMP6 sequestration).
39. What does a high Red cell distribution width (RDW) reflect in IDA? | Anisopoikilocytosis.
40. What is the most sensitive/specific criterion for Iron deficiency erythropoiesis? | Absent bone marrow iron stores.
41. What are the maternal complications (5) of Iron Deficiency Anemia? | 1) Infections
    2) Preterm labor
    3) PPROM
    4) Postpartum hemorrhage
    5) Increased mortality.
42. What are the fetal complications (3) of Maternal Iron Deficiency Anemia? | 1) Low birth weight
    2) IUGR
    3) Impaired long-term neurodevelopment.
43. What is the result of severe fetal anemia on the Fetal heart? | High-output heart failure (Hydrops).

MEGALOBLASTIC AND APLASTIC ANEMIA

44. What is the pathogenesis of Megaloblastic Anemia? | Impaired DNA synthesis (Folate/B12 deficiency).
45. What are the hallmark findings (2) of Megaloblastic Anemia? | 1) Megaloblasts in marrow
    2) Hypersegmented neutrophils.
46. What is the treatment for Megaloblastic Anemia? | 5-15 mg oral folic acid with iron.
47. What is the pathogenesis of Aplastic Anemia? | Decline in committed marrow stem cells.
48. What is the clinical hallmark of Aplastic Anemia? | Pancytopenia.
49. What is the management (3) for Aplastic Anemia? | 1) Immunosuppression
    2) Antimicrobials
    3) Bone marrow transplant.
50. Which vitamin deficiency is common in users of Anticonvulsants? | Folate deficiency.
51. Which population is typically affected by Vitamin B12 deficiency? | Vegetarians/Vegans or malabsorption patients.
52. How are Megaloblasts formed? | Impaired nuclear division with normal cytoplasm maturation.
53. What marrow finding characterizes Aplastic anemia? | Markedly hypocellular bone marrow.
54. What are the pregnancy risks associated with Diamond-Blackfan anemia? | Preeclampsia and Fetal Growth Restriction.
55. What is the enzyme deficiency in Gaucher disease? | Acid β-glucosidase.
56. What is the target hematocrit for Red cell transfusions in aplastic anemia? | Above 20 percent.

HEMOLYTIC ANEMIA AND HEMOGLOBINOPATHIES

57. What is the diagnostic finding for Autoimmune Hemolysis? | Positive Direct and Indirect Coombs tests.
58. What is the mutation and risk in Paroxysmal Nocturnal Hemoglobinuria (PNH)? | 1) PIG-A mutation
    2) 40% Thrombosis risk.
59. What is the hallmark lab finding for Hereditary Spherocytosis? | Increased osmotic fragility.
60. What is the protein substitution in Sickle Cell (Hb SS)? | Beta-globin glutamic acid to valine.
61. What hemoglobin markers (2) define Thalassemia types? | 1) Hb Bart (Alpha major)
    2) High HbA2 (Beta minor).
62. What is Evans syndrome? | Autoimmune hemolysis with thrombocytopenia.
63. What drug is used to treat Paroxysmal Nocturnal Hemoglobinuria (PNH)? | Eculizumab.
64. What triggers episodic anemia in G6PD deficiency? | Drugs (e.g., Macrodantin) or infections.
65. What is the management (3) for Sickle-cell crisis in pregnancy? | 1) IV fluids
    2) Opioid analgesia
    3) Oxygen.
66. What are the symptoms (3) of Acute chest syndrome? | 1) Pleuritic chest pain
    2) Fever
    3) New lung infiltrates.
67. What is the primary risk of Sickle-cell trait (Hb AS) in pregnancy? | Asymptomatic bacteriuria.
68. What is the state of anemia in Hemoglobin E homozygotes (Hb EE)? | Marked microcytosis but little anemia.
69. What is the outcome of Alpha-thalassemia major (Hb Bart disease)? | Incompatible with survival (hydrops fetalis).
70. What Hemoglobin A2 level indicates Beta-thalassemia minor? | Greater than 3.5%.
71. What mutation is associated with Polycythemia vera? | JAK2 mutation.

PLATELET AND MICROANGIOPATHIC DISORDERS

72. What is the hallmark of Gestational Thrombocytopenia? | Platelets > 70,000.
73. What deficiency confirms Thrombotic thrombocytopenic purpura (TTP)? | ADAMTS13 activity < 10%.
74. What are the laboratory hallmarks (2) of HELLP? | 1) High AST/ALT
    2) LDH > 600.
75. What causes Complement-mediated TMA (aHUS)? | Complement gene mutations (Auto-FH antibodies).
76. What percentage of pregnancy thrombocytopenia is Gestational thrombocytopenia? | 75 percent.
77. What are the general features (3) of Thrombotic microangiopathy (TMA)? | 1) MAHA
    2) Schizocytes
    3) End-organ damage.
78. What is the primary treatment for Thrombotic thrombocytopenic purpura (TTP)? | Plasmapheresis.
79. Name the components of the TTP clinical pentad (5). | 1) Thrombocytopenia 2) Hemolytic anemia 3) Fever 4) Neuro symptoms 5) Renal injury.
80. Does delivery improve Thrombotic thrombocytopenic purpura (TTP)? | No. (Delivery reverses HELLP).
81. What is the preferred treatment for aHUS and PNH? | Eculizumab.

INHERITED COAGULATION DEFECTS

82. Why can female carriers of Hemophilia A and B experience bleeding? | Factor levels <20% (due to lyonization).
83. What drug stimulates Factor VIII release in Hemophilia A? | Desmopressin.
84. Compare von Willebrand Disease Type 1 vs Type 3. | Type 1: Partial quantitative deficiency
    Type 3: Complete deficiency.
85. Which von Willebrand Disease types have high risk for postpartum hemorrhage? | Type 2 or 3.
86. Give examples (2) of Inherited thrombophilias that increase VTE risk. | 1) Factor V Leiden
    2) Prothrombin G20210A.
87. Why is Antithrombin deficiency significant in pregnancy? | It is a high-risk inherited thrombophilia.

PHILIPPINE CONTEXT AND PUBLIC HEALTH

88. What is the goal of the 8-Point Action Agenda (2023-2028)? | Ensure every Filipino health and well-being.
89. How does the Philippine Diet contribute to iron/zinc deficiency? | Rice dependence and lack of diversity.
90. What is Biofortification? | Enriching rice with micronutrients for vulnerable populations.
91. How does actual Hemophilia prevalence in PH compare to diagnosed cases? | May be 10 times higher than diagnosed.

HIGH-YIELD DIFFERENTIATION AND COMPARISON

92. Contrast Physiologic vs Iron Deficiency Anemia. | Physiologic: Hemodilution
    IDA: Hgb < 11 g/dL with iron lack.
93. Compare Hb SS vs Hb SC disease mortality. | Hb SS: Significantly higher maternal mortality (OR 11-23).
94. Compare TTP vs HELLP liver enzymes. | HELLP: Transaminitis (High AST/ALT)
    TTP: Absent/mild.
95. Compare TTP vs HELLP ADAMTS13 activity. | TTP: <10% activity
    HELLP: Mildly reduced.
96. How does Delivery affect HELLP vs TTP? | Delivery reverses HELLP but has no effect on TTP.
97. How is Beta-thalassemia diagnosed? | Elevated HbA2 levels.
98. Contrast the inheritance of Hemophilia vs von Willebrand Disease. | Hemophilia: X-linked
    vWD: Autosomal.
99. Contrast Alpha-thalassemia major vs trait. | Major: Hydrops fetalis
    Trait: Mild microcytic anemia.
100. When can Ferritin be falsely elevated in IDA? | Liver disease or infection (up to 100 ng/mL).
101. Compare Heterozygous vs Homozygous Factor V Leiden risk. | Heterozygous: Low-risk
     Homozygous: High-risk.
102. Contrast Relative vs Absolute Polycythemia. | Relative: Volume loss
     Absolute: JAK2 mutation/increased RBC mass.
103. Contrast the causes of B12 vs Folate deficiency. | B12: Vegan/Gastric surgery
     Folate: Malnutrition/Anticonvulsants.
104. Contrast Spherocytosis vs G6PD deficiency labs. | Spherocytosis: Osmotic fragility
     G6PD: Episodic (oxidant triggered).
105. Contrast Hemophilia A vs B factor deficiency. | A: Factor VIII
     B: Factor IX.
106. In which condition is Schizocyte fragmentation most marked? | Thrombotic thrombocytopenic purpura (TTP).

8.3 - DM in Pregnancy

Summary

text

DIABETES MELLITUS IN PREGNANCY: OVERVIEW AND COMPARISON

EPIDEMIOLOGY AND RISK FACTORS

• Filipino women are considered a high-risk ethnic group for hyperglycemia in pregnancy, with an estimated prevalence of 6-20% in the Philippines.
• Southeast Asian race is a significant risk factor as this population has the highest global risk for hyperglycemia.
• History of Macrosomia (defined as a birthweight of $\geq$ 9 lbs or 4 kg) is a major risk factor for Gestational Diabetes Mellitus and may indicate undiagnosed GDM in previous pregnancies.
• Advanced Maternal Age (e.g., 36 years old) increases the risk of developing glucose intolerance during pregnancy.
• Obesity (BMI $\geq$ 30 or BMI $\geq$ 25 in Asians) contributes to GDM through central adiposity and the release of leptin and proinflammatory cytokines.
• Polycystic Ovary Syndrome (PCOS) is a pertinent risk factor for GDM due to its underlying insulin resistance.
• History of unexplained stillbirths or abortions is a clinical indicator for screening, as increased sugar can cause a lack of oxygen and sudden cessation of the fetal heartbeat.
• Persistent glycosuria (measured as +3 or +4 glucose in urine) warrants immediate investigation for diabetes in pregnancy.
• Strong family history of diabetes is a critical factor; if a direct relative has DM, the chance of the patient developing it is significantly high.

MATERNAL AND FETAL PATHOPHYSIOLOGY

• Pregnancy-related hormones (Progesterone, Placentally derived Growth Hormone, Prolactin, Cortisol) are elevated in the 2nd trimester and naturally increase insulin resistance to maintain fetal growth.
• Maternal metabolic adaptations to pregnancy include fasting hypoglycemia, postprandial hyperglycemia, and hyperinsulinemia.
• Proinflammatory cytokines (TNF-alpha, IL-6, IGF-1) evoke insulin resistance during pregnancy, contributing to the pathogenesis of GDM.
• Maternal hyperglycemia leads to the transfer of excess glucose to the fetus, which stimulates the fetal pancreas to secrete its own insulin.
• Fetal hyperinsulinemia acts as a growth hormone, promoting fat deposition and excessive anabolism, leading to Fetal Macrosomia.
• Aerobic metabolism of glucose consumes oxygen; extreme maternal hyperglycemia can lead to fetal hypoxemia because the baby uses excessive oxygen to process high glucose levels.
• Placental development is usually fully established by the 24-28th week, which is why screening is most effective at this interval to detect placentally-derived glucose elevation.

SCREENING AND DIAGNOSTIC CRITERIA (IADPSG)

• Universal screening for GDM is recommended for all pregnant women, regardless of risk, because the Filipino race itself is a high-risk factor.
• First prenatal visit screening aims to categorize patients: FBS $\leq$ 92 mg% is normal, 92-125 mg% is GDM, and $\geq$ 126 mg% is overt DM.
• Low-risk patients should undergo a 75-g OGTT at 24-28 weeks gestation.
• High-risk patients (obese, family history) should receive an immediate 75-g OGTT at the first visit, even if the initial FBS is normal.
• 75-g OGTT Procedure (IADPSG) requires 6-8 hours of fasting, blood collection at baseline, 1 hour, and 2 hours after drinking the glucose solution.
• IADPSG Diagnostic Thresholds for GDM (75-g OGTT) require only ONE value to be met or exceeded:
  1. Fasting Blood Sugar (FBS) $\geq$ 92 mg/dL
  2. 1-hour postprandial $\geq$ 180 mg/dL
  3. 2-hour postprandial $\geq$ 153 mg/dL
• Overt Diabetes in pregnancy is diagnosed if any of the following are met: FBS $\geq$ 126 mg/dL, HbA1c $\geq$ 6.5%, or Random Plasma Glucose $\geq$ 200 mg/dL.
• 75-g OGTT at 32 weeks should be repeated if signs of DM appear, such as polyhydramnios, macrosomia, polyphagia, polydipsia, or polyuria.

MANAGEMENT AND GLYCOSE TARGETS

• Medical Nutrition Therapy (MNT) is the first-line management for 2 weeks; it was formerly known as Diet Restriction Management.
• Pinggang Pinoy and small, frequent meals are encouraged to decrease the incidence of glucose spikes.
• MNT Dietary Composition (ACOG) suggests 33–40% carbohydrates, ~20% protein, and ~40% fat. Note that low carbohydrate intake may lead to IUGR.
• Insulin is the "Gold Standard" for pharmacological management and is initiated if target glucose levels are not achieved through MNT and exercise.
• Insulin safety in pregnancy is high because it does NOT cross the placenta.
• Self-Monitored Capillary Blood Glucose (CBG) Targets:
  • Fasting $\leq$ 95 mg/dL
  • 1-hour postprandial $\leq$ 140 mg/dL
  • 2-hour postprandial $\leq$ 120 mg/dL
• Metformin is considered a second-line option for pharmacological management in selected cases.
• Folic Acid supplementation should be 5 mg/day (lecturer) or 400 $\mu$g/day (book) given periconceptionally to reduce the risk of neural tube defects.
• Weight Gain Guidelines are based on BMI: Obese (BMI $\ge$ 30) should only gain 5-9 kg total (0.21 kg/week in 2nd/3rd trimesters).

ANTENATAL SURVEILLANCE AND COMPLICATIONS

• Congenital Heart Defects are the most common congenital anomaly affected by high maternal blood sugar before conception.
• Congenital Anomaly Scan (CAS) with fetal ECHO is specifically indicated at 20-24 weeks for diabetic pregnancies to monitor for cardiac and CNS anomalies.
• Fetal Kick Counting should begin at 26-28 weeks every night; a normal count is 10 movements in 2 hours.
• Biophysical Profile (BPS) should be performed every 2 weeks starting at 28-37 weeks, increasing to twice a week if the patient is on insulin.
• Aspirin (60-150 mg/day) is given from 12-16 weeks until delivery as prophylaxis for preeclampsia.
• Shoulder Dystocia and birth trauma (e.g., Clavicular fracture) are major labor complications due to fetal macrosomia and enlargement of the fetal trunk.
• Respiratory Distress Syndrome (RDS) in neonates occurs because elevated sugar levels delay the formation of lung surfactant.
• Neonatal metabolic complications include hypoglycemia, hypocalcemia, and hypomagnesemia.
• Neonatal polycythemia (increased hematocrit) is caused by hyperglycemia-induced increases in blood cell formation.
• Hydramnios / Polyhydramnios is caused by hyperglycemia increasing osmolality, which leads to a transfer of fluids and increased amniotic fluid.

DELIVERY AND POSTNATAL CARE

• Timing of delivery for well-controlled GDM is usually planned at 39 to 39 6/7 weeks.
• Timing of delivery for insulin-treated GDM is recommended at 38-39 weeks.
• Poorly controlled GDM requires earlier delivery at 37-38 weeks.
• Elective Cesarean Section should be considered if the estimated fetal weight is $\geq$ 4500 g to prevent brachial plexus injury.
• Postpartum glucose metabolism assessment involves a repeat 75-g, 2-hr OGTT at 6-12 weeks after delivery.
• Postpartum classification uses non-pregnant thresholds: DM if FBS $\geq$ 126 mg/dL or 2-hr $\geq$ 200 mg/dL.
• GDM recurrence risk is significant, with a 50-75% likelihood of developing Type 2 DM within 15-25 years.

DIFFERENTIATING SIMILAR ENTITIES IN EXAMS

1. GDM vs. Overt DM (AOG): GDM is recognized later in pregnancy (typically after 20 weeks/2nd trimester), while Overt DM is discovered in the 1st trimester (before 20 weeks).
2. GDM vs. Overt DM (FBS criteria): Overt DM requires an FBS $\geq$ 126 mg/dL; GDM is diagnosed with an FBS between 92-125 mg/dL.
3. IADPSG vs. ADA Screening: IADPSG requires only ONE abnormal value on the 75-g OGTT, whereas ADA criteria traditionally require TWO abnormal values.
4. GDM FBS vs. Non-pregnant FBS: The cutoff for fasting glucose in pregnancy is lower ($\geq$ 92 mg/dL) compared to the non-pregnant cutoff ($\geq$ 100 mg/dL/126 mg/dL).
5. Macrosomia vs. LGA: Macrosomia usually refers to an absolute birth weight (e.g., >4000g), while Large for Gestational Age (LGA) refers to a weight above the 90th percentile for a specific AOG.
6. Fetal Kick Counting (Normal vs. Abnormal): 10 movements within 2 hours is normal; fewer movements require further biophysical evaluation.
7. Insulin vs. Glucose Placental Transfer: Glucose crosses the placenta easily (facilitated diffusion), causing fetal hyperglycemia; Insulin does NOT cross the placenta.
8. Maternal Hypoglycemia vs. Neonatal Hypoglycemia: Maternal hypoglycemia occurs due to the continuous glucose draw by the fetus; Neonatal hypoglycemia occurs post-delivery because the baby still has high insulin levels but the maternal glucose supply is cut off.
9. Insulin Regimens (Parkland vs. UAB): Parkland uses a split-dose mix (Breakfast: 2/3 total dose; Dinner: 1/3 total dose), while UAB uses a Basal-Bolus approach (50% long-acting at bedtime; 50% split rapid-acting before meals).
10. Hypertension in Pregnancy Types: Pregnancy-induced hypertension and preeclampsia are both associated with GDM due to shared vascular damage mechanisms.
11. Polyhydramnios vs. Polyphagia: Polyhydramnios is an objective sign of excess amniotic fluid; Polyphagia is a subjective symptom of excessive hunger.
12. Postpartum screening timing: Persistent overt diabetes is checked at 1-3 days post-delivery; GDM re-classification is performed at 6-12 weeks postpartum.
13. CAS vs. Fetal ECHO: The Congenital Anomaly Scan (CAS) is a general head-to-toe survey; the Fetal ECHO is a specialized view looking specifically for cardiac defects (the #1 anomaly).
14. MODY 1-6 (Obese vs. Autosomal Dominant): One form of Maturity-Onset Diabetes of the Young is common in obese adolescents, while the other is a rare autosomal dominant condition in thin young adults.
15. Glycolysis vs. Hypoxemia: Excessive glucose metabolism (Glycolysis) in the fetus consumes oxygen; if disproportionate, it leads to fetal hypoxemia and potential stillbirth.

QA

text

DIABETES MELLITUS IN PREGNANCY: OVERVIEW AND COMPARISON

1. What is the pathogenesis of Type 1 Diabetes? | Pancreatic $\beta$-cell destruction
   Leading to absolute insulin deficiency.
2. What is the pathogenesis of Type 2 Diabetes? | Insulin resistance
   Ranges from resistance to secretory defect with resistance.
3. What is the pathogenesis of Gestational Diabetes (GDM)? | Pregnancy-induced insulin resistance
   Accompanied by inadequate $\beta$-cell compensation.
4. What is the pathogenesis of Overt Diabetes? | Pre-existing Type 2 DM
   Likely undocumented before pregnancy.
5. When is the typical onset of Type 1 Diabetes? | Before age 30
   Usually clinically apparent.
6. What lifestyle factors relate to the onset of Type 2 Diabetes? | Lifestyle, obesity, heredofamilial factors.
7. When is Gestational Diabetes (GDM) typically recognized? | 24-28 weeks
   Onset or first recognition during pregnancy.
8. When is Overt Diabetes discovered during pregnancy? | 1st trimester
   Discovered for the 1st time during pregnancy.
9. When is typical screening performed for Type 1 Diabetes? | Before reproductive age
   Identified early in life.
10. When is Type 2 Diabetes identified relative to pregnancy? | Before or early pregnancy.
11. What is the universal screening interval for Gestational Diabetes (GDM)? | 24-28 weeks
    Can be earlier if patient is high risk.
12. How is Overt Diabetes screened at the first prenatal visit? | Fasting Blood Sugar (FBS).
13. What diagnosis criteria are used for Type 1 and Type 2 Diabetes? | Standard non-pregnant criteria.
14. What are the IADPSG 75-g OGTT diagnostic values for Gestational Diabetes (GDM)? (3) | FBS $\geq$ 92, 1h $\geq$ 180, 2h $\geq$ 153.
15. What are the diagnosis criteria for Overt Diabetes? (3) | FBS $\geq$ 126, HbA1c $\geq$ 6.5%, RPG $\geq$ 200.
16. What is the management requirement for Type 1 Diabetes? | Insulin always required.
17. What is the initial management for Type 2 Diabetes? | Medical Nutrition Therapy (MNT).
18. How long is the trial of MNT for Gestational Diabetes (GDM)? | 2 weeks
    Insulin is added if uncontrolled.
19. What is the immediate pharmacological management for Overt Diabetes? | Insulin or Metformin.

EPIDEMIOLOGY AND RISK FACTORS

20. What is the GDM prevalence for Filipino women? | 6-20%
    Filipinos are considered a high-risk ethnic group.
21. Which global population has the highest risk for hyperglycemia? | Southeast Asian race.
22. How is History of Macrosomia defined by birthweight? | $\geq$ 9 lbs or 4 kg.
23. What may a History of Macrosomia indicate? | Undiagnosed GDM
    Refers to previous pregnancies.
24. At what age is Advanced Maternal Age a risk factor for glucose intolerance? | 36 years old.
25. How does Obesity contribute to GDM pathologically? | Central adiposity
    Release of leptin and proinflammatory cytokines.
26. What is the BMI cutoff for Obesity in Asians? | BMI $\geq$ 25.
27. Why is Polycystic Ovary Syndrome (PCOS) a risk factor for GDM? | Underlying insulin resistance.
28. In unexplained stillbirths, what causes sudden cessation of fetal heartbeat? | Lack of oxygen
    Caused by increased sugar levels.
29. What level of Persistent glycosuria warrants immediate investigation? | +3 or +4 glucose
    Measured in urine.
30. How does Strong family history affect DM risk? | Significantly high risk
    Applies if a direct relative has Diabetes Mellitus.

MATERNAL AND FETAL PATHOPHYSIOLOGY

31. Name the Pregnancy-related hormones that increase insulin resistance. (4) | Progesterone, Growth Hormone, Prolactin, Cortisol.
32. When do Pregnancy-related hormones peak to maintain fetal growth? | 2nd trimester.
33. List the Maternal metabolic adaptations to pregnancy. (3) | Fasting hypoglycemia, postprandial hyperglycemia, hyperinsulinemia.
34. Name the Proinflammatory cytokines that evoke insulin resistance. (3) | TNF-alpha, IL-6, IGF-1.
35. How does Maternal hyperglycemia affect the fetal pancreas? | Stimulates insulin secretion
    Due to transfer of excess glucose to the fetus.
36. What is the role of Fetal hyperinsulinemia in macrosomia? | Growth hormone
    Promotes fat deposition and excessive anabolism.
37. How does Aerobic metabolism of glucose lead to fetal hypoxemia? | Consumes oxygen
    Baby uses excessive oxygen to process high glucose.
38. Why is GDM screening most effective at 24-28 weeks? | Placental development established
    Placentally-derived glucose elevation is detectable.

SCREENING AND DIAGNOSTIC CRITERIA (IADPSG)

39. Why is Universal screening recommended for all Filipina women? | High-risk ethnic group.
40. Under First prenatal visit screening, what FBS is considered normal? | $\leq$ 92 mg%.
41. Under First prenatal visit screening, what FBS indicates GDM? | 92-125 mg%.
42. Under First prenatal visit screening, what FBS indicates overt DM? | $\geq$ 126 mg%.
43. When should Low-risk patients undergo OGTT? | 24-28 weeks gestation.
44. When should High-risk patients receive a 75-g OGTT? | First prenatal visit
    Even if the initial FBS is normal.
45. What is the fasting requirement for the 75-g OGTT Procedure? | 6-8 hours.
46. When is blood collected during a 75-g OGTT? (3) | Baseline, 1 hour, 2 hours.
47. How many abnormal values are needed for GDM diagnosis under IADPSG Thresholds? | One value.
48. What is the IADPSG Fasting Blood Sugar threshold for GDM? | $\geq$ 92 mg/dL.
49. What is the IADPSG 1-hour postprandial threshold for GDM? | $\geq$ 180 mg/dL.
50. What is the IADPSG 2-hour postprandial threshold for GDM? | $\geq$ 153 mg/dL.
51. What HbA1c level diagnoses Overt Diabetes in pregnancy? | $\geq$ 6.5%.
52. What Random Plasma Glucose diagnoses Overt Diabetes? | $\geq$ 200 mg/dL.
53. When should 75-g OGTT be repeated if signs like polyhydramnios appear? | 32 weeks gestation.
54. List symptoms that warrant a repeat OGTT at 32 weeks. (5) | Polyhydramnios, macrosomia, polyphagia, polydipsia, polyuria.

MANAGEMENT AND GLUCOSE TARGETS

55. What is the first-line management for GDM for 2 weeks? | Medical Nutrition Therapy (MNT).
56. What dietary model is encouraged for GDM? | Pinggang Pinoy
    Small, frequent meals decrease glucose spikes.
57. In MNT Dietary Composition, what is the recommended carbohydrate %? | 33–40%.
58. In MNT Dietary Composition, what are the protein and fat %? | Protein ~20%; Fat ~40%.
59. What may result from very low carbohydrate intake in GDM management? | intrauterine growth restriction (IUGR).
60. What is the "Gold Standard" for GDM pharmacological management? | Insulin.
61. Why is Insulin safety high in pregnancy? | Does NOT cross placenta.
62. What is the CBG Target for Fasting? | $\leq$ 95 mg/dL.
63. What is the CBG Target for 1-hour postprandial? | $\leq$ 140 mg/dL.
64. What is the CBG Target for 2-hour postprandial? | $\leq$ 120 mg/dL.
65. What is the second-line pharmacological option for GDM? | Metformin.
66. What dose of Folic Acid is recommended by the lecturer? | 5 mg/day.
67. What dose of Folic Acid is recommended by the book? | 400 $\mu$g/day.
68. What is the total weight gain guideline for Obese patients (BMI $\ge$ 30)? | 5-9 kg total.
69. What is the weekly weight gain for Obese patients in the 2nd/3rd trimesters? | 0.21 kg/week.

ANTENATAL SURVEILLANCE AND COMPLICATIONS

70. What are the most common congenital anomalies in Diabetic pregnancies? | Congenital Heart Defects.
71. When is a CAS with fetal ECHO indicated for diabetic pregnancies? | 20-24 weeks.
72. When should Fetal Kick Counting begin? | 26-28 weeks.
73. What is a normal Fetal Kick Count? | 10 movements in 2 hours.
74. How often is a Biophysical Profile (BPS) performed for general GDM? | Every 2 weeks
    Starting at 28-37 weeks.
75. How often is BPS performed if the patient is on insulin? | Twice a week.
76. What is the dose and timing for Aspirin prophylaxis? | 60-150 mg/day
    12-16 weeks until delivery.
77. Aspirin is used as prophylaxis for which condition? | Preeclampsia.
78. List common labor complications of Fetal Macrosomia. (2) | Shoulder Dystocia, Clavicular fracture.
79. Why does RDS occur in neonates of diabetic mothers? | Delayed lung surfactant formation
    Caused by elevated sugar levels.
80. List the Neonatal metabolic complications. (3) | Hypoglycemia, hypocalcemia, hypomagnesemia.
81. What causes Neonatal polycythemia in GDM? | Hyperglycemia-induced blood cell formation
    Results in increased hematocrit.
82. What causes Hydramnios in diabetic pregnancies? | Hyperglycemia increasing osmolality
    Leads to fluid transfer and increased amniotic fluid.

DELIVERY AND POSTNATAL CARE

83. What is the delivery timing for well-controlled GDM? | 39 to 39 6/7 weeks.
84. What is the delivery timing for insulin-treated GDM? | 38-39 weeks.
85. What is the delivery timing for poorly controlled GDM? | 37-38 weeks.
86. At what fetal weight is Elective Cesarean Section considered? | $\geq$ 4500 g.
87. Why is Elective C-section done for macrosomia? | Prevent brachial plexus injury.
88. When is Postpartum glucose assessment performed? | 6-12 weeks after delivery
    Uses a repeat 75-g, 2-hr OGTT.
89. What 2-hr OGTT value defines Postpartum DM? | $\geq$ 200 mg/dL.
90. What is the long-term risk of GDM recurrence as Type 2 DM? | 50-75% likelihood
    Within 15-25 years.

DIFFERENTIATING SIMILAR ENTITIES

91. Compare GDM vs. Overt DM by typical AOG. | GDM: after 20 weeks.
    Overt DM: before 20 weeks (1st trimester).
92. Compare GDM vs. Overt DM by FBS diagnosis. | GDM: 92-125 mg/dL.
    Overt DM: $\geq$ 126 mg/dL.
93. Compare IADPSG vs. ADA OGTT requirements. | IADPSG: One abnormal value.
    ADA: Two abnormal values.
94. Compare Pregnant vs. Non-pregnant Fasting cutoffs. | Pregnancy: $\geq$ 92 mg/dL.
    Non-pregnant: $\geq$ 100/126 mg/dL.
95. Compare Macrosomia vs. LGA. | Macrosomia: Absolute weight (>4000g).
    LGA: >90th percentile for AOG.
96. Compare Normal vs. Abnormal Kick Count. | Normal: 10 movements in 2 hours.
    Abnormal: Fewer movements.
97. Compare Insulin vs. Glucose placental transfer. | Glucose: Crosses (facilitated diffusion).
    Insulin: Does NOT cross.
98. What causes Neonatal hypoglycemia post-delivery? | High fetal insulin levels
    Maternal glucose supply is suddenly cut off.
99. Contrast Parkland vs. UAB insulin regimens. | Parkland: Split-dose mix (2/3 AM, 1/3 PM).
    UAB: Basal-Bolus approach.
100. Why is Hypertension associated with GDM? | Shared vascular damage mechanisms.
101. Define Polyhydramnios vs. Polyphagia. | Polyhydramnios: Excess amniotic fluid.
     Polyphagia: Excessive hunger.
102. Compare Postpartum screening timing for overt DM vs. GDM. | Overt DM: 1-3 days.
     GDM re-classification: 6-12 weeks.
103. Define CAS vs. Fetal ECHO scope. | CAS: General survey.
     Fetal ECHO: Cardiac specific (anomaly #1).
104. Contrast the two presentations of MODY. | Type 1: Obese adolescents.
     Type 2: Rare autosomal dominant in thin adults.
105. How does excessive Glycolysis lead to stillbirth? | Consumption of oxygen
     Leads to fetal hypoxemia.

8.4 - Endocrine Disorders

Summary

text

SYSTEMATIC SUMMARY OF ENDOCRINE DISORDERS IN PREGNANCY

ENDOCRINE PHYSIOLOGY BULLET POINTS

• Maternal endocrine physiology is constantly changed across pregnancy, partially due to the development of the maternal-fetal unit in the placenta which acts as a temporary gland.
• First trimester hCG acts as a strong stimulator for TSH receptors, resulting in increased thyroid function and a mirroring decrease in TSH levels.
• Gestational thyrotoxicosis is the clinical condition where TSH is decreased because of high hCG levels; TSH typically increases back to normal after 12 weeks as hCG decreases.
• Total thyroxine (T4) increases early in pregnancy due to increased liver synthesis of thyroxin-binding globulin (TBG) stimulated by high placental estradiol.
• Free thyroxine (fT4) should be maintained at the upper limit of the nonpregnant reference range to be considered normal for healthy pregnant women.
• Maternal thyroid hormones pass through the placenta in small amounts as early as 6 weeks and are critical for embryogenesis and fetal brain development.
• Biologically inactive rT3 is produced by type III deiodinase in the placenta, which inactivates maternal T4; this activity increases in the second half of pregnancy.
• Maternal Thyrotropin-releasing hormone (TRH) can cross the placenta and is also synthesized by the placenta to stimulate fetal pituitary thyroid function.
• Maternal TSH does not cross the placenta and has no direct effect on the fetus.
• Fetal thyroid gland starts functioning after 12 weeks of gestation but remains dependent on maternal thyroxine for 30% of its needs at term.
• Thyroxine-binding globulin (TBG) levels are affected by maternal nutrition; TBG binds fT4, decreasing its bioavailability.
• The Pituitary Gland is considered the "Master Gland," while the thyroid is the central gland in metabolic regulation.
• Regulatory positive feedback in the HPO axis occurs when a mid-cycle surge in estrogen stimulates LH release, triggering ovulation.

HYPERTHYROIDISM AND THYROID STORM

• Most common cause of thyrotoxicosis in pregnancy is Graves' Disease, an autoimmune disorder featuring TSH-receptor antibodies.
• Clinical hyperthyroidism diagnosis is suggested by excessive tachycardia, thyromegaly, exophthalmos, and weight loss despite adequate intake.
• Adverse pregnancy outcomes linked to poorly controlled hyperthyroidism include miscarriage, preterm birth, preeclampsia, and heart failure.
• Offspring of hyperthyroid mothers face higher risks of epilepsy and autism spectrum disorders.
• Growth restriction occurs in hypermetabolic mothers because the mother consumes massive energy for her own metabolic processes, leaving insufficient nutrients/oxygen for the fetus.
• Fetal goiter can occur even if the mother is euthyroid because testing only captures maternal levels and not fetal thyroid status.
• Subclinical hyperthyroidism is characterized by low TSH and normal T4; it generally requires no antithyroid treatment due to potential fetal risks.
• Rare but life-threatening Thyroid Storm is a hypermetabolic state that can lead to pulmonary hypertension and heart failure (cardiomyopathy).
• Propylthiouracil (PTU) is the preferred thionamide for the first trimester because it has less placental transfer and inhibits T4 to T3 conversion, despite the FDA warning for hepatotoxicity.
• Methimazole (MMI) is preferred after 16 weeks of gestation; its use in the first trimester is avoided due to rare embryopathy like aplasia cutis or choanal atresia.
• Switching from PTU to MMI is done at a 20:1 dose ratio.
• Thyroidectomy in pregnancy is only recommended in the 2nd trimester if medical therapy is toxic or fails (e.g., doses >450mg/day PTU).
• Radioactive iodine (RAI) is strictly contraindicated in pregnancy as it can destroy the fetal thyroid gland.
• Management of thyroid storm (Parkland Hospital protocol) involves loading PTU (1000 mg), followed by iodine (e.g., Sodium iodide/Lugol's) after 1-2 hours, and potential dexamethasone.
• Gestational Transient Thyrotoxicosis (GTT) is caused by hCG stimulating TSH receptors; it requires no antithyroid drug treatment and normalizes by mid-pregnancy.
• Molar pregnancy causes T4 elevation in 25-65% of cases because the excess hCG overstimulates TSH receptors; normalization follows molar evacuation.

HYPOTHYROIDISM AND IODINE

• Hashimoto thyroiditis is the most common cause of hypothyroidism in pregnancy, evidenced by anti-TPO antibodies.
• Overt hypothyroidism is confirmed by an abnormally high TSH and an abnormally low T4.
• Severe maternal hypothyroidism is associated with infertility, higher miscarriage rates, and a twofold greater risk of severe preeclampsia.
• Metabolic syndrome is found in 36% of adult Filipinos with hypothyroidism, significantly increasing the presence of DM and hypertension.
• Levothyroxine dosing for overt hypothyroidism is 1-2μg/kg/d (approx 100μg/day), with higher requirements starting as early as 5 weeks' gestation.
• Monitoring of TSH during hypothyroidism treatment should occur every 4 weeks in the first half of pregnancy and at least once in the third trimester.
• Isolated maternal hypothyroxemia features normal TSH but low free T4; current guidelines recommend against routine treatment.
• Euthyroid autoimmune thyroid disease (positive anti-TPO with normal TSH/T4) is associated with a 2-5x increased risk of early pregnancy loss and preterm birth.
• Iodine requirements are higher in pregnancy (220-250 μg/day) due to increased thyroid hormone production, renal losses, and fetal needs.
• Severe iodine deficiency is associated with endemic cretinism; the ATA advises against exceeding 500 μg/day (twice the recommended intake).
• Early thyroxine replacement is critical for newborns with Congenital Hypothyroidism to prevent neurological damage.

THYROIDITIS, NODULES, AND CANCER

• Postpartum thyroiditis occurs in 5-10% of women within the first year after childbirth; it presents initially as a thyrotoxic phase followed by a hypothyroid phase.
• Thyrotoxic phase of postpartum thyroiditis (1-4 months PP) is caused by hormone release from glandular disruption and is treated with beta-blockers if symptoms are severe.
• Hypothyroid phase of postpartum thyroiditis (4-8 months PP) is more symptomatic and requires levothyroxine (25-75 μg/day) for 6-12 months.
• Palpable thyroid nodules found in pregnancy require Fine-needle aspiration (FNA) under ultrasound guidance as pregnancy does not affect cytological diagnosis.
• Solitary thyroid nodules are 90-95% benign; biopsy is recommended for nodules >5 mm persistent at 3 months post-delivery.
• Surgery for thyroid cancer is deferred until postpartum if the cancer is non-aggressive or diagnosed in the third trimester; surgery is performed in the 1st/2nd trimester for aggressive cases.
• Papillary thyroid cancer is the most common thyroid cancer; it is usually slow-growing and non-invasive.

PARATHYROID DISORDERS

• Calcium homeostasis during pregnancy is maintained by Parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D (calcitriol).
• Elemental calcium requirement is 1.5-2 g daily from the 20th week of gestation until the end of pregnancy (WHO).
• Primary hyperparathyroidism (PHPT) is mostly caused by a single parathyroid adenoma; in the Philippines, it is predominantly diagnosed when overtly symptomatic.
• Hypercalcemic crisis (Ca >14 mg/dL) is a postpartum risk of hyperparathyroidism characterized by nausea, vomiting, and mental status changes.
• Maternal hyperparathyroidism suppresses the fetal parathyroid gland, leading to a 15-25% incidence of severe neonatal hypocalcemia/tetany after birth.
• Surgical removal of a symptomatic parathyroid adenoma is the preferred treatment, ideally performed in the 2nd trimester.
• Emergency treatment for severe hypercalcemia involves IV normal saline diuresis, furosemide, and calcitonin to decrease skeletal calcium release.
• Hypoparathyroidism symptoms include neuromuscular manifestations like numbness, tingling, and muscle cramps.

ADRENAL AND DISORDERS

• Cushing's syndrome symptoms like hypertension and DM overlap with pregnancy findings, making late detection common.
• Active Cushing's syndrome carries a 66% risk of preterm birth and a 52% risk of cesarean delivery.
• Adrenalectomy surgery remains the definitive cure for Cushing's syndrome caused by an adrenal adenoma.
• Addison disease (Adrenal Insufficiency) requires increased corticosteroid replacement (stress doses) during labor and delivery to match the normal adrenal response.

PITUITARY DISORDERS

• Pituitary gland enlarges by approximately one-third during normal pregnancy due to estrogen-induced lactotrophic hyperplasia.
• Sheehan syndrome is postpartum pituitary necrosis caused by severe hemorrhage/hypovolemic shock; the earliest sign is failure of lactation.
• Prolactinoma is the most common pituitary tumor in women of childbearing age; complications include amenorrhea, galactorrhea, and visual field defects.
• Microadenomas (pituitary) are ≤10 mm, while Macroadenomas are >10 mm.
• Visual field testing (bitemporal hemianopia) is used to detect tumor expansion impinging on the optic chiasm.
• Bromocriptine is a dopamine-receptor agonist used to restore ovulation in hyperprolactinemic women and to treat symptomatic tumor enlargement during pregnancy.
• MRI imaging is considered safe for pregnant women needing visualization of pituitary tumors.
• Acromegaly diagnosis is confirmed by elevated IGF-1 and lack of GH suppression after a glucose load (GH <1 ug/L is normal).
• Octreotide and pegvisomant are somatostatin and GH analogues used to treat pregnant women with acromegaly.
• Lymphocytic hypophysitis is a rare autoimmune pituitary disorder that presents close to delivery with headaches and visual disturbances.
• Desmopressin (dDAVP) is the standard treatment for Central Diabetes Insipidus and is considered safe for the fetus and lactating mothers.
• Water deprivation test is used to differentiate DI types; nothing by mouth is advised during the test, with hourly measurement of urine tests/body weight.

COMPARISON AND DIFFERENTIATION FOR EXAMS

• PTU vs. Methimazole: PTU is used in the 1st trimester due to lower placental transfer but has hepatotoxicity risk; MMI is used in 2nd/3rd trimester due to higher potency but is avoided in the 1st trimester due to aplasia cutis risk.
• TRH vs. TSH: TRH is produced in the placenta and crosses to the fetus; TSH does not cross the placenta.
• Thyroid Storm vs. Hyperemesis Gravidarum: Both feature tachycardia and vomiting, but Thyroid Storm is a life-threatening hypermetabolic state with decompensation (heart failure), while HG is often transient and TSH/T4 normalize by mid-pregnancy.
• Graves' Disease vs. Gestational Thyrotoxicosis (GTT): Graves' usually has a pre-pregnancy history, thyromegaly, or exophthalmos and requires thionamides; GTT is transient, hCG-mediated, requires no antithyroid medications, and improves after 12 weeks.
• Overt Hypothyroidism vs. Subclinical Hypothyroidism: Overt has high TSH and low fT4 and must be treated with levothyroxine (100μg); Subclinical has high TSH but normal fT4 and is treated selectively (e.g., if antibodies present or TSH >10).
• Central vs. Nephrogenic DI: Central DI responds to Desmopressin (dDAVP) with increased urine osmolality; Nephrogenic DI is resistant to Desmopressin and involves the renal tubules.
• Diabetes Insipidus vs. Primary Polydipsia: Both feature polyuria/polydipsia, but primary polydipsia is psychogenic and shows a higher response in urine osmolality during Desmopressin testing compared to organic DI.
• Sheehan Syndrome vs. Prolactinoma: Sheehan syndrome presents with lactation failure and breast atrophy (low prolactin); Prolactinoma features galactorrhea and secondary amenorrhea (high prolactin).
• Cushing's Syndrome vs. Normal Pregnancy: Both feature weight gain and striae; however, Cushing's is distinguished by more severe hypertension, hyperglycemia, and suppressed ACTH with high UFC.
• Cushing's Syndrome: Pregnant vs. Non-pregnant: In pregnancy, it is mostly an adrenal adenoma; in non-pregnant adults, 60% is caused by ACTH-dependent pituitary-dependent adrenal hyperplasia.
• Neonatal Hyperparathyroidism vs. Hypoparathyroidism: Maternal hyperparathyroidism suppresses the fetal gland, leading to transient neonatal hypoparathyroidism (severe hypocalcemia) after birth.
• Bitemporal Hemianopia vs. Normal Vision: A patient with bitemporal hemianopia (seen in pituitary tumors) can see the medial/central portion but has lost peripheral vision.
• dDAVP vs. Insulin: dDAVP is safe for the fetus in DI treatment; insulin for DM is also safe but requires closer management for maternal-fetal metabolic side effects.
• Prolactinoma: Micro vs. Macro: Microadenomas are ≤10mm and rarely enlarge symptomatically in pregnancy (2.4%); Macroadenomas are >10mm and have a 21% risk of symptomatic enlargement.
• Postpartum Thyroiditis Phases: The Thyrotoxic phase occurs 1-4 months PP (treated with Beta-blockers); the Hypothyroid phase occurs 4-8 months PP (treated with Levothyroxine).
• TSH-hCG mirroring: In early pregnancy, as hCG rises (peaks at 12 wks), TSH falls; as hCG falls after 12 wks, TSH rises back to baseline.

QA

SYSTEMATIC SUMMARY - THYROID DISORDERS

1. What is the pathogenesis of Hyperthyroidism (Graves')? | TSH-receptor antibodies.
   Stimulate the thyroid; worsened by hCG in the 1st trimester.
2. What is the pathogenesis of Hypothyroidism (Hashimoto's)? | Anti-TPO antibodies.
   Causes autoimmune glandular destruction.
3. What are the diagnostic laboratory findings for Hyperthyroidism (Graves')? | Suppressed TSH, elevated fT4.
4. What are the diagnostic laboratory findings for Hypothyroidism (Hashimoto's)? | Elevated TSH, low fT4.
5. What are the high-yield clinical findings (4) for Hyperthyroidism (Graves')? | 1) Exophthalmos
   2) Thyromegaly
   3) Weight gain failure
   4) Tachycardia
6. Why is Hypothyroidism (Hashimoto's) difficult to diagnose clinically in pregnancy? | Symptom overlap.
   Fatigue and weight gain are common in normal pregnancy.
7. What are the maternal risks (3) of Hyperthyroidism (Graves')? | 1) Preeclampsia
   2) Heart failure
   3) Thyroid storm
8. What are the maternal risks (3) of Hypothyroidism (Hashimoto's)? | 1) Preeclampsia
   2) Placental abruption
   3) Cardiac dysfunction
9. What are the fetal risks (4) of Hyperthyroidism (Graves')? | 1) Preterm birth
   2) FGR
   3) Stillbirth
   4) Neonatal Graves'
10. What are the fetal risks (4) for Hypothyroidism (Hashimoto's)? | 1) Infertility
    2) Miscarriage
    3) Stillbirth
    4) Low birthweight
11. What is the trimester-specific management for Hyperthyroidism (Graves')? | 1st: PTU; 2nd/3rd: Methimazole.
    Goal is high-normal fT4.
12. What is the management and TSH goal for Hypothyroidism (Hashimoto's)? | Levothyroxine (1-2μg/kg/d).
    Goal is TSH ~2.5 mU/L.

SYSTEMATIC SUMMARY - ADRENAL DISORDERS

13. What is the primary cause of Cushing's Syndrome in pregnancy? | Autonomous Adrenal Adenoma.
14. What are the primary causes (2) of Adrenal Insufficiency (Addison's)? | Autoimmune (Global) and Tuberculosis (Philippines/Poor areas).
15. What are the clinical features (4) of Cushing's Syndrome? | 1) Hypertension
    2) DM
    3) Preeclampsia
    4) Cushingoid facies
16. What are the clinical features (4) of Adrenal Insufficiency (Addison's)? | 1) Hypotension
    2) Nausea
    3) Weakness
    4) Hyperpigmentation
17. How is Cushing's Syndrome diagnosed? | Elevated 24-hr UFC.
    Accompanied by suppressed ACTH.
18. How is Adrenal Insufficiency (Addison's) diagnosed? | Blunted cortisol response.
    Occurs after insulin hypoglycemia or ACTH stimulation.
19. What is the definitive treatment for Cushing's Syndrome? | Surgical Adrenalectomy.
20. What is the treatment for Adrenal Insufficiency (Addison's) during labor? | Stress dose corticosteroids.
    Must increase dose to match labor stress.

SYSTEMATIC SUMMARY - DIABETES INSIPIDUS (DI)

21. What is the etiology of Central Diabetes Insipidus? | ADH deficiency.
    Due to hypothalamus or pituitary lesions.
22. What is the etiology of Nephrogenic Diabetes Insipidus? | Renal resistance to ADH.
23. What is the etiology of Gestational Diabetes Insipidus? | Increased ADH degradation.
    Caused by placental vasopressinase.
24. How does Central Diabetes Insipidus respond to Desmopressin? | Increased urine osmolality.
25. How does Nephrogenic Diabetes Insipidus respond to Desmopressin? | No change.
    Urine osmolality remains the same.
26. When does Gestational Diabetes Insipidus typically occur? | Late 3rd trimester.
    It is a transient condition.
27. What are the associated conditions (3) for Central Diabetes Insipidus? | trauma, tumor, infection.
28. What is the primary population for hereditary Nephrogenic Diabetes Insipidus? | Mostly males.
    It is rare in females.
29. What conditions (3) are associated with Gestational Diabetes Insipidus? | 1) Preeclampsia
    2) HELLP
    3) AFLP

ENDOCRINE PHYSIOLOGY BULLET POINTS

30. Why does maternal endocrine physiology change during pregnancy? | Maternal-fetal unit development.
    The placenta acts as a temporary gland.
31. How does hCG affect thyroid function in the first trimester? | Stimulates TSH receptors.
    Results in increased thyroid function and decreased TSH.
32. Define Gestational thyrotoxicosis. | Decreased TSH via high hCG.
    TSH typically normalizes after 12 weeks.
33. Why does total thyroxine (T4) increase early in pregnancy? | Increased TBG synthesis.
    Stimulated by high placental estradiol in the liver.
34. What is the target level for free thyroxine (fT4) in healthy pregnant women? | Upper limit.
    Target is the upper limit of the nonpregnant reference range.
35. When do maternal thyroid hormones first cross the placenta? | As early as 6 weeks.
    Crucial for fetal brain development.
36. What is the function of rT3 (reverse T3) in the placenta? | Inactivating maternal T4.
    Produced by type III deiodinase.
37. Does maternal Thyrotropin-releasing hormone (TRH) cross the placenta? | Yes.
    Also synthesized by the placenta to stimulate fetal thyroid.
38. Does maternal TSH cross the placenta? | No.
    It has no direct effect on the fetus.
39. At what week does the fetal thyroid gland start functioning? | After 12 weeks.
    Still depends on mother for 30% of thyroxine at term.
40. How does maternal nutrition affect Thyroxine-binding globulin (TBG)? | Affects TBG levels.
    TBG binds fT4, decreasing its bioavailability.
41. Which gland is considered the Pituitary Gland vs. the thyroid? | Pituitary is "Master Gland".
    Thyroid is central for metabolic regulation.
42. When does positive feedback occur in the HPO axis? | Mid-cycle estrogen surge.
    Stimulates LH release to trigger ovulation.

HYPERTHYROIDISM AND THYROID STORM

43. What is the most common cause of thyrotoxicosis in pregnancy? | Graves' Disease.
44. What clinical signs (4) suggest hyperthyroidism? | 1) Tachycardia
    2) Thyromegaly
    3) Exophthalmos
    4) Weight loss
45. List pregnancy outcomes of poorly controlled hyperthyroidism. (4) | 1) Miscarriage
    2) Preterm birth
    3) Preeclampsia
    4) Heart failure
46. What neurodevelopmental risks do offspring of hyperthyroid mothers face? | Epilepsy and Autism.
47. Why does fetal growth restriction occur in hypermetabolic mothers? | Maternal energy consumption.
    Mother consumes nutrients leaving insufficient amounts for the fetus.
48. Can a fetal goiter occur if the mother is euthyroid? | Yes.
    Maternal testing may not reflect fetal thyroid status.
49. What labs define subclinical hyperthyroidism? | Low TSH, normal T4.
50. What life-threatening state leads to Thyroid Storm complications? | Hypermetabolic state.
    Leads to pulmonary hypertension and heart failure.
51. Why is Propylthiouracil (PTU) preferred in the 1st trimester? | Less placental transfer.
    Inhibits T4 to T3 conversion.
52. Why is Methimazole (MMI) avoided in the 1st trimester? | Rare embryopathy.
    Risk of aplasia cutis or choanal atresia.
53. What is the dose ratio for switching PTU to MMI? | 20:1 ratio.
54. When is thyroidectomy recommended during pregnancy? | 2nd trimester.
    Only if medical therapy fails or is toxic.
55. Why is radioactive iodine (RAI) contraindicated in pregnancy? | Destroys fetal thyroid.
56. What is the first-line drug and dose for thyroid storm management? | PTU 1000 mg (loading).
    Followed by iodine after 1-2 hours.
57. What causes Gestational Transient Thyrotoxicosis (GTT)? | hCG stimulating TSH receptors.
58. Why does molar pregnancy cause T4 elevation? | Excess hCG.
    Overstimulates TSH receptors; normalizes after evacuation.

HYPOTHYROIDISM AND IODINE

59. What is the most common cause of Hashimoto thyroiditis? | Anti-TPO antibodies.
60. What lab values confirm overt hypothyroidism? | High TSH, low T4.
61. What risks (3) are associated with severe maternal hypothyroidism? | 1) Infertility
    2) Miscarriage
    3) Severe preeclampsia
62. What percentage of hypothyroid Filipinos have metabolic syndrome? | 36%.
63. What is the standard levothyroxine dosing for overt hypothyroidism? | 1-2μg/kg/d (approx 100μg/day).
64. How often should TSH monitoring occur during treatment? | Every 4 weeks.
    In the first half of pregnancy.
65. Define isolated maternal hypothyroxemia. | Normal TSH, low fT4.
66. What are the risks of euthyroid autoimmune thyroid disease? | Pregnancy loss and preterm birth.
    (Positive anti-TPO with normal TSH/T4).
67. What are the iodine requirements in pregnancy? | 220-250 μg/day.
68. What condition results from severe iodine deficiency? | Endemic cretinism.
69. Why is early thyroxine replacement critical in newborns? | Prevents neurological damage.
    Used for Congenital Hypothyroidism.

THYROIDITIS, NODULES, AND CANCER

70. When does postpartum thyroiditis typically occur? | Within the first year.
    Features a thyrotoxic phase then a hypothyroid phase.
71. How is the thyrotoxic phase of postpartum thyroiditis treated? | Beta-blockers.
    Treats symptoms of hormone release.
72. How long is levothyroxine given for the hypothyroid phase of thyroiditis? | 6-12 months.
    (Dose: 25-75 μg/day).
73. What is the preferred diagnostic test for thyroid nodules in pregnancy? | Fine-needle aspiration (FNA).
74. A biopsy is recommended for solitary thyroid nodules if they are what size? | >5 mm persistent at 3 months PP.
75. When is surgery for thyroid cancer performed if diagnosed in the 3rd trimester? | Deferred until postpartum.
    Unless it is aggressive.
76. What is the most common and non-invasive type of thyroid cancer? | Papillary thyroid cancer.

PARATHYROID DISORDERS

77. Which two factors maintain calcium homeostasis? | PTH and Calcitriol (1,25-dihydroxyvit D).
78. What is the WHO recommendation for elemental calcium daily intake? | 1.5-2 g daily.
    From 20th week until term.
79. What is the most common cause of primary hyperparathyroidism? | Single parathyroid adenoma.
80. What are the symptoms (3) of a hypercalcemic crisis? | Nausea, vomiting, mental status changes.
81. Maternal hyperparathyroidism causes neonatal hypocalcemia via what mechanism? | Suppression of fetal parathyroid gland.
82. When is surgical removal of a parathyroid adenoma best performed? | 2nd trimester.
83. Name the emergency treatment for severe hypercalcemia. (3) | 1) IV Saline diuresis
    2) Furosemide
    3) Calcitonin
84. What are the neuromuscular symptoms of hypoparathyroidism? | Numbness, tingling, muscle cramps.

ADRENAL DISORDERS

85. Why is Cushing's syndrome detection often late in pregnancy? | Symptom overlap.
    Hypertension and DM overlap with normal pregnancy findings.
86. Active Cushing's syndrome increases the risk of what? (2) | Preterm birth (66%) and Cesarean (52%).
87. What is the cure for Cushing's syndrome via adrenal adenoma? | Adrenalectomy.
88. Addison disease management during labor requires what? | Stress dose corticosteroids.

PITUITARY DISORDERS

89. Why does the pituitary gland enlarge in pregnancy? | Lactotrophic hyperplasia.
    Induced by estrogen.
90. What is the earliest sign of Sheehan syndrome? | Failure of lactation.
    Caused by postpartum pituitary necrosis.
91. What are the complications (3) of a prolactinoma? | 1) Amenorrhea
    2) Galactorrhea
    3) Visual field defects
92. Differentiate Microadenomas vs Macroadenomas by size. | Micro ≤10 mm; Macro >10 mm.
93. What specific visual defect is seen in pituitary tumor expansion? | Bitemporal hemianopia.
94. Use of Bromocriptine in hyperprolactinemic women. | Restores ovulation.
    Also treats symptomatic tumor enlargement.
95. Is MRI imaging safe for visualizing pituitary tumors in pregnancy? | Yes.
96. How is Acromegaly diagnosis confirmed? | Elevated IGF-1.
    Lack of GH suppression after glucose load.
97. Name the drugs used for acromegaly in pregnant women. | Octreotide and pegvisomant.
98. When does lymphocytic hypophysitis usually present? | Close to delivery.
    Presents with headaches and visual disturbances.
99. Why is Desmopressin (dDAVP) used in DI? | ADH replacement.
    Standard treatment for Central DI.
100. What is mandatory during a water deprivation test? | Nothing by mouth (NPO).
     Hourly urine/weight monitoring.

COMPARISONS

101. Compare PTU vs. Methimazole trimester use. | PTU (1st Tri); MMI (2nd/3rd Tri).
102. Compare TRH vs. TSH placental transfer. | TRH crosses; TSH does not.
103. Differentiate Thyroid Storm vs. Hyperemesis Gravidarum. | Storm is life-threatening/decompensated.
     HG is transient; TSH normalizes mid-pregnancy.
104. Differentiate Graves' vs. Gestational Thyrotoxicosis (GTT). | Graves' needs thionamides/history.
     GTT is hCG-mediated/transient.
105. Overt vs. Subclinical Hypothyroidism labs. | Overt: High TSH, Low fT4.
     Subclinical: High TSH, Normal fT4.
106. Central vs. Nephrogenic DI Desmopressin response. | Central responds; Nephrogenic is resistant.
107. DI vs. Primary Polydipsia. | Polydipsia is psychogenic.
     Shows higher urine osmolality response to dDAVP.
108. Sheehan Syndrome vs. Prolactinoma prolactin levels. | Sheehan: Low prolactin.
     Prolactinoma: High prolactin.
109. Cushing's vs. Normal Pregnancy symptoms. | Cushing's is more severe.
     Features high UFC and suppressed ACTH.
110. Cushing's Syndrome Cause: Pregnant vs Non-pregnant. | Pregnant: Adrenal Adenoma.
     Non-pregnant: Pituitary-dependent hyperplasia.
111. Neonatal Hyper- vs Hypoparathyroidism. | Maternal Hyper causes Neonatal Hypo.
112. Define Bitemporal Hemianopia vision loss. | Loss of peripheral vision.
     Medial/central vision remains intact.
113. dDAVP vs. Insulin safety. | Both are generally safe.
114. Prolactinoma risk of enlargement: Micro vs Macro. | Micro (2.4%); Macro (21%).
115. Timing of Postpartum Thyroiditis Phases. | Thyrotoxic: 1-4 months PP.
     Hypothyroid: 4-8 months PP.
116. Explain TSH-hCG mirroring. | As hCG rises, TSH falls.
     As hCG falls, TSH rises back.

8.5 - Connective Tissue Disorders

Summary

text

CONNECTIVE TISSUE DISORDERS (CTDs) IN PREGNANCY

I. GENERAL EPIDEMIOLOGY AND FILIPINO CONTEXT

II. SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

III. ANTIPHOSPHOLIPID SYNDROME (APS)

IV. RHEUMATOID ARTHRITIS (RA) & SYSTEMIC SCLEROSIS

V. INHERITED DISORDERS (MARFAN, OI, EDS)

COMPREHENSIVE BULLET POINTS (REPRESENTATIVE FOR FLASHCARDS)

• In Mixed Connective Tissue Disease (MCTD), the Alarcon-Segovia Criteria is used for diagnosis, and high titers of anti-U1RNP are characteristic findings.
• Patients with Systemic Lupus Erythematosus (SLE) have placentas that are typically smaller with vascular lesions like decidual vasculopathy, thrombosis, and infarction.
• Neonatal Lupus Erythematosus (NLE) is caused by the transplacental passage of maternal anti-SSA (Ro) or anti-SSB (La) autoantibodies.
• The most common manifestation of Neonatal Lupus (NLE) is a photosensitive skin rash, which usually resolves within 3 to 6 months as maternal antibodies clear.
• A permanent and serious complication of Neonatal Lupus (NLE) is congenital heart block (CHB), though the lecturer notes this was not seen in the specific Filipino study reviewed.
• Hydroxychloroquine (HCQ) is the only maternal treatment for SLE that has been shown to lower the risk of Neonatal Lupus.
• For pregnant women with Systemic Lupus Erythematosus (SLE), non-fluorinated corticosteroids (Prednisone, Hydrocortisone) are preferred because they are inactivated by the placenta.
• Aspirin at 81mg/day should be initiated at 12 weeks of gestation in all SLE patients to decrease the occurrence of preeclampsia.
• Lupus flares in pregnancy are often difficult to distinguish from preeclampsia; however, decreased complement levels (C3, C4) and increased anti-dsDNA titers strongly suggest a flare.
• The Lupus Anticoagulant (LAC) is the only antiphospholipid antibody consistently associated with adverse pregnancy outcomes despite being named an "anticoagulant" due to its in vitro effects.
• Annexin V is a natural anticoagulant expressed by the syncytiotrophoblast that may be targeted by pathogenetic antibodies in Antiphospholipid Syndrome (APS).
• Catastrophic Antiphospholipid Antibody Syndrome (CAPS), also known as Asherson Syndrome, involves a "cytokine storm" affecting three or more organ systems and has a high mortality rate.
• Heparin (UFH or LMWH) is the mainstay for thrombosis prevention in Antiphospholipid Syndrome (APS) because it prevents cellular damage by binding to beta-2-glycoprotein-I.
• Warfarin is strictly avoided during pregnancy in Antiphospholipid Syndrome (APS) management because it is a Vitamin K antagonist that is teratogenic and causes fetal bleeding.
• Symptom improvement in Rheumatoid Arthritis (RA) during pregnancy is correlated with higher serum levels of pregnancy-associated alpha2-glycoprotein (PAG).
• In Systemic Sclerosis, Labetalol must be avoided for hypertension management because it can cause peripheral vasospasm.
• Captopril (ACE inhibitor) is the treatment of choice if a Scleroderma Renal Crisis (SRC) is suspected, though typically used post-natally unless life-threatening.
• Polyarteritis Nodosa (PAN) is a necrotizing vasculitis of small and medium-sized arteries that may present peripartum with tender subcutaneous nodules and myositis.
• Marfan Syndrome risk is highest during the third trimester and postpartum due to cardiovascular changes like increased stroke volume and hormonal wall changes.
• In Ehlers-Danlos Syndrome (EDS), patients are at high risk for postpartum hemorrhage (PPH) and should receive prompt episiotomies to prevent irregular perineal tears.
• Osteogenesis Imperfecta (OI) patients may experience a fracture rate increase in the third trimester due to pregnancy-induced bone loss and transient decreases in bone mineral density.
• Pregnancy is generally discouraged in patients with severe CTD manifestations, specifically those with pulmonary hypertension or recent stroke.
• Methotrexate and Mycophenolate Mofetil must be discontinued 1-3 months and 6 weeks respectively before attempting pregnancy due to high teratogenic risk.

DIFFERENTIATING SIMILAR ENTITIES (FOR EXAMS)

• Lupus Flare vs. Preeclampsia: In Lupus Flare, complement levels (C3/C4) are decreased and anti-dsDNA is increased; in Preeclampsia, complements are usually normal and anti-dsDNA is negative.
• Lupus Flare vs. Preeclampsia: Urinary cellular casts and hematuria are highly characteristic of an SLE renal flare, whereas they are absent in pure preeclampsia.
• Lupus Flare vs. Preeclampsia: Uric acid is typically elevated in preeclampsia but remains normal in an SLE flare.
• Chronic Arterial vs. Venous Insufficiency: Arterial insufficiency presents with decreased/absent pulses and pale skin on elevation; Venous insufficiency has normal pulses and brown skin pigmentation.
• Arterial vs. Venous Ulcers: Arterial ulcers occur on toes or trauma points; Venous ulcers occur at the medial ankle.
• SLE vs. RA: SLE is multisystemic with hallmark malar rash and nephritis; RA is primarily an inflammatory synovitis of peripheral joints.
• APS Lab Markers: Lupus Anticoagulant (LAC) is the most predictive of pregnancy loss, while Anticardiolipin (ACA) is directed specifically against mitochondrial/platelet membranes.
• OI Type I vs. Type II: Type I is the mildest form and compatible with successful pregnancy; Type II is typically lethal in the neonatal period or in utero.
• EDS vs. Marfan: Both involve connective tissue, but Marfan is primarily a fibrillin-1 defect with aortic risks, while EDS is a collagen defect with skin/joint fragility risks.
• Heparin vs. Aspirin: Heparin inhibits the coagulation cascade (common pathway); Aspirin inhibits platelet aggregation by blocking Thromboxane A2.
• Systemic Sclerosis (Limited vs. Diffuse): Limited (CREST) is more benign and slow; Diffuse features rapid skin and GI fibrosis.
• Neonatal Lupus vs. SLE: Neonatal Lupus is a passive transfer of antibodies that resolves (except heart block); SLE is an endogenous autoimmune disease of the patient.
• Prednisone vs. Dexamethasone: Prednisone is preferred for maternal SLE treatment (placenta inactivates it); Dexamethasone is used only if the goal is to treat the fetus (crosses placenta).
• Labetalol in CTDs: Preferred in preeclampsia but contraindicated in Scleroderma due to potential to worsen Raynaud's/vasospasm.
• Thrombosis (APS): Arterial thrombosis often presents as stroke or MI; Venous thrombosis typically presents as DVT or PE.

QA

1. How is Hereditary Connective Tissue Disorder typically inherited? | Autosomal dominant trait.

2. Which sexes are equally affected by Hereditary Connective Tissue Disorder? | Males and females.

3. Contrast the origin of Autoimmune Connective Tissue Disorder vs Hereditary types. | Acquired (not inherited).

4. What triggers Autoimmune Connective Tissue Disorder in genetically predisposed individuals? | External factors.

5. In Filipinos, which sex predominantly develops Mixed Connective Tissue Disease (MCTD)? | Females.

6. What is the median age of onset for Mixed Connective Tissue Disease (MCTD) in Filipinos? | 30.5 years.

7. What is the most common chief complaint (67%) in Filipino Mixed Connective Tissue Disease (MCTD)? | Joint pain.

8. What is the second most common complaint (13%) in Filipino Mixed Connective Tissue Disease (MCTD)? | Skin tightness.

9. What was the most frequent initial diagnosis in Filipino patients later confirmed with Mixed Connective Tissue Disease (MCTD)? | Systemic lupus erythematosus (SLE).

10. What is the musculoskeletal hallmark (100%) of Mixed Connective Tissue Disease (MCTD)? | Arthritis.

11. What is the vascular hallmark (93%) of Mixed Connective Tissue Disease (MCTD)? | Raynaud’s phenomenon.

12. What is the cutaneous hallmark (71%) of Mixed Connective Tissue Disease (MCTD)? | Skin tightness.

13. How is Systemic Lupus Erythematosus (SLE) defined regarding its clinical course? | Relapses (flares) and remissions.

14. What is the mandatory entry criterion for Systemic Lupus Erythematosus (SLE) classification? | Antinuclear antibodies (ANA).

15. What ANA titer on HEp-2 cells is required to classify Systemic Lupus Erythematosus (SLE)? | ≥1:80.

16. What total score is required for Systemic Lupus Erythematosus (SLE) classification after ANA positivity? | 10 points or more.

17. Which renal findings carry the highest weight (10 points) in Systemic Lupus Erythematosus (SLE) classification? | Class III/IV lupus nephritis.

18. What cardiac criterion for Systemic Lupus Erythematosus (SLE) yields 6 points? | Acute pericarditis.

19. What serosal criterion for Systemic Lupus Erythematosus (SLE) yields 5 points? | Pleural/pericardial effusion.

20. What specific photosensitive skin manifestation is seen in Systemic Lupus Erythematosus (SLE)? | Malar rash.

21. What hair-related manifestation is a criterion for Systemic Lupus Erythematosus (SLE)? | Non-scarring alopecia.

22. What mucosal finding is part of the Systemic Lupus Erythematosus (SLE) clinical criteria? | Oral ulcers.

23. How is Antiphospholipid Syndrome (APS) defined? | Acquired thrombophilia.

24. What are the two core clinical features of Antiphospholipid Syndrome (APS)? | Thrombosis or pregnancy morbidity.

25. How many occasions must Lupus anticoagulant (LAC) be present for APS diagnosis? | ≥2 occasions.

26. What is the minimum time interval between positive Lupus anticoagulant (LAC) tests? | 12 weeks.

27. What titers of Anticardiolipin antibodies (ACA) IgG/IgM are required for APS? | Medium-high (>40 GPL/MPL).

28. How many weeks apart must Anticardiolipin antibodies (ACA) be measured? | 12 weeks.

29. What percentile threshold is used for Anti-beta-2 glycoprotein I antibody in APS? | >99th percentile.

30. Define the fetal death criterion for Antiphospholipid Syndrome (APS). | ≥1 death (≥10 weeks).

31. Define the preterm birth criterion for Antiphospholipid Syndrome (APS). | <34 weeks.

32. What causes preterm birth in Antiphospholipid Syndrome (APS) criteria? | Preeclampsia/placental insufficiency.

33. Define the abortion criterion for Antiphospholipid Syndrome (APS). | ≥3 consecutive (<10 weeks).

34. Where is Beta-2 Glycoprotein-I expressed in high concentrations during pregnancy? | Syncytiotrophoblast.

35. How do antibodies affect Beta-2 Glycoprotein-I in APS? | Reverse natural anticoagulant activity.

36. What process is inhibited by Antiphospholipid Syndrome (APS) in the placenta? | Syncytiotrophoblast differentiation (SYNCI).

37. What may be considered the definitive treatment for Antiphospholipid Syndrome (APS)? | Delivery.

38. What percentage of Rheumatoid Arthritis (RA) patients improve during pregnancy? | 70%.

39. What is the likely cause of Rheumatoid Arthritis (RA) improvement in pregnancy? | HLA disparity (mother-fetus).

40. What percentage of Rheumatoid Arthritis (RA) women experience a postpartum flare-up? | 40-50%.

41. What is the minimum score required for Rheumatoid Arthritis (RA) classification? | Score ≥6.

42. Which joints are weighted higher in the Rheumatoid Arthritis (RA) scoring system? | Small joints.

43. Which lab titers are part of Rheumatoid Arthritis (RA) classification? | RF and ACPA.

44. Which inflammatory markers are used in Rheumatoid Arthritis (RA) diagnosis? | ESR and CRP.

45. Why must Methotrexate be strictly avoided in Rheumatoid Arthritis (RA) pregnancy? | Causes abortion.

46. What screening must be done before starting a Rheumatoid Arthritis (RA) patient on Methotrexate? | Pregnancy screen.

47. What is the pathognomonic feature of Systemic Sclerosis? | Overproduction of normal collagen.

48. Enumerate the components of CREST Syndrome. (5) | 1) Calcinosis
    2) Raynaud’s
    3) Esophageal involvement
    4) Sclerodactyly
    5) Telangiectasia

49. What is the leading cause of death in Systemic Sclerosis? | Pulmonary Arterial Hypertension (PAH).

50. What percentage of Systemic Sclerosis patients are affected by Pulmonary Arterial Hypertension? | 15%.

51. Marfan Syndrome is caused by a mutation in which gene? | FBN1 gene.

52. On which chromosome is the gene for Marfan Syndrome located? | 15q21.

53. The FBN1 gene in Marfan Syndrome encodes for which protein? | Fibrillin-1.

54. What is the most serious pregnancy complication in Marfan Syndrome? | Aortic Dissection (AoD).

55. How is Ehlers-Danlos Syndrome (hEDS) Types I-III generally tolerated in pregnancy? | Well-tolerated.

56. What are the two main risks for Ehlers-Danlos Syndrome (hEDS) patients in pregnancy? | Joint hypermobility; skin fragility.

57. Which type of Ehlers-Danlos Syndrome (EDS) is high-risk for maternal vessel/uterine rupture? | Type IV (Vascular).

58. Enumerate the classic features of Osteogenesis Imperfecta (OI). (3) | 1) Brittle bones
    2) Blue sclerae
    3) Hearing loss

59. Which type of Osteogenesis Imperfecta (OI) is typically lethal in utero? | Type II.

60. Which criteria are used for Mixed Connective Tissue Disease (MCTD) diagnosis? | Alarcon-Segovia Criteria.

61. Which antibody is characteristic of Mixed Connective Tissue Disease (MCTD)? | Anti-U1RNP.

62. Describe the typical placenta in Systemic Lupus Erythematosus (SLE). | Smaller than normal.

63. Enumerate the vascular lesions found in Systemic Lupus Erythematosus (SLE) placentas. (3) | 1) Decidual vasculopathy
    2) Thrombosis
    3) Infarction

64. What causes Neonatal Lupus Erythematosus (NLE)? | Transplacental maternal antibodies.

65. Which specific antibodies (2) cause Neonatal Lupus Erythematosus (NLE)? | Anti-SSA (Ro); anti-SSB (La).

66. What is the most common manifestation of Neonatal Lupus (NLE)? | Photosensitive skin rash.

67. When does the skin rash in Neonatal Lupus (NLE) usually resolve? | 3 to 6 months.

68. What permanent cardiac complication can occur in Neonatal Lupus (NLE)? | Congenital heart block (CHB).

69. Which maternal SLE treatment reduces the risk of Neonatal Lupus? | Hydroxychloroquine (HCQ).

70. Why are non-fluorinated corticosteroids preferred for SLE in pregnancy? | Inactivated by the placenta.

71. Enumerate the preferred non-fluorinated corticosteroids for SLE. (2) | 1) Prednisone
    2) Hydrocortisone

72. What dosage of Aspirin is used in SLE to prevent preeclampsia? | 81mg/day.

73. At what gestational age should Aspirin be initiated for SLE patients? | 12 weeks.

74. Distinguish Lupus Flare vs. Preeclampsia based on complement (C3, C4). | Flare: Decreased;
    Preeclampsia: Normal.

75. Distinguish Lupus Flare vs. Preeclampsia based on anti-dsDNA. | Flare: Increased;
    Preeclampsia: Negative.

76. Which APS antibody is most consistently associated with adverse pregnancy outcomes? | Lupus Anticoagulant (LAC).

77. Which natural syncytiotrophoblast anticoagulant is targeted in Antiphospholipid Syndrome (APS)? | Annexin V.

78. What is the alternative name for Catastrophic Antiphospholipid Antibody Syndrome (CAPS)? | Asherson Syndrome.

79. How many organ systems must be affected for Catastrophic APS (CAPS)? | Three or more.

80. What is the main treatment for thrombosis prevention in Antiphospholipid Syndrome (APS)? | Heparin (UFH or LMWH).

81. How does Heparin prevent damage in APS? | Binds to beta-2-glycoprotein-I.

82. Why is Warfarin strictly avoided in APS during pregnancy? | Teratogenic (fetal bleeding).

83. Which protein's high serum levels correlate with Rheumatoid Arthritis (RA) improvement? | Pregnancy-associated alpha2-glycoprotein (PAG).

84. Why is Labetalol avoided in Systemic Sclerosis? | Causes peripheral vasospasm.

85. What is the treatment of choice for Scleroderma Renal Crisis (SRC)? | Captopril (ACE inhibitor).

86. Define Polyarteritis Nodosa (PAN). | Necrotizing vasculitis.

87. Enumerate findings of peripartum Polyarteritis Nodosa (PAN). (2) | 1) Subcutaneous nodules
    2) Myositis

88. When is the risk of Marfan Syndrome complication highest? | Third trimester and postpartum.

89. Ehlers-Danlos Syndrome (EDS) patients are at high risk for which delivery complication? | Postpartum hemorrhage (PPH).

90. What is the recommended management for Ehlers-Danlos Syndrome (EDS) at delivery? | Prompt episiotomy.

91. Why does Osteogenesis Imperfecta (OI) fracture rate increase in the 3rd trimester? | Pregnancy-induced bone loss.

92. Severe CTD manifestations (e.g. stroke) result in what recommendation regarding pregnancy? | Pregnancy is discouraged.

93. How long before attempting pregnancy should Methotrexate be discontinued? | 1-3 months.

94. How long before attempting pregnancy should Mycophenolate Mofetil be discontinued? | 6 weeks.

95. Distinguish Lupus Flare vs. Preeclampsia based on urinary findings. | Flare: Cellular casts/hematuria;
    Preeclampsia: Absent.

96. Distinguish Lupus Flare vs. Preeclampsia based on uric acid levels. | Flare: Normal;
    Preeclampsia: Elevated.

97. Distinguish Insufficiency (Arterial vs. Venous) based on pulses. | Arterial: Decreased/absent;
    Venous: Normal.

98. Distinguish Ulcers (Arterial vs. Venous) based on location. | Arterial: Toes/trauma points;
    Venous: Medial ankle.

99. Compare SLE vs. RA primary pathology. | SLE: Multisystemic/Nephritis;
    RA: Inflammatory synovitis.

100. Contrast OI Type I vs. Type II pregnancy compatibility. | Type I: Successful pregnancy;
     Type II: Lethal in utero.

101. Compare Marfan vs. EDS structural defects. | Marfan: Fibrillin-1 (Aortic risk);
     EDS: Collagen (Skin/Joint risk).

102. Compare Heparin vs. Aspirin inhibition targets. | Heparin: Coagulation cascade;
     Aspirin: Platelet aggregation.

103. Contrast Systemic Sclerosis (Limited vs. Diffuse) progression. | Limited: Benign/Slow;
     Diffuse: Rapid skin/GI fibrosis.

104. Contrast Neonatal Lupus vs. SLE origin. | Neonatal: Passive antibody transfer;
     SLE: Endogenous autoimmune.

105. Compare Prednisone vs. Dexamethasone fetal effect. | Prednisone: Inactivated (maternal use);
     Dexamethasone: Crosses (fetal use).

GYNE

1

Summary

text

Infertility and Assisted Reproductive Technology (ART) Overview

Definitions & Epidemiology

• Infertility is defined as the inability of a couple to achieve pregnancy within one year of unprotected frequent sexual contact.
• Early Infertility evaluation (after 6 months) is warranted for women >35 years old or those with oligo/amenorrhea, known tubal disease, severe endometriosis, or male factors.
• Fecundability is the monthly ability of a normal fertile couple to get pregnant, typically approximately 20%.
• Female Infertility factors account for 54% of cases, with Ovulatory Disorders (27%) and Tubal Disorders (22%) being the most common.
• Unexplained Infertility occurs in approximately 17-20% of couples where all standard diagnostic tests are normal.
• Infertility prevalence increases with the age of the female partner: 1 in 7 if age 30-34, 1 in 5 if age 35-40, and 1 in 4 if age 40-44.
• Azoospermic husbands: Even with donor insemination, the pregnancy rate in women decreases from 73% (age <25) to 55.8% (age 36-40).
• Diminished Ovarian Reserve is the most common diagnostic category among women undergoing IVF.

Physiology & Optimal Timing

• Oocyte lifespan: An egg disintegrates less than 24 hours after reaching the ampulla.
• Sperm lifespan: Normal sperm retain fertilizing ability in the oviduct for up to 72 hours.
• Optimal conception time: Intercourse on the day before ovulation or daily for 3 days at mid-cycle yields the highest pregnancy rate (30%).
• LH Surge detection (First morning urine): If positive, ovulation occurs on the same day of detection.
• LH Surge detection (Random urine): Ovulation occurs 12 to 24 hours after a positive result (the suivant day).
• Conception blockers: Vaginal lubricants, saliva, cigarette smoking, and douching decrease the chance of conception.

Ovulation & Ovarian Reserve Assessment

• Serum Progesterone (Midluteal phase): Values >3-5 ng/mL suggest some ovulatory function; ≥10 ng/mL suggests a normal ovulatory cycle and potential conception.
• Basal Body Temperature (BBT): Based on the thermogenic effect of progesterone on the hypothalamus; requires taking sublingual temperature shortly after awakening after 6 hours of sleep.
• Endometrial Biopsy: Formerly used to diagnose luteal phase defects, but is no longer indicated for routine infertility workup because it is invasive and subjective.
• Ovarian Reserve Testing: Primarily recommended for women >35, those with unexplained infertility, smokers, or those with a history of ovarian surgery/chemo/radiation.
• Serum FSH (Day 2 or 3): Elevated levels (>10 mIU/mL) indicate decreased ovarian reserve; >20 mIU/mL indicates a poor prognosis.
• Serum Estradiol (E2): Levels >70 pg/mL early in the cycle suggest poor prognosis or may invalidate FSH readings.
• Anti-Müllerian Hormone (AMH): Produced by granulosa cells; <0.5 ng/mL indicates decreased ovarian reserve, while >2 ng/mL indicates more follicles are available.
• AMH Menopause prediction: An AMH level of 0.05 ng/mL suggests menopause will occur within 4-5 years.
• Antral Follicle Count (AFC): Measured via TVS on cycle day 2 to 4; a count of 10 or more follicles (2-10 mm size) suggests good ovarian reserve.

Semen Analysis & Male Evaluation

• Male Infertility workup: Includes 2-3 days of abstinence before semen collection; entire specimen should be collected in a wide-mouthed jar.
• Sperm motility: Begins to decline 2 hours after ejaculation; specimen must be examined within this period and kept warm.
• Sperm morphology: A subjective test reflecting sperm production from 3 months prior; only normal forms (Kruger criteria 4%) have fertilization ability.
• Low normal sperm values (WHO 2010): Concentration 15 million/mL, total number 39 million/ejaculate, and 40% motility.
• Intrauterine Insemination (IUI): Sperm must be washed and separated from seminal fluid; Unwashed seminal fluid must NOT be used because it contains prostaglandins that cause severe uterine cramps and infection.
• IUI Limitations: Less successful if significant oligospermia (<5 million motile sperm) is present.

Hysterosalpingography (HSG) & Tubal Disease

• HSG Timing: Performed on the 10th day of the cycle (follicular phase) to avoid pregnancy and ensure better endometrial definition.
• HSG Contraindications: History of untreated salpingitis or tenderness on pelvic exam.
• Water-soluble contrast: Currently preferred over oil-soluble contrast to avoid peritoneal irritation and granulomas.
• Doxycycline (100 mg BID): Prophylactic antibiotic given for 1-2 weeks if hydrosalpinx is visualized on HSG.
• Hydrosalpinx (HSG): Appears as distal blockage with "ballooning" and a sausage-like appearance; spillage of dye is absent.
• Proximal Tubal Obstruction: May be due to true block (SIN, infection) or cornual spasm (false block).
• Laparoscopic Salpingectomy: Recommended prior to IVF for women with large hydrosalpinx because the fluid affects embryo implantation and decreases IVF success rates by 40%.
• Tubal wall thickness: The best prognostic factor for pregnancy after tubal reconstructive surgery.
• Tubal Tuberculosis: Radiographically appears as a "pipe stem" configuration; women with pelvic TB are considered sterile.

Medical Management of Anovulation

• Clomiphene Citrate (CC): A selective estrogen receptor antagonist; first-line for oligomenorrhea with sufficient estrogen. Dose is 50-150 mg for 5 days starting on day 3-5.
• Clomiphene side effects: 8% incidence of multiple gestations, ovarian cysts, vasomotor flushes, hair loss, and blurring of vision.
• "Stair-step" CC Regimen: If no follicle develops, the dose is increased immediately within the same cycle to avoid waiting for menses.
• Letrozole: An aromatase inhibitor; preferred over CC in PCOS patients due to higher live birth rates and lower multiple pregnancy rates.
• Metformin: An insulin-sensitizing biguanide used as an adjunct in obese PCOS patients; start "low and slow" to minimize GI side effects (nausea/vomiting).
• Gonadotropins (FSH/HMG): Used when patients are unresponsive to CC/Letrozole; requires ultrasound monitoring to prevent OHSS.
• HCG (5,000-10,000 IU): Used as a "trigger" to induce ovulation, which occurs 36-48 hours after administration.
• Dopamine Agonists: Specific treatment for anovulation caused by Hyperprolactinemia.

Ovarian Hyperstimulation Syndrome (OHSS)

• OHSS Pathogenesis: Excessive ovarian stimulation leads to high E2 and VEGF secretion, causing increased vascular permeability and massive fluid shifts.
• OHSS Mild: Ovarian enlargement ≤5 cm with abdominal discomfort.
• OHSS Moderate: Ovarian enlargement 6-10 cm, nausea/GI symptoms, and mild ascites (not clinically evident).
• OHSS Severe: Clinically evident ascites, hydrothorax, hematocrit >45%, and increased WBC. Requires hospitalization.
• OHSS Critical: Oliguria, creatinine >1.6 mg/dL, thrombosis, infection, and potential DIC.
• OHSS Prevention: Use of GnRH agonist trigger instead of HCG, lowering gonadotropin doses, or "coasting."

In-Vitro Fertilization (IVF) Specifics

• IVF Indications: Blocked tubes, severe male factor, advanced maternal age, unexplained infertility failed IUI, and genetic screening.
• Intracytoplasmic Sperm Injection (ICSI): Single sperm injection into a mature oocyte; preferred for male factor infertility, prior failed fertilization, and frozen oocytes.
• Oocyte Harvesting: Performed 34-36 hours after HCG trigger; requires at least 3 mature follicles (≥18 mm) on ultrasound.
• Embryo Transfer (Day 3 vs Day 5): Blastocysts (Day 5) have higher implantation and pregnancy rates than cleavage-stage (Day 3) embryos.
• Assisted Hatching (AH): Drilling a hole in the zona pellucida with laser/acid; useful for older women (>37) but increases risk of monozygotic twinning.
• Elective Single Embryo Transfer (eSET): Recommended for women <35 to minimize the risk of high-risk multifetal pregnancies.
• In-Vitro Maturation (IVM): Harvesting immature eggs to mature them outside the body; primarily used in PCOS to eliminate OHSS risk.
• Frozen Embryo Transfer (FET): Requires estrogen therapy to prime the endometrium and progesterone supplementation 4-6 days before transfer.
• Recurrent Implantation Failure: Defined as 3 failed transfers of good embryos or 2 failed transfers of euploid blastocysts; may require Endometrial Receptivity Analysis (ERA).

Genetic Testing & Fertility Preservation

• PGT-A: Genetic testing for aneuploidy (abnormal chromosome number); recommended for advanced maternal age (>37) or recurrent loss.
• PGT-M: Genetic testing for monogenic diseases (e.g., Cystic Fibrosis, Tay-Sachs, Huntington’s).
• Trophectoderm Biopsy: The preferred method for PGT, performed on Day 5 or 6 blastocysts.
• Social Freezing: Oocyte cryopreservation in healthy young women to delay childbearing and mitigate the age effect on fecundity.
• GnRH agonist (in chemotherapy): Administered 7-10 days before chemo to protect ovaries by suppressing the HPG axis and reducing blood flow.
• Ovarian tissue cryopreservation: Option for cancer patients, but contraindicated in leukemias due to the risk of malignant cell re-seeding.

Differentiating Similar Entities & Exam High-Yield Points

1. Fecundability (20%) is the monthly probability of pregnancy, whereas Fecundity is the monthly probability of a live birth.
2. LH Test (First morning urine) means ovulation is now (today); LH Test (Random urine) means ovulation is tomorrow (12-24 hours).
3. Clomiphene Citrate is an estrogen receptor antagonist (systemic); Letrozole is an aromatase inhibitor (inhibits conversion to estrogen).
4. Letrozole is superior to Clomiphene specifically in PCOS patients; they are roughly equal in unexplained infertility.
5. Serum Progesterone >3 ng/mL proves ovulation happened; Serum Progesterone ≥10 ng/mL is the threshold for healthy spontaneous conception.
6. Hydrosalpinx vs. Salpingitis Isthmica Nodosa (SIN): Hydrosalpinx is distal ballooning; SIN is proximal nodular scarring (often from infection).
7. IUI vs. IVF-ICSI: IUI still requires patent tubes and decent sperm; IVF-ICSI can bypass blocked tubes and severe sperm counts.
8. OHSS Moderate vs. Severe: Moderate has ascites on ultrasound only; Severe has clinically evident ascites (distended abdomen) and hemoconcentration (Hct >45%).
9. OHSS Severe vs. Critical: Severe has ascites/effusions; Critical adds organ failure (Oliguria, Creatinine >1.6, or Thrombosis).
10. Azoospermia (Obstructive vs. Non-obstructive): Obstructive (e.g., absent vas deferens) has a better prognosis for sperm retrieval than Non-obstructive (e.g., genetic failure).
11. Y-Chromosome Microdeletions: Sperm can be retrieved in AZFb/AZFc deletions, but NOT in AZFa deletions.
12. AMH vs. FSH: AMH is cycle-independent (can be taken anytime); FSH must be taken on Day 2-3 to be accurate.
13. Day 3 vs. Day 5 Embryo Transfer: Day 3 are cleavage-stage (6-8 cells); Day 5 are blastocysts (ready for implantation).
14. PGT-A vs. PGT-M: PGT-A is for chromosomal quantity (e.g., Down Syndrome); PGT-M is for specific single-gene mutations (e.g., Cystic Fibrosis).
15. Intramural Myoma >4 cm decreases pregnancy rates; Submucous Myoma (any size) decreases pregnancy rates and requires removal.
16. Oil-based vs. Water-based HSG contrast: Oil-based potentially increases pregnancy rates but risk granuloma; Water-based is safer and more common.
17. Endometrial Biopsy vs. ERA: Endometrial biopsy for "dating" is obsolete; ERA is a modern genetic analysis used for recurrent implantation failure.
18. Basal Body Temperature (BBT) only confirms that ovulation happened after it occurred; it is not good for timing intercourse in the same cycle.
19. Infertility Workup: A single abnormal semen analysis is not diagnostic; it must be repeated after 4 weeks because sperm takes ~3 months to mature.
20. GIFT vs. ZIFT: GIFT is Gamete transfer (pre-fertilization) into the tube; ZIFT is Zygote transfer (post-fertilization) into the tube. Both are rarely used compared to IVF-ET.

QA

text

Infertility and Assisted Reproductive Technology (ART) Overview

1. What is the definition of Infertility? | Inability to conceive
   After 1 year of unprotected sex (6 months if >35).
2. What are the clinical manifestations of Infertility? (3) | Oligo/amenorrhea,
   Tubal obstruction,
   Endometriosis
3. What is the diagnosis and work-up for Infertility? | Comprehensive History and PE
   Ancillary testing (Semen analysis, HSG).
4. What are the treatment options for Infertility? (3) | Ovulation induction,
   IUI,
   IVF
5. What is the pathogenesis of Male Factor Infertility? | Issues with sperm
   Producton, motility, or morphology issues (25% of cases).
6. What are the clinical findings of Male Factor Infertility? | Oligospermia or azoospermia
   Low sperm count or absence of sperm.
7. What is the primary diagnostic tool for Male Factor Infertility? | Semen Analysis
   Based on WHO 2010 criteria.
8. What are the WHO 2010 criteria for Semen Analysis? (4) | Vol ≥1.5mL,
   Conc ≥15M/mL,
   Motility ≥40%,
   Morph ≥4%
9. What is the management for Male Factor Infertility? | Lifestyle changes, IUI, or IVF-ICSI.
10. What is the pathogenesis of Ovulatory Disorders? | HPO axis dysfunction
    Leading to anovulation (27% of female factors).
11. What are the clinical manifestations of Ovulatory Disorders? | Irregular cycles
    Associated with low midluteal progesterone.
12. What diagnostic tests are used for Ovulatory Disorders? (2) | Serum Progesterone
    Basal Body Temperature (BBT)
13. What is the first-line treatment for Ovulatory Disorders? | Clomiphene Citrate or Letrozole.
14. What are the common Tubal/Uterine Factors in infertility? | Physical blockages
    Structural abnormalities like hydrosalpinx or myomas.
15. How are Tubal/Uterine Factors diagnosed? (2) | HSG and Laparoscopy. |
16. What is the management for Tubal/Uterine Factors? | Tubal surgery,
    Myomectomy, or IVF.
17. Define the pathogenesis of Endometriosis in infertility. | Inflammatory disease
    Affects 40% of infertile women.
18. What are the clinical manifestations of Endometriosis? (3) | Pain,
    Reduced fecundity,
    Mechanical obstruction
19. What is the gold standard for Endometriosis diagnosis? | Laparoscopy
    Provides a visual diagnosis.
20. What is the treatment for infertility caused by Endometriosis? | COS + IUI
    IVF if no pregnancy after 3-6 cycles.
21. What is Ovarian Hyperstimulation Syndrome (OHSS)? | Iatrogenic complication
    Result of gonadotropin therapy.
22. What are clinical signs of OHSS? (3) | Ovarian enlargement,
    Ascites,
    Hemoconcentration
23. How is OHSS managed? | Supportive care
    Fluids, electrolytes, and avoiding HCG trigger.

Definitions & Epidemiology

24. Define Infertility (General definition). | Inability to conceive
    Within 1 year of unprotected sexual contact.
25. When is an Early Infertility evaluation warranted (after 6 months)? (5) | Women >35,
    Oligo/amenorrhea,
    Tubal disease,
    Endometriosis,
    Male factors
26. What is Fecundability? | Monthly pregnancy probability
    Typically approximately 20% in fertile couples.
27. What percentage of infertility is due to Female Infertility factors? | 54% of cases.
28. What are the two most common Female Infertility factors? | Ovulatory (27%) and Tubal (22%).
29. What is Unexplained Infertility? | Normal diagnostic tests
    Occurs in 17-20% of couples.
30. How does Infertility prevalence change for age 30-34? | 1 in 7 couples.
31. How does Infertility prevalence change for age 35-40? | 1 in 5 couples.
32. How does Infertility prevalence change for age 40-44? | 1 in 4 couples.
33. How does age affect pregnancy rates for Azoospermic husbands using donor insemination? | Decreases with age
    73% if <25 years; 55.8% if 36-40 years.
34. What is the most common diagnostic category in women undergoing IVF? | Diminished Ovarian Reserve.

Physiology & Optimal Timing

35. What is the Oocyte lifespan? | Less than 24 hours
    After reaching the ampulla.
36. What is the Sperm lifespan in the oviduct? | Up to 72 hours.
37. What is the Optimal conception time? | Day before ovulation
    Or daily for 3 days at mid-cycle.
38. When does ovulation occur if LH Surge detection (First morning urine) is positive? | Same day of detection.
39. When does ovulation occur if LH Surge detection (Random urine) is positive? | 12 to 24 hours later
    Technically the "suivant" or next day.
40. Name four Conception blockers. | Vaginal lubricants,
    Saliva,
    Cigarette smoking,
    Douching

Ovulation & Ovarian Reserve Assessment

41. What Serum Progesterone value suggests some ovulatory function? | >3-5 ng/mL.
42. What Serum Progesterone value suggests a normal ovulatory cycle? | ≥10 ng/mL.
43. What is the physiological basis for Basal Body Temperature (BBT) testing? | Thermogenic effect of progesterone
    Acting on the hypothalamus.
44. What are the requirements for accurate BBT measurement? | Sublingual temperature
    Immediately after awakening after 6 hours sleep.
45. Why is Endometrial Biopsy no longer indicated for routine workup? | Invasive and subjective
    Formerly used for luteal phase defects.
46. Who should undergo Ovarian Reserve Testing? (4) | Women >35,
    Unexplained infertility,
    Smokers,
    History of ovarian surgery/chemo/radiation
47. What does an FSH level >10 mIU/mL on Day 2 or 3 indicate? | Decreased ovarian reserve.
48. What does an FSH level >20 mIU/mL indicate? | Poor prognosis for pregnancy.
49. What Serum Estradiol (E2) level indicates a poor prognosis early in the cycle? | >70 pg/mL.
50. What is Anti-Müllerian Hormone (AMH) produced by? | Granulosa cells.
51. What AMH level indicates decreased ovarian reserve? | <0.5 ng/mL.
52. What AMH level indicates many follicles are available? | >2 ng/mL.
53. What AMH level predicts menopause within 4-5 years? | 0.05 ng/mL.
54. How is the Antral Follicle Count (AFC) measured? | Transvaginal ultrasound (TVS)
    On cycle day 2 to 4.
55. What Antral Follicle Count (AFC) suggests good ovarian reserve? | 10 or more follicles
    Follicles sized 2-10 mm.

Semen Analysis & Male Evaluation

56. What is the required abstinence period for a Male Infertility workup? | 2-3 days of abstinence.
57. When does Sperm motility begin to decline after ejaculation? | After 2 hours.
58. What is the significance of Sperm morphology? | Reflects production from 3 months prior
    Subjective test using Kruger criteria.
59. What is the Kruger criteria threshold for fertilization ability? | 4% normal forms.
60. What are the WHO 2010 Low normal sperm values? (3) | 15 M/mL concentration,
    39 M/ejaculate total,
    40% motility
61. Why must Unwashed seminal fluid NOT be used in IUI? | Causes severe uterine cramps
    Contains prostaglandins and risk of infection.
62. In what condition is Intrauterine Insemination (IUI) less successful? | Significant oligospermia
    <5 million motile sperm.

Hysterosalpingography (HSG) & Tubal Disease

63. What is the optimal HSG Timing? | 10th day of cycle
    Ensures follicular phase/no pregnancy.
64. What are the HSG Contraindications? (2) | Untreated salpingitis
    Tenderness on pelvic exam.
65. Why is Water-soluble contrast preferred in HSG? | Avoids peritoneal irritation
    Prevents oil-induced granulomas.
66. When is Doxycycline prophylaxis given for HSG? | If hydrosalpinx is visualized
    100 mg BID for 1-2 weeks.
67. How does Hydrosalpinx appear on HSG? | Distal blockage with ballooning
    Sausage-like appearance with no dye spillage.
68. What causes Proximal Tubal Obstruction? | True block (SIN, infection)
    Or cornual spasm (false block).
69. Why is Laparoscopic Salpingectomy recommended before IVF for large hydrosalpinx? | Fluid reduces success rates
    Embryo implantation decreased by 40%.
70. What is the best prognostic factor for pregnancy after Tubal reconstructive surgery? | Tubal wall thickness.
71. How does Tubal Tuberculosis appear radiographically? | Pipe stem configuration.
72. What is the fertility prognosis for women with Pelvic Tuberculosis? | Considered sterile.

Medical Management of Anovulation

73. What is the mechanism of Clomiphene Citrate (CC)? | Selective estrogen receptor antagonist.
74. What is the typical dose and timing for Clomiphene Citrate? | 50-150 mg for 5 days
    Starting on cycle day 3-5.
75. Name four Clomiphene side effects. | Multiple gestations (8%),
    Ovarian cysts,
    Vasomotor flushes,
    Blurring of vision
76. What is the "Stair-step" CC Regimen? | Immediate dose increase
    Used if no follicle develops within the same cycle.
77. What is the mechanism of Letrozole? | Aromatase inhibitor.
78. Why is Letrozole preferred for PCOS patients? | Higher live birth rates
    Lower incidence of multiple pregnancy.
79. What is the role of Metformin in infertility? | Adjunct for obese PCOS
    Insulin-sensitizing biguanide.
80. When are Gonadotropins (FSH/HMG) indicated? | Unresponsive to CC/Letrozole.
81. Why is ultrasound monitoring required for Gonadotropins? | To prevent OHSS.
82. What is the function of HCG (5,000-10,000 IU) in ART? | Trigger for ovulation
    Occurs 36-48 hours after administration.
83. What is the treatment for anovulation due to Hyperprolactinemia? | Dopamine Agonists.

Ovarian Hyperstimulation Syndrome (OHSS)

84. What is the OHSS Pathogenesis? | High E2 and VEGF secretion
    Leads to vascular permeability/fluid shifts.
85. Define OHSS Mild. | Ovarian enlargement ≤5 cm
    Accompanied by abdominal discomfort.
86. Define OHSS Moderate. | Ovarian enlargement 6-10 cm
    Nausea and mild ascites (on ultrasound).
87. Define OHSS Severe. | Clinically evident ascites/hydrothorax
    Hematocrit >45% and high WBC.
88. Define OHSS Critical. (4) | Oliguria,
    Creatinine >1.6 mg/dL,
    Thrombosis,
    DIC
89. How is OHSS prevented in ART? (3) | GnRH agonist trigger,
    Lowering gonadotropin doses,
    "Coasting"

In-Vitro Fertilization (IVF) Specifics

90. List four IVF Indications. | Blocked tubes,
    Severe male factor,
    Advanced maternal age,
    Failed IUI
91. What is Intracytoplasmic Sperm Injection (ICSI)? | Single sperm injection
    Directly into a mature oocyte.
92. When is ICSI preferred? (3) | Male factor,
    Failed fertilization,
    Frozen oocytes
93. When is Oocyte Harvesting performed? | 34-36 hours after HCG trigger.
94. What are the ultrasound requirements for Oocyte Harvesting? | ≥3 mature follicles
    Size ≥18 mm.
95. Compare Embryo Transfer (Day 3 vs Day 5). | Day 5 (Blastocysts)
    Higher implantation and pregnancy rates.
96. What is the risk associated with Assisted Hatching (AH)? | Monozygotic twinning.
97. What is Elective Single Embryo Transfer (eSET)? | Recommended for women <35
    To minimize high-risk multifetal pregnancies.
98. What is the advantage of In-Vitro Maturation (IVM) in PCOS? | Eliminates OHSS risk
    Harvests and matures immature eggs outside the body.
99. What does Frozen Embryo Transfer (FET) require? | Estrogen therapy
    And progesterone 4-6 days before transfer.
100. Define Recurrent Implantation Failure. | 3 failed good embryo transfers
     Or 2 failed euploid blastocyst transfers.
101. What test is used for Recurrent Implantation Failure? | Endometrial Receptivity Analysis (ERA).

Genetic Testing & Fertility Preservation

102. What is PGT-A? | Testing for aneuploidy
     Abnormal chromosome number.
103. What is PGT-M? | Testing for monogenic diseases
     e.g., Cystic Fibrosis, Tay-Sachs.
104. What is the preferred method for PGT Biopsy? | Trophectoderm Biopsy
     Performed on Day 5 or 6 blastocysts.
105. What is Social Freezing? | Oocyte cryopreservation
     To delay childbearing/delay age effect.
106. Why is a GnRH agonist used during chemotherapy? | To protect ovaries
     Suppresses HPG axis and reduces blood flow.
107. When is Ovarian tissue cryopreservation contraindicated? | Leukemias
     Risk of malignant cell re-seeding.

Differentiating Similar Entities & Exam High-Yield Points

108. Compare Fecundability vs Fecundity. | Fecundability: Monthly pregnancy probability (20%)
     Fecundity: Monthly live birth probability.
109. Compare LH Test (First morning vs Random urine) timing. | First morning: Ovulation today
     Random: Ovulation tomorrow (12-24h).
110. Compare Clomiphene Citrate vs Letrozole mechanism. | CC: Estrogen receptor antagonist
     Letrozole: Aromatase inhibitor.
111. Compare Letrozole vs Clomiphene in PCOS. | Letrozole is superior
     Higher live birth rates.
112. Compare Serum Progesterone levels (>3 vs ≥10 ng/mL). | >3: Confirms ovulation
     ≥10: Threshold for healthy conception.
113. Compare Hydrosalpinx vs SIN location. | Hydrosalpinx: Distal ballooning
     SIN: Proximal nodular scarring.
114. Compare IUI vs IVF-ICSI requirements. | IUI: Patent tubes/decent sperm
     IVF-ICSI: Can bypass blocked tubes/severe male factor.
115. Compare OHSS Moderate vs Severe (Ascites). | Moderate: Ascites on U/S only
     Severe: Clinically evident ascites.
116. Contrast OHSS Severe vs Critical. | Critical adds organ failure
     Creatinine >1.6 or thrombosis.
117. Compare Azoospermia (Obstructive vs Non-obstructive) prognosis. | Obstructive has better sperm retrieval prognosis
     e.g., absent vas deferens vs genetic failure.
118. Can sperm be retrieved in Y-Chromosome Microdeletions? | Yes in AZFb/AZFc
     No in AZFa deletions.
119. Compare AMH vs FSH cycle timing. | AMH: Cycle-independent
     FSH: Must be Day 2-3.
120. Compare Day 3 vs Day 5 Embryos. | Day 3: Cleavage-stage (6-8 cells)
     Day 5: Blastocysts.
121. Compare PGT-A vs PGT-M targets. | PGT-A: Chromosomal quantity
     PGT-M: Specific single-gene mutations.
122. Compare Intramural vs Submucous Myoma. | Intramural (>4cm): Decreases rate
     Submucous (any size): Decreases rate/requires removal.
123. Compare Oil-based vs Water-based HSG contrast. | Oil: Potential pregnancy increase/risk granuloma
     Water: Safer and more common.
124. Compare Endometrial Biopsy vs ERA. | Biopsy: Obsolete for dating
     ERA: Modern genetic analysis for implantation failure.
125. Why is Basal Body Temperature (BBT) bad for timing? | Only confirms ovulation occurred
     Retroactive confirmation only.
126. Why is one Semen analysis result not diagnostic? | Sperm takes 3 months to mature
     Must repeat after 4 weeks.
127. Compare GIFT vs ZIFT. | GIFT: Gametes into tube
     ZIFT: Zygote into tube.

2

Summary

text

I. Overview of Immunologic Response

• Pattern Recognition Receptors (PRRs) are germline-encoded receptors on effector cells that detect Pathogen-Associated Molecular Patterns (PAMPs) on microbes to trigger inflammation.
• Toll-Like Receptors (TLRs) are a type of PRR that stimulates type 1 interferon (IFN), which possesses antimicrobial, antiviral, and anticancer properties.
• Natural Killer (NK) Cells are very important in cancer management; they directly kill infected or tumor cells that lack MHC class I molecules.
• Complement System activation leads to C3 cleavage and the formation of membrane pores via C6, C7, C8, and C9 proteins, resulting in cell lysis.
• Humoral Immunity (B cells) involves B cells originating in the bone marrow and differentiating into plasma cells to secrete antibodies (immunoglobulins).
• Antibody Structure consists of two heavy and two light chains; the Variable (V) region provides antigen specificity, while the Constant (C) region binds to phagocytes.
• IgM is the first antibody produced in an immune response and is a potent activator of the complement system.
• IgG serves in the later immune response, provides neonatal immunity via placental transfer, and coats antigens for phagocytosis (opsonization).
• Cellular Immunity (T cells) requires direct cell-to-cell contact and recognizes peptide antigens only when presented on MHC molecules.
• Class I MHC is found on all nucleated cells and activates CD8+ Cytotoxic T Lymphocytes (CTLs) to destroy tumor or infected cells.
• Class II MHC is found only on Antigen-Presenting Cells (APCs) and activates CD4+ Helper T cells.
• Regulatory T Cells (Tregs) are CD4+ T cells that suppress the immune response; in cancer, they may prevent the immune system from recognizing tumor "self-antigens."
• Th1 Cells secrete IL-2 and IFN-γ to promote cell-mediated inflammatory responses, while Th2 Cells secrete IL-4, IL-5, IL-6, and IL-10 to promote antibody production.

II. Cancer Immunity Cycle & Immunotypes

• The Cancer Immunity Cycle is a 7-step iterative process: 1) Release of antigens, 2) Antigen presentation, 3) Priming/Activation, 4) Trafficking to tumors, 5) Infiltration, 6) Recognition, and 7) Killing of cancer cells.
• Immune Desert immunotype is characterized by a complete paucity of immune cells within the tumor microenvironment (TME).
• Immune Excluded immunotype occurs when T cells are present in the stroma but are prevented from migrating into the actual cancer cell nests by inhibitory barriers.
• Inflamed Tumors contain stimulatory immune cells and tumor-infiltrating lymphocytes (TILs), which increase functional killing of cancer cells.
• Stimulatory Factors (Green) in the cancer cycle include IFN-α, IL-2, and TLR agonists; their presence is used for monitoring and prognostication.
• Inhibitory Factors (Red) such as PD-L1, CTLA-4, and VEGF help cancer cells evade the immune response and are targets for immunotherapy medications.
• CAR-T Therapy involves genetically modifying a patient's T cells to express Chimeric Antigen Receptors targeting specific tumor antigens like mesothelin or MUC16.

III. Cytokines in Oncology

• M1 Macrophages secrete stimulatory cytokines (IL-12, TNF-α) to promote immunity against tumors.
• M2 Macrophages produce immunosuppressive factors (VEGF, IL-10, PGE2) that assist established tumors in growing and evading the immune system.
• Type I Interferons (IFN-α/β) are stimulated by TLRs to inhibit viral replication and increase Class I MHC expression.
• Type II Interferon (IFN-γ) is produced by T cells/NK cells to activate macrophages and promote the Th1 (cellular immunity) pathway.
• TGF-β inhibits T-cell proliferation and is a major contributor to tumor immune evasion.
• Chemokines are small proteins that regulate leukocyte infiltration, promote angiogenesis, and control site-specific metastasis.

IV. Molecular Oncology: Oncogenes & Tumor Suppressors

• Oncogenes are mutated derivatives of normal genes that result in a GAIN OF FUNCTION; alteration mechanisms include gene amplification, translocation, and overexpression.
• Tumor Suppressor Genes control cell growth and proliferation; cancer develops following a LOSS OF FUNCTION (inactivation of both alleles).
• p53 is the "gate keeper of the genome" and the most common deregulated tumor suppressor; located on chromosome 17, it triggers apoptosis (via BAX, bcl-2) in response to DNA damage.
• PTEN (Phosphatase and tensin homologue) is a tumor suppressor on chromosome 10 that is mutated in 50% of endometrioid endometrial cancers and 20% of endometrial hyperplasias.
• Retinoblastoma (Rb) Gene regulates G1 phase arrest; its inactivation follows Knudson’s "two-hit" theory (one inherited mutation, one somatic).
• HPV E6 Oncoprotein (types 16/18) targets p53 for degradation, while HPV E7 Oncoprotein binds to Rb to upregulate cell proliferation in cervical cancer.
• Somatic Mutations occur after conception in any body cell except germ cells and are not passed to offspring.
• Germline Mutations occur in reproductive cells (egg/sperm) and are incorporated into the DNA of every cell in the offspring.

V. BRCA Genes & PARP Inhibitors

• BRCA1 Gene is located on chromosome 17q21; mutation carriers have a 40-50% risk of ovarian cancer by age 70.
• BRCA2 Gene is located on chromosome 13q12.3; carries a 20-25% ovarian cancer risk and is linked to male breast, pancreatic, and biliary cancers.
• BRCA Genetic Testing is indicated for nonmucinous epithelial ovarian cancer at any age, or breast cancer before age 50 with a strong family history.
• PARP Inhibitors (e.g., Olaparib, Rucaparib, Niraparib) kill BRCA-deficient cells by causing an accumulation of DNA double-strand breaks that the cells cannot repair.
• The SOLO-1 Trial demonstrated that Olaparib maintenance therapy reduces disease progression or death by 70% in BRCA-mutated ovarian cancer.

VI. DNA Mismatch Repair (MMR) & Lynch Syndrome

• Mismatch Repair (MMR) Deficiency leads to Microsatellite Instability (MSI); it is found in over 30% of endometrial cancers.
• The MMR Repair Pathway involves the MutS complex (recognition), MutL (excision), and re-synthesis of DNA strands.
• Lynch Syndrome (HNPCC) is an autosomal dominant syndrome caused by germline mutations in MMR genes (MSH2, MLH1, MSH6, PMS2) predisposing to colorectal and endometrial cancers.
• MSH2 (Chr 2) and MLH1 (Chr 3) are the most common mutations in Lynch Syndrome.
• The Amsterdam Criteria II for Lynch diagnosis (the "3-2-1" rule): 3 relatives with HNPCC cancer (one being a 1st-degree relative of others), 2 successive generations, and 1 diagnosed before age 50.
• The Bethesda Guidelines are more sensitive than Amsterdam for identifying patients needing MSI testing, including those with colorectal/uterine cancer diagnosed under age 50.
• Immunotherapy (e.g., Dostarlimab) is highly effective for dMMR/MSI-H recurrent or advanced endometrial cancer.

VII. Recent Advances & Local (Philippine) Context

• CloneSeq-SV is a new technique used in high-grade serous ovarian cancer (HGSOC) to track clonal evolution and drug resistance markers (e.g., CCNE1, MYC) using cell-free DNA.
• High-Grade Serous Ovarian Cancer (HGSOC) drug resistance is often pre-existing at diagnosis, leading to clonal selection during treatment.
• AI-Based Biomarkers use deep learning to quantify TILs or PD-L1/HER2 expression from digitized pathology slides.
• In the Philippines, cervical cancer is the most common gynecologic malignancy, and research is currently focusing on PD-L1 expression for immunotherapy.
• Neoadjuvant Olaparib is being studied for advanced BRCA-mutated ovarian cancer patients who are ineligible for primary surgery.
• Philippine Gynecologic Oncology Research Group (PGOG) conducts multi-center trials to improve local data on gynecologic cancers.

VIII. Comparison of Similar Entities for Exams

1. Innate vs. Adaptive Immunity: Innate is rapid and non-specific with no memory; Adaptive is slow-onset, highly specific, and possesses immunologic memory.
2. MHC Class I vs. MHC Class II: MHC I is on all nucleated cells (presents to CD8+ T cells); MHC II is only on APCs (presents to CD4+ T cells).
3. Oncogenes vs. Tumor Suppressor Genes: Oncogenes result from a Gain of Function (one allele mutated); Tumor Suppressors result from a Loss of Function (both alleles must be inactivated).
4. BRCA1 vs. BRCA2: BRCA1 is on Chr 17 (higher ovarian risk ~50%); BRCA2 is on Chr 13 (lower ovarian risk ~20% and associated with male breast/pancreatic cancer).
5. Amsterdam I vs. Amsterdam II Criteria: Amsterdam I only included colorectal cancer; Amsterdam II was revised to include extracolonic HNPCC cancers (endometrial, small bowel, ureter, etc.).
6. Bethesda vs. Amsterdam II Criteria: Bethesda is more sensitive (catches more potential Lynch cases); Amsterdam II is more specific (higher certainty if criteria are met).
7. M1 vs. M2 Macrophages: M1 promotes tumor killing (pro-inflammatory); M2 promotes tumor growth/evasion (immunosuppressive).
8. Somatic vs. Germline Mutation: Somatic is not heritable (occurs after conception); Germline is heritable (present in reproductive cells and every cell of offspring).
9. Th1 vs. Th2 Cells: Th1 promotes cell-mediated immunity (IFN-γ); Th2 promotes humoral/antibody immunity (IL-4).
10. IgG vs. IgM: IgG crosses the placenta and is part of the late/memory response; IgM is the first produced and stays in the vascular space (pentamer).
11. HPV E6 vs. HPV E7: E6 degrades p53; E7 binds/inactivates Rb.
12. Immune Desert vs. Immune Excluded: In "Desert," immune cells are absent from the TME; in "Excluded," immune cells exist in the stroma but cannot penetrate the tumor nest.
13. G-CSF vs. Erythropoietin (EPO): G-CSF stimulates neutrophil production (innate); EPO stimulates red blood cell production.
14. Cytotoxic T-cells (CTLs) vs. Natural Killer (NK) Cells: CTLs require MHC presentation to recognize targets; NK cells kill targets specifically because they lack MHC I expression.
15. MSI-H vs. dMMR: MSI-H (High Microsatellite Instability) is the phenotype/effect; dMMR (deficient Mismatch Repair) is the mechanism/cause.

QA

code

I. Overview of Immunologic Response

1. Describe the specificity of Innate Immunity. | Non-specific; recognizes broad patterns (PAMPs).
2. Describe the specificity of Adaptive Immunity. | Highly specific to unique pathogens/antigens.
3. Does Innate Immunity possess immunologic memory? | No immunologic memory.
4. How does the response of Adaptive Immunity change on re-exposure? | Response increases with repeated exposure.
5. List the components of Innate Immunity. (6) | 1) Epithelial barriers
   2) Macrophages
   3) NK cells
   4) Neutrophils
   5) Dendritic cells
   6) Complement
6. List the components of Adaptive Immunity. (2) | 1) T cells (Cell-mediated)
   2) B cells (Humoral)
7. Compare the response time of Innate vs. Adaptive Immunity. | Innate is rapid/first line; Adaptive is slower initially.
8. Define Pattern Recognition Receptors (PRRs). | Germline-encoded receptors detecting PAMPs.
9. What is the role of Pattern Recognition Receptors (PRRs) in the immune response? | Trigger inflammation.
10. What are Pathogen-Associated Molecular Patterns (PAMPs)? | Broad patterns on microbes detected by PRRs.
11. What type of PRR stimulates Type 1 Interferon (IFN)? | Toll-Like Receptors (TLRs).
12. List the three properties of Type 1 Interferon (IFN). | Antimicrobial, antiviral, and anticancer.
13. Why are Natural Killer (NK) Cells important in cancer management? | Kill cells lacking MHC class I molecules.
14. Which cells do Natural Killer (NK) Cells directly kill? | Infected or tumor cells.
15. What event occurs first in the Complement System activation? | C3 cleavage.
16. Which proteins form membrane pores in the Complement System? | C6, C7, C8, and C9.
17. What is the final result of membrane pore formation by the Complement System? | Cell lysis.
18. Where do B cells in Humoral Immunity originate? | Bone marrow.
19. What do B cells differentiate into to secrete antibodies in Humoral Immunity? | Plasma cells.
20. Describe the basic Antibody Structure. | Two heavy and two light chains.
21. What is the function of the Variable (V) region of an antibody? | Provides antigen specificity.
22. What is the function of the Constant (C) region of an antibody? | Binds to phagocytes.
23. Which antibody is the first produced in an Immune Response? | IgM.
24. What system is IgM a potent activator of? | Complement system.
25. What is the role of IgG in the immune response? | Serves in the later immune response.
26. How does IgG provide neonatal immunity? | Placental transfer.
27. Define Opsonization by IgG. | Coating antigens for phagocytosis.
28. What does Cellular Immunity (T cells) require for activation? | Direct cell-to-cell contact.
29. When do T cells recognize Peptide Antigens? | Only when presented on MHC molecules.
30. Where is Class I MHC found? | All nucleated cells.
31. Which cells are activated by Class I MHC? | CD8+ Cytotoxic T Lymphocytes (CTLs).
32. What is the target of CD8+ Cytotoxic T Lymphocytes (CTLs)? | Tumor or infected cells.
33. Where is Class II MHC found? | Antigen-Presenting Cells (APCs).
34. Which cells are activated by Class II MHC? | CD4+ Helper T cells.
35. What is the function of Regulatory T Cells (Tregs)? | Suppress the immune response.
36. Identify the markers for Regulatory T Cells (Tregs). | CD4+.
37. How do Regulatory T Cells (Tregs) assist cancer cells? | Prevent recognition of tumor "self-antigens."
38. What cytokines are secreted by Th1 Cells? (2) | IL-2 and IFN-γ.
39. What type of response is promoted by Th1 Cells? | Cell-mediated inflammatory responses.
40. What cytokines are secreted by Th2 Cells? (4) | IL-4, IL-5, IL-6, and IL-10.
41. What is the primary function of Th2 Cells? | Promote antibody production.

II. Cancer Immunity Cycle & Immunotypes

42. How many steps are in the Cancer Immunity Cycle? | 7 steps.
43. List the first three steps of the Cancer Immunity Cycle. | 1) Release of antigens
    2) Antigen presentation
    3) Priming/Activation
44. List the last four steps of the Cancer Immunity Cycle. | 4) Trafficking
    5) Infiltration
    6) Recognition
    7) Killing
45. Describe the Immune Desert immunotype. | Complete paucity of immune cells.
46. Where are T cells located in the Immune Excluded immunotype? | In the stroma.
47. What prevents T cell migration in Immune Excluded tumors? | Inhibitory barriers.
48. What are the components of Inflamed Tumors? | Stimulatory immune cells and TILs.
49. What is the effect of Tumor-Infiltrating Lymphocytes (TILs) in inflamed tumors? | Increase functional killing of cancer cells.
50. List the Stimulatory Factors (Green) in the cancer cycle. (3) | IFN-α, IL-2, and TLR agonists.
51. What is the clinical use of Stimulatory Factors? | Monitoring and prognostication.
52. List Inhibitory Factors (Red) in cancer immunity. (3) | PD-L1, CTLA-4, and VEGF.
53. What is the purpose of Inhibitory Factors for a tumor? | Evade the immune response.
54. Define CAR-T Therapy. | Genetically modifying T cells with Chimeric Antigen Receptors.
55. Name two specific tumor antigens targeted by CAR-T Therapy. | Mesothelin or MUC16.

III. Cytokines in Oncology

56. Which cytokines mediate Innate Immunity? (5) | IL-1, IL-12, IL-18, IL-23, TNF, IFN.
57. Which cytokine links Innate and Adaptive Immunity? | IL-12.
58. List cytokines associated with Adaptive Immunity. (6) | IL-2, IL-4, IL-5, IL-13, TGF-β, IFN-γ.
59. What is the function of IL-2 in adaptive immunity? | Clonal expansion of T cells.
60. Which cytokine aids Tumor Evasion in adaptive immunity? | TGF-β.
61. List cytokines involved in Hematopoiesis. (4) | G-CSF, GM-CSF, IL-3, Erythropoietin (EPO).
62. What is the clinical use of G-CSF? | Manage chemo-induced neutropenia.
63. What do M1 Macrophages secrete? | IL-12 and TNF-α.
64. What is the role of M1 Macrophages? | Promote immunity against tumors.
65. What do M2 Macrophages produce? (3) | VEGF, IL-10, PGE2.
66. How do M2 Macrophages assist tumors? | Growth and immune evasion.
67. What stimulates Type I Interferons (IFN-α/β)? | Toll-Like Receptors (TLRs).
68. What are the two main functions of Type I Interferons? | 1) Inhibit viral replication
    2) Increase Class I MHC.
69. Which cells produce Type II Interferon (IFN-γ)? | T cells and NK cells.
70. What is the role of Type II Interferon (IFN-γ)? | Activate macrophages and promote Th1.
71. How does TGF-β impact T-cells? | Inhibits T-cell proliferation.
72. Define the role of Chemokines in oncology. (3) | 1) Leukocyte infiltration
    2) Angiogenesis
    3) Metastasis.

IV. Molecular Oncology: Oncogenes & Tumor Suppressors

73. Define Oncogenes. | Mutated genes causing Gain of Function.
74. List mechanisms of Oncogene alteration. (3) | Gene amplification, translocation, overexpression.
75. Define Tumor Suppressor Genes. | Genes that control cell growth.
76. What mechanism causes cancer via Tumor Suppressor Genes? | Loss of Function (inactivation of both alleles).
77. What is the nickname for p53? | Gate keeper of the genome.
78. Where is the p53 gene located? | Chromosome 17.
79. How does p53 trigger apoptosis? | Via BAX and bcl-2.
80. Where is PTEN located? | Chromosome 10.
81. In what percentage of Endometrioid Endometrial Cancers is PTEN mutated? | 50%.
82. What does the Retinoblastoma (Rb) Gene regulate? | G1 phase arrest.
83. Define Knudson’s "two-hit" theory for Rb. | One inherited mutation, one somatic.
84. What is the target of HPV E6 Oncoprotein? | p53 degradation.
85. What is the target of HPV E7 Oncoprotein? | Binding/inactivation of Rb.
86. Define Somatic Mutations heritability. | Not passed to offspring.
87. Where do Germline Mutations occur? | Reproductive cells (egg/sperm).
88. Which cells contain the mutation in Germline Mutations? | Every cell in the offspring.

V. BRCA Genes & PARP Inhibitors

89. Where is the BRCA1 Gene located? | Chromosome 17q21.
90. What is the ovarian cancer risk for BRCA1 carriers by age 70? | 40-50%.
91. Where is the BRCA2 Gene located? | Chromosome 13q12.3.
92. What is the ovarian cancer risk for BRCA2 carriers? | 20-25%.
93. List non-breast/ovarian cancers linked to BRCA2. (3) | Male breast, pancreatic, biliary.
94. When is BRCA Genetic Testing indicated for ovarian cancer? | Nonmucinous epithelial at any age.
95. When is BRCA Genetic Testing indicated for breast cancer? | Before age 50 with family history.
96. Provide three examples of PARP Inhibitors. | Olaparib, Rucaparib, Niraparib.
97. How do PARP Inhibitors kill BRCA-deficient cells? | Accumulation of DNA double-strand breaks.
98. What was the outcome of the SOLO-1 Trial? | Olaparib reduced progression/death by 70%.

VI. DNA Mismatch Repair (MMR) & Lynch Syndrome

99. What does Mismatch Repair (MMR) Deficiency lead to? | Microsatellite Instability (MSI).
100. Percentage of Endometrial Cancers with MMR deficiency? | Over 30%.
101. Match MutS and MutL to their functions. | MutS (recognition); MutL (excision).
102. What is Lynch Syndrome (HNPCC)? | Autosomal dominant germline MMR mutation.
103. List the four MMR Genes mutated in Lynch Syndrome. | MSH2, MLH1, MSH6, PMS2.
104. Which two mutations are most common in Lynch Syndrome? | MSH2 and MLH1.
105. State the "3-2-1" rule of Amsterdam Criteria II. | 3 relatives, 2 generations, 1 diagnosed <50.
106. Explain the "3" in the Amsterdam Criteria II. | 3 relatives with HNPCC cancer.
107. What is the advantage of Bethesda Guidelines over Amsterdam? | More sensitive for identifying MSI testing.
108. Which drug is used for dMMR/MSI-H recurrent endometrial cancer? | Dostarlimab.

VII. Recent Advances & Local (Philippine) Context

109. What is CloneSeq-SV used for? | Track clonal evolution using cell-free DNA.
110. List two drug resistance markers tracked by CloneSeq-SV. | CCNE1 and MYC.
111. When is drug resistance typically present in HGSOC? | Pre-existing at diagnosis.
112. How do AI-Based Biomarkers assist pathology? | Quantify TILs or PD-L1/HER2 expression.
113. What is the most common gynecologic malignancy in the Philippines? | Cervical cancer.
114. What is the research focus for Philippine cervical cancer? | PD-L1 expression.
115. Who is eligible for Neoadjuvant Olaparib study? | Advanced BRCA-mutated, surgical ineligible.
116. What is the PGOG? | Philippine Gynecologic Oncology Research Group.

VIII. Comparison of Similar Entities

117. Compare Innate vs. Adaptive memory. | Innate: No memory; Adaptive: Immunologic memory.
118. Compare MHC Class I vs. Class II distribution. | Class I: All nucleated cells; Class II: APCs.
119. Compare MHC Class I vs. Class II activation. | Class I: CD8+ T cells; Class II: CD4+ T cells.
120. Compare Oncogenes vs. Tumor Suppressor Genes mechanism. | Oncogenes: Gain of Function; Tumor Suppressors: Loss of Function.
121. Compare BRCA1 vs. BRCA2 chromosome locations. | BRCA1: Chr 17; BRCA2: Chr 13.
122. Contrast Amsterdam I vs. Amsterdam II. | II includes extracolonic cancers (endometrial, etc).
123. Contrast Bethesda vs. Amsterdam II. | Bethesda is more sensitive; Amsterdam is more specific.
124. Contrast M1 vs. M2 Macrophages. | M1: Tumor killing; M2: Tumor growth/evasion.
125. Contrast Somatic vs. Germline Mutation heritability. | Somatic: Not heritable; Germline: Heritable.
126. Contrast Th1 vs. Th2 Cells immunity type. | Th1: Cell-mediated (IFN-γ); Th2: Humoral (IL-4).
127. Contrast IgG vs. IgM placentation. | IgG: Crosses placenta; IgM: Does not cross.
128. Contrast HPV E6 vs. E7 targets. | E6: p53; E7: Rb.
129. Contrast Immune Desert vs. Excluded. | Desert: Absent cells; Excluded: Stroma-only cells.
130. Contrast G-CSF vs. EPO targets. | G-CSF: Neutrophils; EPO: Red blood cells.
131. Contrast CTLs vs. NK Cells recognition. | CTLs require MHC; NK cells kill if MHC is lacking.
132. Compare MSI-H vs. dMMR relationship. | MSI-H: Phenotype/effect; dMMR: Mechanism/cause.

3

Summary

text

I. Principles of Radiation Therapy & Physics

• Electromagnetic radiation is a form of energy with no mass or charge that travels at the speed of light.
• The inverse square law states that radiation energy per unit area is inversely proportional to the square of the distance from the source (1/r²).
• The fractional cell kill principle establishes that each delivered radiation dose kills a constant fraction (not a constant number) of tumor cells.
• Therapeutic goal of radiation is to achieve maximum local tumor control while minimizing normal tissue damage and adverse symptoms.
• Radiation resistance is associated with cellular hypoxia, nutritional deficiency, or enhanced cell-mediated repair of DNA damage.
• Photons (X-rays and Gamma rays) are the most common source of radiation used in the treatment of gynecologic malignancies.
• Gamma rays are photons that originate from the atomic nucleus.
• X-rays are photons that originate from extranuclear (atomic orbital) interactions.
• Bremsstrahlung ("braking radiation") is produced when accelerated electrons hit a high atomic number (Z) target, generating photons of various energies.
• Particulate radiation includes alpha particles, protons, neutrons, and electrons, which randomly ionize atoms to produce tissue effects.
• Protons demonstrate a characteristic "Bragg peak," where the peak dose is deposited at the end of the particle's range, sparing initial tissue.

II. Photon Interactions & Radiobiology

• Coherent Scattering occurs at low energies (<10 keV) and results in no energy loss or radiobiologic effect.
• Photoelectric Effect (10 to 60 keV) involves total photon absorption and electron ejection; it is responsible for high tissue-bone contrast in imaging.
• Compton Effect (60 keV to 10 MeV) is the predominant interaction in human tissue (90% water) and is the most important interaction at therapeutic energies (4 to 18 MeV).
• Pair Production requires photon energy >1.022 MeV and results in the formation of an electron-positron pair; it is the basis of PET imaging.
• Indirect DNA damage accounts for two-thirds of radiation-induced damage and is caused by the formation of highly reactive hydroxyl radicals (OH) from water.
• Sublethal DNA damage repair occurs more effectively in normal cells than in malignant cells, which often have faulty genomic monitors.
• Intracellular molecular oxygen is essential for "fixing" DNA damage caused by free radicals; tumor hypoxia therefore leads to radiation resistance.
• High-LET (Linear Energy Transfer) radiation, such as neutrons or alpha particles, is densely ionizing and causes cell death independent of tissue oxygenation.
• Amifostine is a radioprotector that scavenges free radicals; it can reduce cisplatin-induced renal toxicity in ovarian cancer.
• Mitotic death is the most common form of radiation-induced cell death, occurring after the cell attempts to divide.

III. Tissue Sensitivity & The Cell Cycle

• M phase (Mitosis) is the most radiosensitive phase of the cell cycle because DNA is tightly packaged.
• S phase (DNA Synthesis) is the most radioresistant phase of the cell cycle due to the presence of repair enzymes used during replication.
• Radiosensitivity is highest in rapidly proliferating cells.
• G1 and G2 phases are more radiosensitive than the S phase but less so than the M phase.
• Hemoglobin levels (>10 mg/dL) are associated with improved tumor oxygenation and superior outcomes in cervical cancer radiation therapy.

IV. Radiation Techniques: Teletherapy & Brachytherapy

• Teletherapy (External Beam) delivers radiation from a source located at a distance from the patient, typically using linear accelerators.
• Intensity-modulated radiotherapy (IMRT) allows the high-dose radiation region to be conformed precisely to the tumor volume, sparing normal tissues like the small bowel.
• Isodose curves connect points in tissue receiving equivalent doses; higher-energy beams (e.g., 22-MeV) penetrate deeper and spare the skin surface.
• Brachytherapy (Internal) involves placing radioactive sources directly within or near the tumor.
• Intracavitary therapy for cervical cancer typically uses the Fletcher-Suit applicator (tandem and ovoids) to deliver dose to the cervix and paracervical tissues.
• High-dose rate (HDR) brachytherapy is performed on an outpatient basis over 3 to 5 hours, usually repeated 3 to 6 times.
• Low-dose rate (LDR) brachytherapy requires a shielded hospital room, bed rest, and prolonged analgesia as the source remains in place for an extended period.
• Cesium-137 (137Cs) is a commonly used radioisotope in gynecologic brachytherapy with a half-life of 30 years.
• Iridium-192 (192Ir) has a half-life of 73.8 days and is frequently used in modern brachytherapy units.

V. Radiation Complications

• Acute radiation effects occur within days to weeks and affect rapidly dividing tissues like skin, intestinal mucosa, and bone marrow.
• Late radiation effects occur months to years later and are caused by vascular damage and connective tissue loss (e.g., fibrosis, fistulas).
• Radiation cystitis presents as dysuria and frequency; it is managed with analgesics like Phenazopyridine.
• Sigmoiditis or enteritis caused by radiation leads to diarrhea, cramping, and malabsorption; management includes a low-roughage diet and antispasmodics.
• Fistulas (vesicovaginal or rectovaginal) typically occur 6 to 24 months post-treatment and often require surgical intervention.
• Radiation recall dermatitis is a skin reaction that occurs when certain chemotherapy agents (e.g., Dactinomycin) are given after previous radiation.

VI. Chemotherapy Principles & Management

• Standard of care for advanced ovarian cancer is six cycles of a taxane-platinum combination (e.g., Paclitaxel + Carboplatin).
• Neoadjuvant chemotherapy is given before surgery to reduce tumor size and improve the likelihood of optimal debulking.
• Maintenance therapy is used to prolong stable disease after the initial primary treatment.
• Myelosuppression is the most common serious toxicity of chemotherapy; it is managed with Granulocyte colony-stimulating factor (G-CSF).
• Body Surface Area (BSA) is the standard metric used to calculate most chemotherapy doses.
• RECIST criteria provide a standardized method for measuring tumor response to treatment via imaging.
• Platinum resistance is defined as tumor recurrence or progression within less than 6 months of completing platinum-based therapy.
• Platinum sensitivity is defined as a disease-free interval of more than 6 months after treatment.

VII. Chemotherapeutic Agents: Details & Toxicity

VIII. PARP Inhibitors & Hormones

• PARP Inhibitors utilize "synthetic lethality" to kill cancer cells that already have deficient DNA repair (e.g., BRCA mutations).
• Olaparib was the first PARP inhibitor approved for BRCA-positive recurrent ovarian cancer.
• Niraparib has shown benefits as consolidation therapy regardless of BRCA status.
• Rucaparib is indicated for platinum-sensitive recurrence after failure of ≥2 lines of chemotherapy.
• Hormonal therapy using Progestins (e.g., Megestrol) is most effective against well-differentiated endometrial carcinomas.

IX. Clinical Trials & Performance Status

• Phase I trials primarily evaluate the safety, toxicity, and maximum tolerated dose of a new drug.
• Phase II trials focus on the therapeutic effectiveness of a drug against a specific tumor type.
• Phase III trials compare a new treatment directly against the current standard of care.
• Karnofsky Performance Status measures a patient's functional condition; a score ≤50 indicates a poor candidate for clinical trials.

X. Pregnancy & Radiation (Williams)

• Fetal radiation exposure may cause malformations, growth restriction, or carcinogenesis depending on dose and gestational age.
• Week 8 to 15 of gestation is the period of highest risk for radiation-induced intellectual disability (threshold ~0.06 Gy).
• Organogenesis (Weeks 2–8) is the period where radiation exposure is most likely to cause structural congenital malformations (threshold 0.1–0.2 Gy).
• Radiotherapy to the maternal abdomen is contraindicated after 25 weeks of gestation.
• Supradiaphragmatic radiotherapy (e.g., for head and neck cancer) can be used during pregnancy if the fetus is shielded.

XI. Comparison of Similar Entities

• Cisplatin vs. Carboplatin: Cisplatin is more nephrotoxic and emetogenic; Carboplatin is more myelosuppressive (thrombocytopenia).
• Teletherapy vs. Brachytherapy: Teletherapy uses an external source at a distance; Brachytherapy uses an internal source placed within or near the tumor.
• Low-LET vs. High-LET: Low-LET (photons) requires oxygen to fix damage; High-LET (alpha/neutrons) kills cells regardless of oxygen presence.
• S-phase vs. M-phase: S-phase is the most radioresistant part of the cell cycle; M-phase is the most radiosensitive.
• Acute vs. Late effects: Acute effects involve rapidly dividing cells (skin/mucosa); Late effects involve slow-renewing tissues (fibrosis/fistula).
• Direct vs. Indirect Action: Direct action is the photon hitting DNA; Indirect action is damage via hydroxyl radicals from water.
• Platinum-sensitive vs. Resistant: Sensitive relapses >6 months after treatment; Resistant relapses <6 months after treatment.
• Paclitaxel vs. Docetaxel: Paclitaxel is derived from Pacific Yew and causes more hypersensitivity; Docetaxel is from English Yew and is more neutropenic.
• Olaparib vs. Niraparib: Olaparib is traditionally for BRCA-mutated patients; Niraparib is often used regardless of BRCA status.
• Phase II vs. Phase III trials: Phase II looks for efficacy in a specific disease; Phase III compares a drug to the gold standard.
• X-rays vs. Gamma rays: X-rays are extranuclear; Gamma rays are nuclear in origin.
• 5-FU vs. Doxorubicin Toxicity: 5-FU and liposomal Doxorubicin both cause Hand-Foot Syndrome; However, Doxorubicin is uniquely cardiotoxic.
• Vincristine vs. Paclitaxel: Both cause neuropathy, but Vincristine prevents microtubule polymerization while Paclitaxel prevents depolymerization.
• Ionization vs. Excitation: Ionization removes an electron from an atom; Excitation merely moves it to a higher energy state.
• Amsterdam vs. Bethesda (Context): While not in this text, remember Bethesda is more sensitive for MSI testing while Amsterdam is specific for Lynch Syndrome.

QA

text

I. Principles of Radiation Therapy & Physics

1. Describe the mass and charge of Electromagnetic radiation. | No mass or charge.
   Travels at the speed of light.
2. What is the mathematical relationship in the inverse square law? | 1/r².
   Radiation energy per unit area is inversely proportional to the square of the distance.
3. Does fractional cell kill eliminate a constant number or fraction? | Constant fraction.
   Each dose kills a constant fraction of tumor cells.
4. What is the primary therapeutic goal of radiation? | Maximum local tumor control.
   While minimizing normal tissue damage and adverse symptoms.
5. List three factors associated with Radiation resistance. (3) | 1) Cellular hypoxia
   2) Nutritional deficiency
   3) Enhanced cell-mediated DNA repair
6. What are the most common Photons used in gynecologic malignancies? | X-rays and Gamma rays.
7. What is the origin of Gamma rays? | Atomic nucleus.
8. What is the origin of X-rays? | Extranuclear interactions.
   Specifically atomic orbital interactions.
9. How is Bremsstrahlung ("braking radiation") produced? | Accelerated electrons hit high-Z target.
   Generates photons of various energies.
10. What particles make up Particulate radiation? (4) | 1) Alpha particles
    2) Protons
    3) Neutrons
    4) Electrons
11. Describe the characteristic Bragg peak of Protons. | Peak dose at end.
    Dose is deposited at the end of the particle's range, sparing initial tissue.

II. Photon Interactions & Radiobiology

12. Energy level and effect of Coherent Scattering? | <10 keV.
    Results in no energy loss or radiobiologic effect.
13. Imaging relevance of the Photoelectric Effect (10-60 keV)? | High tissue-bone contrast.
    Involves total photon absorption and electron ejection.
14. Which interaction is predominant in human tissue (90% water)? | Compton Effect.
    Occurs at 60 keV to 10 MeV.
15. What is the most important interaction at therapeutic energies (4-18 MeV)? | Compton Effect.
16. What is the energy requirement for Pair Production? | >1.022 MeV.
    Results in an electron-positron pair; basis of PET imaging.
17. What causes two-thirds of Indirect DNA damage? | Hydroxyl radicals (OH).
    Formed from water.
18. Comparison of Sublethal DNA damage repair in normal vs. malignant cells? | More effective in normal cells.
    Malignant cells often have faulty genomic monitors.
19. Role of Intracellular molecular oxygen in DNA damage? | "Fixing" DNA damage.
    Required to fix damage caused by free radicals.
20. Consequence of tumor hypoxia on radiation? | Radiation resistance.
21. What is the oxygen-dependency of High-LET radiation cell death? | Independent of oxygenation.
    Densely ionizing (e.g., neutrons or alpha particles).
22. Mechanism and use of Amifostine? | Scavenges free radicals.
    Reduces cisplatin-induced renal toxicity in ovarian cancer.
23. What is the most common form of radiation-induced cell death? | Mitotic death.
    Occurs after the cell attempts to divide.

III. Tissue Sensitivity & The Cell Cycle

24. Why is the M phase (Mitosis) the most radiosensitive? | DNA is tightly packaged.
25. Why is the S phase (DNA Synthesis) the most radioresistant? | Presence of repair enzymes.
    Used during replication.
26. Relationship between proliferation rate and Radiosensitivity? | Highest in rapidly proliferating cells.
27. Relative radiosensitivity of G1 and G2 phases? | Intermediate.
    More sensitive than S phase, less than M phase.
28. Target Hemoglobin levels for cervical cancer radiation? | >10 mg/dL.
    Associated with improved tumor oxygenation and outcomes.

IV. Radiation Techniques: Teletherapy & Brachytherapy

29. Define the source location in Teletherapy (External Beam). | At a distance.
    Typically uses linear accelerators.
30. Benefit of Intensity-modulated radiotherapy (IMRT)? | Precision/Sparing normal tissues.
    Conforms high-dose region to tumor, sparing small bowel.
31. What do Isodose curves represent? | Points of equivalent dose.
32. Benefit of higher-energy beams (e.g., 22-MeV)? | Deeper penetration.
    Sparing the skin surface.
33. Define Brachytherapy (Internal) source placement. | Within or near tumor.
34. Common applicator for Intracavitary therapy in cervical cancer? | Fletcher-Suit applicator.
    Uses tandem and ovoids.
35. Administration details of High-dose rate (HDR) brachytherapy? | Outpatient basis.
    3 to 5 hours, repeated 3 to 6 times.
36. Requirements for Low-dose rate (LDR) brachytherapy? | Shielded room and bed rest.
    Source remains in place for an extended period.
37. Half-life of Cesium-137 (137Cs)? | 30 years.
38. Half-life of Iridium-192 (192Ir)? | 73.8 days.

V. Radiation Complications

39. Timing and targets of Acute radiation effects? | Days to weeks.
    Rapidly dividing tissues (skin, mucosa, bone marrow).
40. Cause of Late radiation effects (months to years)? | Vascular damage.
    And connective tissue loss (fibrosis, fistulas).
41. Management of Radiation cystitis? | Phenazopyridine.
    Presents as dysuria and frequency.
42. Symptoms of Sigmoiditis or enteritis? | Diarrhea and malabsorption.
    Includes cramping.
43. Management of Radiation-induced bowel symptoms? | Low-roughage diet.
    Also antispasmodics.
44. Timing and management of radiation-induced Fistulas? | 6 to 24 months.
    Often require surgical intervention.
45. Define Radiation recall dermatitis. | Skin reaction to chemo.
    Occurs after previous radiation (e.g., Dactinomycin).

VI. Chemotherapy Principles & Management

46. Standard of care for advanced ovarian cancer? | Taxane-platinum combination.
    Example: Paclitaxel + Carboplatin for six cycles.
47. Goal of Neoadjuvant chemotherapy? | Reduce tumor size.
    Improve likelihood of optimal debulking.
48. Purpose of Maintenance therapy? | Prolong stable disease.
    Given after initial primary treatment.
49. Management of the toxicity Myelosuppression? | G-CSF.
    Granulocyte colony-stimulating factor.
50. Standard metric for calculating chemotherapy doses? | Body Surface Area (BSA).
51. Function of RECIST criteria? | Standardized tumor measurement.
    Measuring response via imaging.
52. Definition of Platinum resistance? | Recurrence within <6 months.
    Progression after completing platinum therapy.
53. Definition of Platinum sensitivity? | Interval > 6 months.

VII. Chemotherapeutic Agents: Platinums & Taxanes

54. Key toxicity of Cisplatin? | Nephrotoxic.
    Requires aggressive hydration.
55. Side effects (3) of Cisplatin? | 1) Ototoxicity
    2) Severe N/V
    3) Neuropathy
56. Dosing method for Carboplatin? | Calvert formula (AUC).
57. Dose-limiting toxicity of Carboplatin? | Thrombocytopenia.
58. Mechanism and phase of Paclitaxel? | Stabilizes microtubules (M-phase).
    Derived from Yew trees.
59. Side effects (3) of Paclitaxel? | 1) Peripheral neuropathy
    2) Alopecia
    3) Hypersensitivity
60. Indication for Docetaxel? | Paclitaxel hypersensitivity.
61. Significant toxicity of Docetaxel? | Neutropenia.

VII. Chemotherapeutic Agents: Antibiotics & Topoisomerase

62. Use and phase action of Actinomycin D? | Used for GTD (G1 phase).
63. Toxicities (2) of Actinomycin D? | 1) Myelosuppression
    2) Radiation recall
64. Mechanism and color of Doxorubicin? | Inhibits topoisomerase II (Red color).
65. Toxicities (2) of Doxorubicin? | 1) Irreversible cardiotoxicity (CHF)
    2) Hand-foot syndrome
66. Mechanism of Bleomycin? | Single-strand breaks.
    Via hydroxyl radicals.
67. Unique feature and toxicity of Bleomycin? | NOT myelosuppressive.
    Causes pulmonary fibrosis.
68. Mechanism and toxicity of Topotecan? | Inhibits Topoisomerase I.
    Severe bone marrow suppression.
69. Mechanism and toxicity of Etoposide? | Inhibits Topoisomerase II.
    Myelosuppression.

VII. Chemotherapeutic Agents: Alkylating & Antimetabolites

70. Mechanism of Cyclophosphamide? | DNA cross-links.
71. Toxicity and prevention for Cyclophosphamide? | Hemorrhagic cystitis.
    Prevent with hydration and Mesna.
72. Mechanism of Methotrexate? | Inhibits dihydrofolate reductase.
    Folic acid analog.
73. Toxicities and rescue for Methotrexate? | Stomatitis/Hepatotoxicity.
    Rescue with Folinic acid.
74. Mechanism of 5-Fluorouracil? | Inhibits thymidylate synthase.
75. Toxicities (2) of 5-Fluorouracil? | 1) PPE (Hand-foot syndrome)
    2) Diarrhea

VII. Chemotherapeutic Agents: Vincas & Biologics

76. Mechanism of Vincristine? | Blocks microtubule polymerization.
77. Toxicities (2) of Vincristine? | 1) Severe neurotoxicity
    2) Constipation
78. Mechanism of Bevacizumab? | Monoclonal antibody targeting VEGF.
    Inhibits angiogenesis.
79. Toxicities (3) of Bevacizumab? | 1) Bowel perforation
    2) Hypertension
    3) Proteinuria

VIII. PARP Inhibitors & Hormones

80. Mechanism of PARP Inhibitors? | Synthetic lethality.
    Kills cells with deficient DNA repair (BRCA mutations).
81. First PARP inhibitor for BRCA-positive recurrent ovarian cancer? | Olaparib.
82. Benefit of Niraparib? | Consolidation regardless of BRCA status.
83. Indication for Rucaparib? | Platinum-sensitive recurrence.
    After failure of ≥2 lines of chemotherapy.
84. Best target for Hormonal therapy (Progestins)? | Well-differentiated endometrial carcinomas.

IX. Clinical Trials & Performance Status

85. Purpose of Phase I trials? | Safety and toxicity.
    Determines maximum tolerated dose.
86. Purpose of Phase II trials? | Therapeutic effectiveness.
    Against a specific tumor type.
87. Purpose of Phase III trials? | Compare to standard of care.
88. Poor candidate score for Karnofsky Performance Status? | Score ≤50.

X. Pregnancy & Radiation

89. Fetal risks of Fetal radiation exposure? | Malformations/Growth restriction.
    Also carcinogenesis.
90. Risks during Week 8 to 15 of gestation? | Intellectual disability.
    Threshold ~0.06 Gy.
91. Risks during Organogenesis (Weeks 2–8)? | Structural malformations.
    Threshold 0.1–0.2 Gy.
92. When is Radiotherapy to the maternal abdomen contraindicated? | After 25 weeks of gestation.
93. Condition for using Supradiaphragmatic radiotherapy in pregnancy? | Fetus must be shielded.

XI. Comparison of Similar Entities (Part 1)

94. Compare Cisplatin vs. Carboplatin nephrotoxicity. | Cisplatin is more nephrotoxic.
95. Compare Cisplatin vs. Carboplatin myelosuppression. | Carboplatin is more myelosuppressive.
96. Contrast Teletherapy vs. Brachytherapy source position. | Teletherapy: External source.
    Brachytherapy: Internal source.
97. Contrast Low-LET vs. High-LET oxygen requirement. | Low-LET (photons) requires oxygen.
    High-LET (alpha/neutrons) is oxygen-independent.
98. Contrast S-phase vs. M-phase radiosensitivity. | S-phase: Most radioresistant.
    M-phase: Most radiosensitive.
99. Contrast Acute vs. Late effects tissue types. | Acute: Rapidly dividing (skin/mucosa).
    Late: Slow-renewing (fibrosis/fistula).
100. Contrast Direct vs. Indirect Action. | Direct: Photon hits DNA.
     Indirect: Damage via hydroxyl radicals.

XI. Comparison of Similar Entities (Part 2)

101. Define Platinum-sensitive vs. Resistant based on time. | sensitive: >6 months.
     Resistant: <6 months.
102. Compare Paclitaxel vs. Docetaxel origin and toxicity. | Paclitaxel: Pacific Yew/Hypersensitivity.
     Docetaxel: English Yew/Neutropenic.
103. Compare Olaparib vs. Niraparib BRCA status use. | Olaparib: BRCA-mutated.
     Niraparib: Regardless of BRCA status.
104. Contrast Phase II vs. Phase III trials objective. | Phase II: Efficacy in a disease.
     Phase III: Comparison to gold standard.
105. Contrast X-rays vs. Gamma rays origin. | X-rays: Extranuclear.
     Gamma rays: Nuclear.
106. Compare 5-FU vs. Doxorubicin Toxicity on skin/heart. | Both: Hand-Foot Syndrome.
     Doxorubicin: Cardiotoxic.
107. Contrast Vincristine vs. Paclitaxel microtubule effect. | Vincristine: Prevents polymerization.
     Paclitaxel: Prevents depolymerization.
108. Contrast Ionization vs. Excitation. | Ionization: Removes electron.
     Excitation: Moves electron to higher state.
109. Amsterdam vs. Bethesda context for Lynch Syndrome? | Amsterdam: Specific for Lynch.
     Bethesda: Sensitive for MSI testing.

XII. Additional Detailed Parameters

110. Energy level of the Photoelectric Effect? | 10 to 60 keV.
111. Energy range of the Compton Effect? | 60 keV to 10 MeV.
112. Threshold for radiation-induced intellectual disability (8-15 weeks)? | ~0.06 Gy.
113. Threshold for radiation-induced structural malformations (2-8 weeks)? | 0.1–0.2 Gy.
114. Dactinomycin is associated with what radiation complication? | Radiation recall dermatitis.
115. What is the most common serious chemotherapy toxicity? | Myelosuppression.
116. Primary target of Bevacizumab? | VEGF (Vascular Endothelial Growth Factor).
117. Cyclophosphamide class of agent? | Alkylating agent.
118. Which antibiotic is red in color? | Doxorubicin.
119. Topotecan inhibits which Topoisomerase? | Topoisomerase I.
120. Etoposide inhibits which Topoisomerase? | Topoisomerase II.

4

Summary

text

I. General Principles of Lower Genital Tract Intraepithelial Neoplasia (LGTIN)

• Lower Genital Tract Intraepithelial Neoplasia (LGTIN) refers to a group of premalignant epithelial lesions characterized by dysplastic cellular changes confined to the epithelium of the cervix, vagina, and vulva without invasion of the basement membrane.
• In the pathology of LGTIN, Dysplasia is initially identified microscopically through nuclear and cytoplasmic changes before becoming grossly visible.
• The Lower Genital Tract specifically includes the vulva (external), vagina, and cervix.

II. Cervical Anatomy & The Transformation Zone (TZ)

• The Squamocolumnar Junction (SCJ) is a dynamic point that rarely remains at the external os, changing position in response to puberty, pregnancy, menopause, and hormones.
• In Neonates, the SCJ is located at the exocervix.
• During Menarche, estrogen causes glycogen accumulation, which lactobacilli convert to acid, stimulating normal physiological Squamous metaplasia in the squamocolumnar reserve cells.
• The ideal area for specimen collection for HPV or disease detection is the active squamocolumnar junction.

• The Transformation Zone is highly vulnerable to HPV because it is an area of active squamous metaplasia with high cell turnover where immature basal cells are exposed.

III. Classification of Cervical Intraepithelial Neoplasia (CIN)

• Atypical cells in CIN are microscopically characterized by:
  1. Increased nuclear-cytoplasmic ratio
  2. Increased nuclear size
  3. Loss of polarity
  4. Increased mitotic figures
  5. Hyperchromasia
• In the 2021 Bethesda System, Squamous Cell Abnormalities are divided into:
  • ASC-US: Atypical squamous cells of undetermined significance.
  • ASC-H: Atypical squamous cells, cannot exclude HSIL.
  • LSIL: Low-grade squamous intraepithelial lesion (includes CIN 1 and HPV effects).
  • HSIL: High-grade squamous intraepithelial lesion (includes CIN 2, CIN 3, and CIS).
• In the Bethesda System, Glandular Cell Abnormalities include:
  • AGC: Atypical glandular cells.
  • AIS: Endocervical adenocarcinoma in situ.
• LSIL is characterized by high viral replication with mild alteration in host cell growth, while HSIL involves low viral replication with high cellular dysregulation.

IV. Human Papillomavirus (HPV) Pathogenesis

• Genital HPV is the most common sexually transmitted infection (STI); nearly all sexually active individuals will acquire at least one type in their lifetime.
• HPV 16 is the most common high-risk oncogenic type; other high-risk types include HPV 18, 31, 33, 45, 52, and 58.
• HPV 6 and 11 are low-risk types primarily associated with genital warts (condyloma acuminata).
• For malignancy to occur, the single most important step is Persistent infection with high-risk HPV and failure of host immune clearance.
• During Oncogenic infection, viral DNA integrates into the host genome, which disrupts the E2 gene; because E2 normally suppresses E6 and E7, its loss leads to uncontrolled oncoprotein expression.

• Koilocytosis, characterized by nuclear enlargement and perinuclear clearing, is a hallmark cellular change of early/low-grade HPV lesions.

V. Screening and Risk Factors

• Factors increasing Risk for HPV/CIN include:
  1. Young age at first intercourse
  2. Multiple sex partners
  3. Male partner with multiple partners
  4. Smoking (local immunosuppression)
  5. Nutritional deficiencies
• ACOG/USPSTF Screening Guidelines for average-risk women:
  • Ages 21–24: Cytology (Pap) alone every 3 years.
  • Ages 25–29: Preferred Primary HR-HPV testing every 5 years (ACS) or Pap alone every 3 years.
  • Ages 30–65: Preferred Primary HR-HPV testing every 5 years OR co-testing (Pap + HPV) every 5 years.
• Screening may be Discontinued at age >65 if there is "adequate prior screening" (2 negative HPV/Co-tests or 3 negative Pap tests in 10 years) and no history of CIN 2+ in the last 25 years.
• DES (Diethylstilbestrol) Exposure in utero requires annual cytology due to increased risk of clear cell adenocarcinoma.
• Liquid-based cytology (LBC) (e.g., ThinPrep) was developed to reduce contamination (blood/mucus) and provide more representative samples compared to conventional Pap smears.

VI. Diagnostic Evaluation

• Colposcopy is a low-power binocular microscope exam of the cervix used after abnormal cytology; it is considered "Satisfactory" only if the entire transformation zone is visualized.
• Acetowhite Epithelium appears when 3%–5% acetic acid is applied, coagulating nuclear proteins in dysplastic cells to reflect light.
• Leukoplakia is a white plaque visible on the cervix before the application of acetic acid, caused by a keratin layer.
• Punctation refers to dilated capillaries appearing as dots on the surface; when found in acetowhite areas, they often indicate CIN.
• Schiller’s Test (VILI) uses Lugol's iodine; normal cells (rich in glycogen) stain mahogany brown, while dysplastic cells remain unstained (yellow/pale).
• Endocervical Curettage (ECC) is recommended if the colposcopic exam is unsatisfactory or if there is abnormal cytology without a visible lesion.

VII. Management of Cervical Lesions

• Cryotherapy destroys the surface epithelium by crystallizing intracellular water using Nitrous oxide (-89°C) or CO2 (-65°C); it requires a 3–5–3 double freeze–thaw cycle.
• Cryotherapy Criteria: Acceptable for persistent CIN 1 (24 months) or CIN 2 if the lesion is small, ectocervical, and the ECC is negative.
• Laser Ablation uses a CO2 laser to vaporize tissue to a depth of ~5 mm; it produces no prolonged discharge but provides no tissue specimen.
• Loop Electrosurgical Excision Procedure (LEEP/LLETZ) is the most common US treatment for CIN 2/3; it uses a wire loop to excise the TZ and provide a tissue specimen for pathology.
• Cold Knife Conization (CKC) is an excisional procedure done with a scalpel in an OR; it is preferred for Glandular abnormalities (AIS) or suspected invasive cancer because it avoids thermal artifact on margins.
• Hysterectomy is a treatment of last resort for CIN, indicated for microinvasion, recurrent high-grade CIN, or if other gynecologic issues (e.g., fibroids/prolapse) coexist.

VIII. Vaginal and Vulvar Intraepithelial Neoplasia (VaIN & VIN)

• Vaginal Intraepithelial Neoplasia (VaIN) is most commonly found in the upper third of the vagina and is frequently associated with a history of CIN or cervical cancer.
• VaIN Management: VaIN 1 is monitored via surveillance; VaIN 2 and 3 require treatment (excision or ablation) due to a 2%–5% progression risk to invasive cancer.
• Usual-type VIN (uVIN/HSIL) is the most common form of vulvar neoplasia, caused by high-risk HPV (HPV 16), seen in younger women, and often multifocal.
• Differentiated-type VIN (dVIN) is NOT HPV-related; it is associated with chronic inflammation (lichen sclerosus), occurs in older women, and has a higher risk of progression to squamous cell carcinoma.
• Symptoms of Vulvar Intraepithelial Neoplasia (VIN) include pruritus (itching), burning, and visible color changes (white, red, or pigmented); many remain asymptomatic.
• Imiquimod cream is a topical immune response modifier used for VIN and genital warts; Trichloroacetic acid is used for pregnant women with external warts.

IX. Prophylaxis: HPV Vaccines

• HPV Vaccines work by stimulating neutralizing antibodies; they are prophylactic and cannot treat existing HPV disease or cancer.
• Total abstinence from all genital contact is the most effective prevention method for HPV.

X. Comparison of Similar Entities

• LSIL vs. HSIL Natural History: 60% of LSIL regresses and only 10% progresses to carcinoma, whereas 30% of HSIL regresses and 10% progresses to carcinoma.
• CIN 1 vs. CIN 3 Involvement: CIN 1 involves the lower 1/3 of the epithelium thickness, while CIN 3 involves the full thickness of the epithelium.
• uVIN vs. dVIN Etiology: uVIN is caused by oncogenic HPV (mainly type 16), whereas dVIN is associated with chronic inflammatory conditions like Lichen Sclerosus and is HPV-negative.
• Ablative vs. Excisional Therapy: Ablative therapies (Cryo/Laser) destroy tissue and provide no specimen, while excisional therapies (LEEP/CKC) provide a tissue specimen to rule out invasive cancer.
• LEEP vs. Cold Knife Conization (CKC): LEEP is done in-office with thermal energy (risk of thermal artifact), whereas CKC is done in the OR with a scalpel (preferred for AIS and margin assessment).
• E6 vs. E7 Oncoproteins: E6 binds and degrades p53 (stopping apoptosis), while E7 inactivates Rb (allowing continuous cell cycling).
• Acetowhite vs. Leukoplakia: Acetowhite epithelium only appears after acetic acid application; Leukoplakia is white before any solution is applied.
• Surgical vs. Medical VIN Treatment: Surgical excision/laser is used for localized or suspected invasive VIN, while Imiquimod is a medical topical therapy used for diffuse disease.
• Pregnancy vs. Non-pregnancy CIN Management: In pregnancy, CIN is usually managed expectantly and ECC is contraindicated; postpartum, many low-grade lesions regress.
• Bivalent vs. Quadrivalent Vaccine: Bivalent (16, 18) only covers cancer-causing types, whereas Quadrivalent (6, 11, 16, 18) covers both cancer and genital warts.
• Cytology Sensitivity vs. HPV Testing: Standard Pap smear has lower sensitivity (~51%) compared to HR-HPV testing, leading to the preference for HPV testing in modern screening.

QA

text

I. General Principles of LGTIN

1. Describe Lower Genital Tract Intraepithelial Neoplasia (LGTIN). | Premalignant lesions with dysplastic changes.
2. Where are cellular changes confined in LGTIN? | Epithelium (no basement membrane invasion).
3. Anatomy: Components of the Lower Genital Tract? (3) | Vulva, Vagina, and Cervix.
4. How is Dysplasia initially identified in the pathology of LGTIN? | Microscopically (nuclear and cytoplasmic changes).
5. At what point does Dysplasia in LGTIN become grossly visible? | After microscopic nuclear/cytoplasmic changes occur.

II. Cervical Anatomy & The Transformation Zone (TZ)

6. Location: Columnar Epithelium? | Lines the endocervical canal.
7. Location: Squamous Epithelium? | Covers the exocervix.
8. What is the meeting point of Columnar and Squamous epithelium? | Squamocolumnar Junction (SCJ).
9. Physiology: Columnar Epithelium? | Secretes mucus; undergoes metaplasia.
10. Physiology: Squamous Epithelium? | Protective outer layer.
11. Describe the nature of the Squamocolumnar Junction (SCJ) position. | Dynamic point (rarely at external os).
12. Factors changing the Squamocolumnar Junction (SCJ) position? (4) | Puberty, pregnancy, menopause, and hormones.
13. Where is the SCJ located in neonates? | Exocervix.
14. Effect of estrogen on glycogen in Menarche? | Causes glycogen accumulation.
15. Role of lactobacilli in Squamous metaplasia during menarche? | Converts glycogen to acid.
16. Target of Squamous metaplasia stimulus? | Squamocolumnar reserve cells.
17. Ideal area for HPV or disease detection collection? | Active squamocolumnar junction.
18. Estrogen level: Premenarchal stage? | Low.
19. SCJ Location: Premenarchal stage? | Inside the endocervical canal.
20. Transformation Zone (TZ): Premenarchal stage? | Absent or minimal.
21. Estrogen level: Reproductive stage? | Normal.
22. SCJ Location: Reproductive stage? | Ectocervix.
23. Transformation Zone (TZ): Reproductive stage? | Active and visible.
24. Estrogen level: Pregnancy? | Very High.
25. SCJ Location: Pregnancy? | Widely everted on ectocervix.
26. Transformation Zone (TZ): Pregnancy? | Large and exposed.
27. Estrogen level: Postmenopausal stage? | Low.
28. SCJ Location: Postmenopausal stage? | Regressed inside the canal.
29. Transformation Zone (TZ): Postmenopausal stage? | Regressed/difficult to see.
30. Why is the Transformation Zone highly vulnerable to HPV? | Active metaplasia with high turnover.
31. Cells exposed in the Transformation Zone during metaplasia? | Immature basal cells.

III. Classification of Cervical Intraepithelial Neoplasia (CIN)

32. Epithelial thickness involved: CIN 1? | Atypical cells in < 1/3 thickness.
33. Former dysplasia term: CIN 1? | Mild Dysplasia.
34. Epithelial thickness involved: CIN 2? | 1/3 to 2/3 thickness.
35. Former dysplasia term: CIN 2? | Moderate Dysplasia.
36. Epithelial thickness involved: CIN 3? | Full thickness of epithelium.
37. Former terms (2) for CIN 3? | Severe Dysplasia / Carcinoma in Situ.
38. Microscopic characteristics: Atypical cells in CIN? (5) | 1) High N:C ratio
    2) Large nuclei
    3) Loss of polarity
    4) Mitotic figures
    5) Hyperchromasia.
39. Full name of ASC-US? | Atypical squamous cells of undetermined significance.
40. Full name of ASC-H? | Atypical squamous cells, cannot exclude HSIL.
41. Components included in LSIL? (2) | CIN 1 and HPV effects.
42. Components included in HSIL? (3) | CIN 2, CIN 3, and CIS.
43. Full name of AGC? | Atypical glandular cells.
44. Full name of AIS? | Endocervical adenocarcinoma in situ.
45. Pathogenesis of LSIL? | High viral replication; mild host cell alteration.
46. Pathogenesis of HSIL? | Low viral replication; high cellular dysregulation.

IV. Human Papillomavirus (HPV) Pathogenesis

47. Significance of Genital HPV among STIs? | Most common sexually transmitted infection.
48. Most common high-risk oncogenic HPV type? | HPV 16.
49. List of high-risk HPV types (6)? | 18, 31, 33, 45, 52, and 58.
50. Common low-risk HPV types? (2) | HPV 6 and 11.
51. Condition associated with HPV 6 and 11? | Genital warts (condyloma acuminata).
52. Essential step for malignancy in HPV infection? | Persistent infection.
53. Host factor preventing HPV malignancy? | Host immune clearance.
54. Gene disrupted by HPV DNA integration into host genome? | E2 gene.
55. Result of E2 gene loss in HPV? | Uncontrolled oncoprotein expression (E6/E7).
56. Target of E6 Oncoprotein? | p53 tumor suppressor.
57. Mechanism of E6 Oncoprotein? | Degrades p53; inhibits apoptosis.
58. Target of E7 Oncoprotein? | Retinoblastoma (Rb) protein.
59. Mechanism of E7 Oncoprotein? | Inactivates Rb; uncontrolled G1 to S phase.
60. Cell cycling effect of E7 Oncoprotein? | Continuous cell cycling.
61. Hallmark cellular changes of Koilocytosis? (2) | Nuclear enlargement and perinuclear clearing.
62. Koilocytosis is typical for which grade of HPV lesions? | Early or low-grade.

V. Screening and Risk Factors

63. Risk factors (5) for HPV/CIN? | 1) Young age coitus
    2) Multiple partners
    3) Male partner habits
    4) Smoking
    5) Nutritional deficiencies.
64. Screening ages 21–24: ACOG Guidelines? | Cytology (Pap) alone every 3 years.
65. Preferred screening ages 25–29: ACS/ACOG? | Primary HR-HPV testing every 5 years.
66. Option for ages 25–29: ACOG Screening? | Pap alone every 3 years.
67. Preferred screening ages 30–65? (2 options) | Primary HR-HPV every 5 years OR co-testing every 5 years.
68. When can Screening be discontinued (age)? | >65 years.
69. Criteria for Adequate prior screening at age 65? (2 options) | 2 negative HPV/Co-tests OR 3 negative Paps (in 10 years).
70. History clause to discontinue Screening at age 65? | No CIN 2+ in last 25 years.
71. Screening requirement for DES Exposure? | Annual cytology.
72. Cancer risk associated with DES Exposure? | Clear cell adenocarcinoma.
73. Goal of Liquid-based cytology (LBC) development? | Reduce contamination (blood/mucus).

VI. Diagnostic Evaluation

74. Describe Colposcopy. | Low-power binocular microscope exam of cervix.
75. Requirement for a Satisfactory Colposcopy? | Entire transformation zone visualized.
76. What causes Acetowhite Epithelium? | 3%–5% acetic acid application.
77. Mechanism of Acetowhite Epithelium? | Coagulates nuclear proteins to reflect light.
78. What is Leukoplakia? | White plaque visible before acetic acid.
79. Cause of Leukoplakia? | Keratin layer.
80. Describe Punctation on the cervix. | Dilated capillaries appearing as dots.
81. Clinical significance of Punctation in acetowhite areas? | Often indicates CIN.
82. Solution used in Schiller’s Test (VILI)? | Lugol’s iodine.
83. Appearance of normal cells in Schiller’s Test? | Mahogany brown (rich in glycogen).
84. Appearance of dysplastic cells in Schiller’s Test? | Yellow/pale (unstained).
85. Recommendation for Endocervical Curettage (ECC)? | Unsatisfactory colposcopy or abnormal cytology without lesion.

VII. Management of Cervical Lesions

86. Define Cryotherapy mechanism. | Crystallizing intracellular water to destroy epithelium.
87. Agents used in Cryotherapy? (2) | Nitrous oxide or CO2.
88. Required cycle for Cryotherapy? | 3–5–3 double freeze–thaw cycle.
89. When is Cryotherapy acceptable? (3) | Persistent CIN 1 (24 mo), small CIN 2, negative ECC.
90. Describe Laser Ablation depth? | Vaporizes tissue to ~5 mm.
91. Disadvantage of Laser Ablation? | Provides no tissue specimen.
92. Most common treatment for CIN 2/3 in the US? | Loop Electrosurgical Excision Procedure (LEEP).
93. Benefit of LEEP/LLETZ? | Provides tissue specimen for pathology.
94. Preferred procedure for Glandular abnormalities (AIS)? | Cold Knife Conization (CKC).
95. Why is CKC used for suspected invasive cancer? | Avoids thermal artifact on margins.
96. Indication for Hysterectomy in CIN? (3) | Microinvasion, recurrent high-grade CIN, or coexisting gyn issues.

VIII. Vaginal and Vulvar Intraepithelial Neoplasia (VaIN & VIN)

97. Common location: Vaginal Intraepithelial Neoplasia (VaIN)? | Upper third of the vagina.
98. Common association for VaIN? | Prior history of CIN or cervical cancer.
99. Management: VaIN 1? | Surveillance.
100. Management: VaIN 2 and 3? | Excision or ablation.
101. Risk of progression for untreated VaIN 2/3? | 2%–5% to invasive cancer.
102. Most common form of vulvar neoplasia? | Usual-type VIN (uVIN/HSIL).
103. Etiology: Usual-type VIN? | High-risk HPV (mainly HPV 16).
104. Typical patient profile: uVIN? | Younger women.
105. Etiology: Differentiated-type VIN (dVIN)? | Chronic inflammation (Lichen Sclerosus); HPV-negative.
106. Progression risk: dVIN vs uVIN? | dVIN has higher progression risk to SCC.
107. Symptoms (3): Vulvar Intraepithelial Neoplasia (VIN)? | Pruritus, burning, visible color changes.
108. Medical use: Imiquimod cream? | Topical immune response modifier for VIN/warts.
109. Treatment for external warts in pregnant women? | Trichloroacetic acid.

IX. Prophylaxis: HPV Vaccines

110. HPV types covered: Bivalent (Cervarix)? | 16 and 18.
111. HPV types covered: Quadrivalent (Gardasil)? | 6, 11, 16, and 18.
112. HPV types covered: 9-valent (Gardasil 9)? | 6, 11, 16, 18, 31, 33, 45, 52, 58.
113. Goal: Bivalent Vaccine? | Cervical cancer prevention.
114. Goal: Quadrivalent Vaccine? | Cancer and Genital Warts prevention.
115. Benefit: 9-valent Vaccine? | Broadest cancer and wart protection.
116. Mechanism: HPV Vaccines? | Stimulating neutralizing antibodies.
117. Limitation: HPV Vaccines? | Prophylactic only (cannot treat existing disease).
118. Most effective HPV prevention method? | Total abstinence from genital contact.

X. Comparison of Similar Entities

119. Natural history: LSIL regression rate? | 60%.
120. Natural history: HSIL regression rate? | 30%.
121. Natural history: Carcinoma progression in LSIL vs HSIL? | 10% for both.
122. Compare epithelial thickness: CIN 1 vs. CIN 3? | CIN 1: lower 1/3; CIN 3: full thickness.
123. Etiology: uVIN vs dVIN? | uVIN: Oncogenic HPV; dVIN: HPV-negative/Lichen Sclerosus.
124. Therapy contrast: Ablative vs Excisional? | Ablative: no specimen; Excisional: provides specimen.
125. Feature: LEEP artifact risk? | Thermal artifact.
126. Procedure choice: AIS or margin assessment? | Cold Knife Conization (CKC).
127. Function: E6 vs E7? | E6 degrades p53 (stops apoptosis); E7 inactivates Rb (allows cell cycle).
128. Identification timing: Acetowhite vs Leukoplakia? | Acetowhite: after acid; Leukoplakia: before acid.
129. VIN treatment: Surgical vs Medical usage? | Surgical: localized/invasive; Medical (Imiquimod): diffuse disease.
130. Management difference: Pregnancy vs Non-pregnancy CIN? | Pregnancy: expectant management; ECC is contraindicated.
131. Vaccine coverage: Bivalent vs Quadrivalent? | Bivalent: cancer types; Quadrivalent: cancer + warts.
132. Sensitivity: Cytology vs HR-HPV Testing? | Cytology lower (~51%) than HR-HPV.

IM

1

Summary

text

CHAPTER 356: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

OVERVIEW & EPIDEMIOLOGY

• Systemic Lupus Erythematosus (SLE) is an autoimmune disease where damage to organs is mediated by autoantibodies and immune complex deposits.
• SLE is 5-6 times more common in females than males, with 90% of patients being females of child-bearing age.
• The prevalence of SLE is highest in African-American and Afro-Caribbean women and lowest in white men.
• In most SLE patients, autoantibodies are present for a few years before the first clinical symptom appears.
• The disease course of SLE for ~85% of patients involves active disease or flares annually, with less than 5% achieving permanent complete remission.

SLE: PATHOGENESIS, ETIOLOGY, AND CLINICAL FINDINGS

SLE: CLINICAL MANIFESTATIONS

SLE: DIAGNOSIS AND TREATMENT

CHAPTER 357: ANTIPHOSPHOLIPID SYNDROME (APS)

OVERVIEW, PATHOGENESIS, AND CLINICAL FINDINGS

CHAPTER 365: INFLAMMATORY MYOPATHIES

OVERVIEW AND DIAGNOSIS

• Inflammatory myopathies are a group of diseases characterized by progressive and symmetric proximal muscle weakness, which is initially painful. Sensory function is preserved.
• Five Types: Dermatomyositis (DM), Polymyositis (PM), Immune-mediated necrotizing myopathy (IMNM), Antisynthetase syndrome (AS), and Inclusion body myositis (IBM).
• Diagnostic Modalities:
  • Serum Creatine Kinase (CK): The most sensitive lab marker of muscle destruction.
  • EMG/NCS: Helps localize the lesion to the muscle and guides biopsy.
  • Myositis-Specific Antibodies (MSAs): Help distinguish between the different subtypes.
  • Muscle MRI: Assesses the extent of muscle involvement and guides biopsy.
  • Muscle Biopsy: The definitive diagnostic modality.

TYPES OF INFLAMMATORY MYOPATHIES

TREATMENT OF INFLAMMATORY MYOPATHIES

• First-line: Steroids are the standard treatment for inflammatory myopathies.
• Second-line: Steroid-sparing agents like Methotrexate (preferred), Azathioprine, or Mycophenolate (preferred for ILD) are used for severe disease or to taper steroids.
• Refractory Disease: IV Immunoglobulin (IVIG) or Rituximab may be used.
• IMNM: Requires steroids plus a second-line agent from the start.
• IBM: Often does not respond to immunosuppressive therapy; the main therapy is Physical and Occupational Therapy (PT/OT).
• Monitoring: Treatment adjustments should be based on objective improvement in muscle strength, not just on CK levels.
• Steroid Myopathy: If weakness develops on high-dose steroids with a normal CK level, it may be steroid-induced myopathy rather than a disease relapse.

CHAPTER 361: SJÖGREN'S SYNDROME

HIGH-YIELD COMPARISONS & DIFFERENTIATORS

1. SLE Arthritis vs. RA Arthritis: Both can present in young women with symmetric polyarthritis of the hands. However, SLE arthritis is rarely erosive, while RA is classically erosive and deforming.
2. SLE Mucosal Ulcers: Oral ulcers are painless and do NOT correlate with disease activity, whereas Nasal ulcers (on the lower septum) ARE associated with disease activity.
3. SLE-Specific Antibodies: Anti-dsDNA is specific for SLE and its levels often correlate with disease activity (especially nephritis). Anti-Sm is also highly specific for SLE but its levels do not correlate with disease activity.
4. SLE Cutaneous Rashes:
   • Malar Rash (Acute): Erythematous rash on cheeks, spares nasolabial folds, non-scarring.
   • Subacute Cutaneous Lupus (SCLE): Photosensitive annular or psoriasiform rashes, spares the face, non-scarring, associated with anti-Ro.
   • Discoid Lupus (DLE) (Chronic): Circular, atrophic, hyperpigmented lesions that cause scarring and disfigurement.
5. Polymyositis vs. Dermatomyositis: The key differentiator is the rash. DM has pathognomonic rashes (Heliotrope, Gottron's) and is highly associated with malignancy. PM has no rash. Histologically, PM has endomysial infiltrates, while DM has perimysial infiltrates and perifascicular atrophy.
6. Polymyositis vs. Inclusion Body Myositis (IBM): Both show endomysial inflammation on biopsy. However, IBM occurs in older men (>50), causes asymmetric and distal weakness (finger flexors), has rimmed vacuoles on biopsy, is associated with the anti-cN-1A antibody, and responds poorly to treatment.
7. Dermatomyositis vs. Antisynthetase Syndrome (AS): AS is a subtype of DM. Differentiators for AS are the triad of myositis, ILD, and non-erosive arthritis, plus the presence of mechanic's hands and anti-synthetase antibodies (e.g., anti-Jo-1). Importantly, AS does not carry the increased malignancy risk seen in classic DM.
8. SLE vs. Sjögren's Syndrome: Both are autoimmune, affect women, and can have positive anti-Ro/La. SLE is a systemic disease with prominent features like nephritis and malar rash. Sjögren's is defined by sicca symptoms (dry eyes/mouth) from exocrine gland destruction and carries a significant risk of lymphoma.
9. SLE Hematologic Findings: SLE is unique among many connective tissue diseases for causing leukopenia, lymphopenia, and thrombocytopenia. Other inflammatory conditions often cause leukocytosis.
10. Lupus Nephritis Induction Meds: For fertility concerns, Mycophenolate Mofetil (MMF) is preferred over Cyclophosphamide, which carries a high risk of permanent ovarian failure.
11. Life-Threatening vs. Non-Life-Threatening SLE: Treatment differs drastically. Non-life-threatening disease (skin, joints) is managed with NSAIDs, Hydroxychloroquine, and low-dose steroids. Life-threatening disease (renal, CNS, cardiac, severe hematologic) requires high-dose glucocorticoids and potent immunosuppressants.
12. Antiphospholipid Antibodies: Lupus Anticoagulant (LA) is the strongest predictor of thrombosis. Anti-β2-Glycoprotein I is the most specific antibody for APS diagnosis (97% specificity). Positive lab tests must be confirmed ≥12 weeks apart to be diagnostically significant.
13. Relapse of Myositis vs. Steroid Myopathy: Both cause weakness. A myositis relapse is typically associated with a rising CK level. Steroid-induced myopathy occurs on high-dose steroids and is characterized by a normal CK level.

QA

text

CHAPTER 356: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

OVERVIEW & EPIDEMIOLOGY

1. How is organ damage mediated in Systemic Lupus Erythematosus (SLE)? | By autoantibodies and immune complex deposits.
2. In SLE, what is the prevalence ratio of females to males? | 5-6 times more common in females.
3. What percentage of SLE patients are females of child-bearing age? | 90%.
4. In which populations is the prevalence of SLE highest and lowest? | Highest: African-American and Afro-Caribbean women.
   Lowest: white men.
5. In most SLE patients, when do autoantibodies appear relative to the first clinical symptom? | For a few years before the first clinical symptom appears.
6. What is the typical disease course for approximately 85% of SLE patients? | Involves active disease or flares annually.
7. What percentage of SLE patients achieve permanent complete remission? | Less than 5%.

SLE: PATHOGENESIS, ETIOLOGY, AND CLINICAL FINDINGS 8. What is the core mechanism of SLE pathogenesis? | Interactions between susceptible genes and environmental factors. 9. What is a key initiating step in SLE pathogenesis involving innate immunity? | Activation of innate immunity (dendritic cells, monocyte/macrophages). 10. What do activated innate immune cells produce in SLE, creating a genetic "signature"? | IFN-alpha. 11. What percentage of known predisposing genes for SLE influence IFN production/function? | Approximately 50%. 12. What is the most characteristic increased gene expression pattern for SLE? | The pattern related to IFN-alpha. 13. Describe the dysfunction of B and T cells in SLE pathogenesis. | Lowered activation thresholds of B and T cells. 14. What process is reduced in SLE pathogenesis regarding waste clearance? | Reduced clearance of immune complexes and apoptotic cells. 15. SLE is described as what kind of genetic disease? | A multigenetic disease. 16. What gene is associated with End-Stage Renal Disease (ESRD) in all ancestries with SLE? | The MYH9/APOL1 gene. 17. In which ancestry are APOL1G1/G2 variants associated with ESRD? | Only in African Americans. 18. Which spectrum of UV light is a more potent trigger for SLE? | The UV-B spectrum. 19. Which infection is particularly noted to activate autoreactive T and B cells in SLE? | Epstein-Barr Virus (EBV). 20. How can female hormones like estradiol contribute to SLE? | Increasing the activation, survival, and activity of abnormal immune cells. 21. Name four other environmental triggers for SLE. | Tobacco smoking,
prolonged exposure to silica,
air pollution,
pesticides. 22. What is the primary purpose of SLE classification criteria (like SLICC or EULAR/ACR)? | To standardize patient groups in clinical trials. 23. According to SLICC Criteria (2012), how is a patient classified with SLE? | At least 4 criteria, with at least 1 clinical and 1 immunologic criterion. 24. What is the entry criterion for the 2019 EULAR/ACR criteria for SLE? | A positive ANA test (≥1:80). 25. What score is needed to classify a patient as having SLE using the 2019 EULAR/ACR criteria? | A score of 10 or more points.

SLE: CLINICAL MANIFESTATIONS 26. What are common initial systemic symptoms of SLE? (3) | Fatigue, myalgias, and arthralgias. 27. How can severe systemic illness in SLE present? (4) | Fever, weight loss, anemia, and prostration. 28. Describe the SLE Malar Rash. | An erythematous, elevated, pruritic rash that spares the nasolabial folds. 29. What is a key feature of Subacute Cutaneous Lupus (SCLE) lesions? | Scaly red patches (psoriasiform) or circular flat red-rimmed lesions (annular). 30. Which antibody is often associated with Subacute Cutaneous Lupus (SCLE)? | Anti-Ro (SS-A) antibodies. 31. Describe the appearance of Discoid Lupus (DLE) lesions. | Circular, raised, scaly, hyperpigmented rims with depigmented, atrophic centers. 32. What percentage of people with Discoid Lupus (DLE) develop systemic SLE? | Only 5%. 33. Describe the alopecia associated with SLE. | Non-scarring; hair typically grows back. 34. Which SLE mucosal ulcers are typically painless and NOT associated with disease activity? | Oral ulcers. 35. Which SLE mucosal ulcers ARE associated with disease activity? | Nasal ulcers (on the lower nasal septum). 36. How does SLE arthritis differ from Rheumatoid Arthritis? | It is RARELY the erosive type. 37. What musculoskeletal manifestation can SLE cause besides arthritis? | Proximal muscle myositis. 38. What is the most serious manifestation of SLE and a leading cause of mortality? | Lupus Nephritis (LN). 39. What is crucial for the diagnosis and for guiding therapy in Lupus Nephritis? | A renal biopsy. 40. Which classes of Lupus Nephritis require aggressive treatment? (3) | Classes III, IV, and V. 41. Enumerate the 6 classes of Lupus Nephritis. | Class I: Minimal Mesangial LN
Class II: Mesangial Proliferative LN
Class III: Focal LN
Class IV: Diffuse LN
Class V: Membranous LN
Class VI: Advanced Sclerosis LN. 42. How can CNS Lupus present? (2 ways) | A diffuse process (headache, psychosis) or a vascular occlusive disease (stroke, TIA). 43. What must be ruled out when considering CNS Lupus-related psychosis? | Steroid-induced psychosis. 44. What is the most common pulmonary manifestation of SLE? | Pleuritis, with or without pleural effusion. 45. Name three other serious pulmonary manifestations of SLE. | Lupus Pneumonitis,
Interstitial Lung Disease (ILD),
shrinking lung syndrome. 46. What is the most frequent cardiac manifestation of SLE? | Pericarditis. 47. What specific valvular heart disease is associated with SLE? | Libman-Sacks vegetations (on mitral/aortic valves). 48. What is the most frequent hematologic manifestation of SLE? | Anemia, typically normochromic normocytic anemia of chronic illness. 49. What type of anemia is also a key feature of SLE? | Hemolytic anemia. 50. What three hematologic findings distinguish SLE from other connective tissue diseases? | Leukopenia, lymphopenia, and thrombocytopenia. 51. What are common GI symptoms in SLE? (3) | Nausea, vomiting, and diarrhea. 52. In active SLE, what may be elevated, requiring exclusion of primary liver problems? | Liver enzymes. 53. What are common ocular manifestations in SLE? (2) | Sicca syndrome (Sjögren's) and nonspecific conjunctivitis. 54. Name two serious, vision-threatening ocular manifestations of SLE. | Retinal vasculitis and optic neuritis.

SLE: DIAGNOSIS AND TREATMENT 55. What is the most important screening test for SLE? | Antinuclear Antibody (ANA) Test. 56. What are the two highly specific antibodies for SLE? | Anti-dsDNA and Anti-Sm. 57. Which SLE-specific antibody's levels often correlate with disease activity? | Anti-dsDNA. 58. The presence of Antiphospholipid (APS) Antibodies in SLE increases the risk for what? (2) | Thrombosis and fetal loss. 59. What happens to Complement C3 and C4 levels in active SLE? | Levels are often low. 60. What are two essential standard screening tests for SLE? | Complete blood count (CBC) and urinalysis. 61. What medication should all lupus patients take for non-life-threatening disease? | Hydroxychloroquine. 62. Name three other standard treatments for non-life-threatening SLE. | Low-dose or topical steroids, NSAIDs, sunscreen (SPF 30). 63. What is the mainstay of treatment for life-threatening SLE? | High-dose glucocorticoids. 64. For Lupus Nephritis induction therapy, which immunosuppressant is preferred for fertility preservation? | Mycophenolate Mofetil (MMF). 65. What is required after induction therapy for Lupus Nephritis to prevent flares? | Lifelong maintenance therapy (Azathioprine or Mycophenolate). 66. Name two biologics that may be used for severe or refractory SLE. | Rituximab or Belimumab or Anifrolumab. 67. Are fertility rates in SLE patients normal? | Yes, fertility rates are normal. 68. The rate of fetal loss is increased in SLE, especially with what three conditions? | High disease activity, active nephritis, or positive antiphospholipid antibodies. 69. For a better pregnancy outcome, SLE patients should be in remission for how long prior to conception? | At least 6 months. 70. Why must ALL pregnant women with SLE be tested for anti-Ro antibodies? | High risk for congenital heart block in the fetus. 71. Which three medications are teratogenic and must be stopped before conception in SLE patients? | Methotrexate, Mycophenolate, and Cyclophosphamide.

CHAPTER 357: ANTIPHOSPHOLIPID SYNDROME (APS)

72. What is Antiphospholipid Syndrome (APS)? | An autoantibody-mediated acquired thrombophilia.
73. What is Catastrophic APS (CAPS)? | A rapidly progressive thromboembolic disease involving three or more organs.
74. What percentage of SLE patients have positive antiphospholipid antibodies? | About 30-40%.
75. What is the proposed theory for the pathogenesis of Antiphospholipid Syndrome? | A "two-hit" theory.
76. What is the purpose of the Lupus Anticoagulant (LA) test? | A functional test that detects antibodies prolonging coagulation tests.
77. What is the most specific antibody for Antiphospholipid Syndrome (APS)? | Anti-β2-Glycoprotein I (Anti-β2GPI) antibodies (97% specificity).
78. When should Antiphospholipid Syndrome (APS) be strongly suspected? | In patients <55 years with unprovoked thrombosis, stroke, or pregnancy morbidity.
79. What does the Revised Sapporo Criteria for APS require for diagnosis? | ≥1 clinical criterion AND ≥1 laboratory criterion confirmed ≥12 weeks apart.
80. According to the ACR/EULAR 2023 criteria, how is a patient classified with APS? | Score ≥3 points in clinical domain and ≥3 points in laboratory domain.
81. How is a high-risk profile defined in Antiphospholipid Syndrome? (3) | Presence of LA, double/triple antibody positivity, or persistently high titers.
82. How is asymptomatic high-risk Antiphospholipid Syndrome treated? | Low-dose aspirin (LDA) 75-100 mg/day.
83. How is Obstetric APS (history of pregnancy loss only) treated during pregnancy? | LDA + prophylactic heparin.
84. What is the treatment for Thrombotic APS (history of thrombosis)? | Lifelong anticoagulation with a Vitamin K Antagonist (Warfarin).

CHAPTER 365: INFLAMMATORY MYOPATHIES

85. What characterizes Inflammatory Myopathies? | Progressive and symmetric proximal muscle weakness, initially painful.
86. Name the five types of Inflammatory Myopathies. | Dermatomyositis (DM), Polymyositis (PM), IMNM, Antisynthetase syndrome (AS), and Inclusion body myositis (IBM).
87. What is the most sensitive lab marker of muscle destruction in Inflammatory Myopathies? | Serum Creatine Kinase (CK).
88. What is the definitive diagnostic modality for Inflammatory Myopathies? | Muscle Biopsy.
89. How does Polymyositis (PM) present? | Symmetric proximal muscle weakness with NO RASH.
90. What does histopathology show in Polymyositis (PM)? | Inflammatory cell infiltrates in the endomysium.
91. How does Dermatomyositis (DM) present? | As polymyositis WITH A RASH.
92. Dermatomyositis (DM) is highly associated with what condition? | Malignancy (15% risk within 3 years).
93. Name two pathognomonic rashes of Dermatomyositis (DM). | Heliotrope rash and Gottron's sign/papules.
94. Which two MSAs in Dermatomyositis (DM) are associated with increased cancer risk? | Anti-TIF1 & Anti-NXP2.
95. What does histopathology show in Dermatomyositis (DM)? | Perimysial/perivascular infiltrates and perifascicular atrophy.
96. Antisynthetase Syndrome is characterized by what specific finding on the hands? | Mechanic's hands.
97. Does Antisynthetase Syndrome (AS) increase the risk for malignancy? | No.
98. What is the most common antibody in Antisynthetase Syndrome (AS)? | Anti-Jo-1.
99. What antibody is associated with statin-induced Immune-Mediated Necrotizing Myopathy (IMNM)? | Anti-HMGCR.
100. What does histopathology show in Immune-Mediated Necrotizing Myopathy (IMNM)? | Necrotic fibers with a paucity of inflammatory cells.
101. What is the most common myopathy in individuals aged >50? | Inclusion Body Myositis (IBM).
102. How does the muscle weakness present in Inclusion Body Myositis (IBM)? | Slowly progressive, asymmetric, may start distally.
103. What is a highly specific diagnostic marker for Inclusion Body Myositis (IBM)? | Anti-cN-1A antibody.
104. What distinguishes Inclusion Body Myositis (IBM) histopathology from Polymyositis? | Presence of rimmed vacuoles and amyloid deposits.
105. What is the first-line treatment for Inflammatory Myopathies? | Steroids.
106. Which second-line agent is preferred for Inflammatory Myopathies with ILD? | Mycophenolate.
107. Which Inflammatory Myopathy requires steroids plus a second-line agent from the start? | Immune-Mediated Necrotizing Myopathy (IMNM).
108. What is the main therapy for Inclusion Body Myositis (IBM)? | Physical and Occupational Therapy (PT/OT).
109. How should treatment adjustments be monitored for Inflammatory Myopathies? | Based on objective improvement in muscle strength, not just CK levels.
110. How can steroid-induced myopathy be differentiated from a disease relapse? | Steroid myopathy occurs with a normal CK level.

CHAPTER 361: SJÖGREN'S SYNDROME

111. What is Sjögren's Syndrome characterized by? | Lymphocyte infiltration of exocrine glands and B-cell hyperactivity.
112. What are the two key autoantibodies in Sjögren's Syndrome? | Anti-Ro/SS-A and Anti-La/SS-B.
113. What are the hallmark glandular symptoms of Sjögren's Syndrome? | Sicca symptoms: Dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia).
114. Patients with Sjögren's Syndrome have an increased risk of developing what malignancy? | Lymphoma.
115. What are the two definitive tests for diagnosing Sjögren's Syndrome? | Positive serology (Anti-Ro/SS-A or Anti-La/SS-B) or a minor salivary gland biopsy.
116. Name two secretagogue medications used to treat Sjögren's Syndrome. | Pilocarpine or Cevimeline.
117. What medication is used for arthralgias in Sjögren's Syndrome? | Hydroxychloroquine.
118. What classes of medications should be avoided in Sjögren's Syndrome as they can worsen dryness? | Diuretics, anticholinergics, and some antidepressants.

HIGH-YIELD COMPARISONS & DIFFERENTIATORS

119. How does SLE arthritis differ from RA arthritis regarding erosions? | SLE arthritis is rarely erosive.
120. In SLE, which mucosal ulcers ARE associated with disease activity? | Nasal ulcers.
121. Compare Anti-dsDNA and Anti-Sm antibodies in SLE regarding disease activity correlation. | Anti-dsDNA levels correlate with activity; Anti-Sm levels do not.
122. Differentiate Malar rash, SCLE, and DLE in SLE based on scarring. | Malar and SCLE are non-scarring; DLE causes scarring.
123. What is the key differentiator between Polymyositis and Dermatomyositis? | The rash in Dermatomyositis.
124. Compare the muscle weakness pattern in Polymyositis vs. Inclusion Body Myositis. | PM: symmetric/proximal.
     IBM: asymmetric/distal.
125. How does Antisynthetase Syndrome (AS) differ from classic Dermatomyositis (DM) regarding malignancy risk? | AS does not carry the increased malignancy risk.
126. What is the defining feature of Sjögren's Syndrome compared to SLE? | Sicca symptoms (dry eyes/mouth).
127. What hematologic finding is characteristic of SLE compared to other inflammatory conditions? | Leukopenia, lymphopenia, and thrombocytopenia.
128. For lupus nephritis induction, which drug is preferred to preserve fertility instead of Cyclophosphamide? | Mycophenolate Mofetil (MMF).
129. How does treatment differ for life-threatening vs. non-life-threatening SLE? | Life-threatening requires high-dose glucocorticoids and immunosuppressants.
130. In Antiphospholipid Syndrome, which antibody is the most specific for diagnosis? | Anti-β2-Glycoprotein I.
131. How is a myositis relapse differentiated from steroid myopathy? | Myositis relapse has a rising CK level; steroid myopathy has a normal CK.

2

Summary

text

CHAPTER 363: THE VASCULITIS SYNDROMES

I. GENERAL PRINCIPLES

• Definition of Vasculitis: Vasculitis is characterized by inflammation of blood vessels, which compromises the vessel lumen and leads to ischemia of the tissues it supplies.
• Primary vs. Secondary Vasculitis: Primary vasculitis is when vasculitis is the sole disease manifestation. Secondary vasculitis occurs as part of another underlying disease (e.g., Hepatitis C, HIV).
• Constitutional Signs/Symptoms of Vasculitis: Common features of inflammation include fever, elevated ESR/CRP, anemia (of chronic disease or from bleeding), leukocytosis, and thrombocytosis.
• Diagnosis of Vasculitis: A tissue biopsy provides the definitive diagnosis. An arteriogram is used for medium- to large-vessel vasculitis if a biopsy cannot be done. It is crucial to rule out other diseases that can mimic vasculitis.
• General Signs/Symptoms Suggestive of Vasculitis: Systemic symptoms (malaise, fever, weight loss), respiratory symptoms (cough, hemoptysis), skin changes (purpura, ulcers), ENT issues (epistaxis, sinusitis), GI pain, and neurologic deficits are common but vague.